Protein tyrosine phosphatase inhibitors and methods of use thereof

Abstract

Provided are compounds, compositions, and methods useful for inhibiting protein-tyrosine phosphatases, e.g., non-receptor protein-tyrosine phosphatase type 2 (PTPN2) and / or non-receptor protein-tyrosine phosphatase type 1 (PTPN1), and for treating associated diseases, disorders, and conditions that respond favorably to treatment with PTPN1 or PTPN2 inhibitors, e.g., cancers or metabolic diseases.SOLUTION: A [1-fluoro-3-hydroxynaphthalen-2-yl] - 1 λ 6,2,5 - thiadiazolidine - 1,1,3 - trione derivative represented by the following formula: (R1 to R3 are each independently H, halogen, substitutable C1 to 6 alkyl, substitutable C1 to 6 alkoxy, or the like; R4 and R5 are each independently H, halogen, substitutable C1 to 6 alkyl, or the like; R6 and R7 are each independently H. ) SELECTED DRAWING: None

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Application No. 62 / 949,613, filed December 18, 2019, the contents of which are incorporated herein by reference in their entirety. [Background technology]

[0002] background Cancer immunotherapy regimens that target immune evasion mechanisms, including checkpoint blockade (e.g., PD-1 / PD-L1 and CTLA-4 blocking antibodies), have been shown to be effective in treating a variety of cancers and dramatically improve outcomes in populations resistant to conventional therapies. However, incomplete clinical responses and the development of intrinsic or acquired resistance continue to limit the patient population that could potentially benefit from checkpoint blockade.

[0003] Non-receptor type 2 protein tyrosine phosphatase (PTPN2), also known as T-cell protein tyrosine phosphatase (TC-PTP), is an intracellular member of the class 1 subfamily of phosphotyrosine-specific phosphatases that controls multiple cellular regulatory processes by removing phosphate groups from tyrosine substrates. PTPN2 is ubiquitously expressed, but expression is highest in hematopoietic and placental cells (Mosinger, B. Jr. et al., Proc Natl Acad Sci USA 89:499-503; 1992). In humans, PTPN2 expression is posttranscriptionally regulated by the existence of two splice variants: a 45-kDa form containing a nuclear localization signal at the C-terminus upstream of the splice junction, and a 48-kDa canonical form with a C-terminal ER retention motif (Tillmann U. et al., Mol Cell Biol 14:3030-3040; 1994). The 45-kDa isoform can passively penetrate the cytosol under certain conditions of cellular stress. Both isoforms share an N-terminal phosphorylation tyrosine phosphatase catalytic domain. PTPN2 negatively regulates signal transduction of nonreceptor tyrosine kinases (e.g., JAK1 and JAK3), receptor tyrosine kinases (e.g., INSR, EGFR, CSF1R, and PDGFR), transcription factors (e.g., STAT1, STAT3, and STAT5a / b), and Src family kinases (e.g., Fyn and Lck). As a key negative regulator of the JAK-STAT pathway, PTPN2 functions to directly regulate signal transduction through cytokine receptors, including IFNγ. The PTPN2 catalytic domain shares 74% sequence identity with PTPN1 (also called PTP1B) and shares similar enzyme kinetics (Romsicki Y. et al., Arch Biochem Biophys 414:40-50; 2003).

[0004] Data from a loss-of-function in vivo genetic screen using CRISPR / Cas9 genome editing in a mouse B16F10 transplantable tumor model showed that deletion of the Ptpn2 gene in tumor cells improved response to an immunotherapy regimen consisting of a GM-CSF-secreting vaccine (GVAX) plus a PD-1 checkpoint blockade (Manguso RT et al., Nature 547:413-418; 2017). Loss of Ptpn2 sensitized tumors to immunotherapy by enhancing IFNγ-mediated antigen presentation and growth suppression. The same screen also revealed that under the selective pressure of immunotherapy, genes known to be involved in immune evasion, including PD-L1 and CD47, were depleted, while genes involved in the IFNγ signaling pathway, including IFNGR, JAK1, and STAT1, were enriched. These observations suggest a putative role for therapeutic strategies that enhance IFNγ sensing and signaling in enhancing the efficacy of cancer immunotherapy regimens.

[0005] Non-receptor type 1 protein tyrosine phosphatase (PTPN1), also known as protein tyrosine phosphatase-1B (PTP1B), has been shown to play an important role in insulin and leptin signaling and is a major mechanism for downregulating both insulin and leptin receptor signaling pathways (Kenner KA et al., J Biol Chem 271: 19810-19816, 1996). Animals lacking PTP1B have improved glucose regulation and lipid profiles and are resistant to weight gain when fed a high-fat diet (Elchebly M. et al., Science 283: 1544-1548, 1999). Therefore, PTP1B inhibitors are expected to be useful for the treatment of type 2 diabetes, obesity, and metabolic syndrome. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Mosinger, B. Jr. et al., Proc Natl Acad Sci USA 89:499-503;1992 [Non-Patent Document 2] Tillmann U. et al., Mol Cell Biol 14:3030-3040;1994 [Non-Patent Document 3] Romsicki Y. et al., Arch Biochem Biophys 414:40-50;2003 [Non-Patent Document 4] Manguso R. T. et al., Nature 547:413-418;2017 [Non-Patent Document 5] Kenner K. A. et al., J Biol Chem 271: 19810-19816, 1996 [Non-Patent Document 6] Elchebly M. et al., Science 283: 1544-1548, 1999 [Summary of the Invention]

[0007] The present disclosure relates, at least in part, to compounds, compositions, and methods for inhibiting protein tyrosine phosphatases, such as non-receptor type 2 protein tyrosine phosphatase (PTPN2) and / or non-receptor type 1 protein tyrosine phosphatase (PTPN1), also known as protein tyrosine phosphatase-1B (PTP1B). In some embodiments, disclosed herein are inhibitors of protein tyrosine phosphatases, such as PTPN2 and / or PTP1B, comprising compounds disclosed herein, e.g., compounds of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V). In other embodiments, disclosed herein are methods for treating a disease or disorder, e.g., cancer, type 2 diabetes, obesity, metabolic disease, or any other disease, disorder, or condition that responds favorably to treatment with a PTPN2 or PTP1B inhibitor, comprising administering an effective amount of a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0008] For example, disclosed herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof: TIFF2026004380000001.tif30128 formula, R 1 is hydrogen, halogen, C 1~6 Alkyl, C 3~6 Cycloalkyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, and -C 1~6 alkylene-5-6 membered heterocyclyl, wherein C 1~6 Alkyl, C 3~6 Cycloalkyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, and -C 1~6 The alkylene-5- to 6-membered heterocyclyl may optionally be substituted with R on one or more available carbons. gand optionally substituted by one, two, three or more substituents selected from -C 1~6 When the alkylene-5- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by R 2 is hydrogen, halogen, hydroxyl, -CHF2, -CH2OH, -CH2CN, -CH2-OC 1~6 Alkyl, -CH2-N(R a )-C 1~6 Alkyl, C 2~6 Alkyl, C 2~6 Alkenyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, -OC(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-OC 1~6 Alkyl, -C 3~6 Cycloalkyl, -OC 3~6 Cycloalkyl, C 1~6 Alkylene-C 3~6 Cycloalkyl, -C 1~6 Alkenylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, -OC 1~6 alkylene-5-6 membered heteroaryl, -O-4-6 membered heterocyclyl, -N(R a )-4 to 6-membered heterocyclyl, -C 1~6 Alkylene-4 to 6-membered heterocyclyl, and -OC 1~6 alkylene-4 to 6 membered heterocyclyl, wherein -CH2-OC 1~6 Alkyl, -CH2-N(R a )-C1~6 Alkyl, C 2~6 Alkyl, C 2~6 Alkenyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, -OC(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-OC 1~6 Alkyl, -C 3~6 Cycloalkyl, -OC 3~6 Cycloalkyl, -C 1~6 Alkylene-C 3~6 Cycloalkyl, -C 1~6 Alkenylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, 5-6 membered heteroaryl, -OC 1~6 alkylene-5-6 membered heteroaryl, 4-6 membered heterocyclyl, -O-4-6 membered heterocyclyl, -N(R a )-4 to 6-membered heterocyclyl, -C 1~6 Alkylene-4 to 6-membered heterocyclyl, and -OC 1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and may be substituted by one, two, three or more substituents selected from 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, -N(R a )-4 to 6-membered heterocyclyl, -C 1~6 Alkylene-4 to 6-membered heterocyclyl, or -OC 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by Or, R 1 and R 2together with the atom to which they are attached form a 5-6 membered aryl or heteroaryl, wherein the aryl or heteroaryl is optionally selected from halogen, hydroxyl, cyano, C 1~6 Alkyl, and C 1~6 and optionally substituted by one or more substituents each independently selected from the group consisting of alkoxy, wherein C 1~6 Alkyl and C 1~6 The alkoxy is optionally independently selected from R p and optionally substituted by one, two, three or more substituents selected from R 3 is hydrogen, halogen, hydroxyl, -NH2, -C 1~6 Alkyl, -OC 1~6 Alkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-N(R a )-C(O)-OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -N(R a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, and -C 1~6 alkylene-4 to 6 membered heterocyclyl, wherein -C 1~6 Alkyl, -OC 1~6 Alkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-N(R a )-C(O)-OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -N(R a )-C 1~6 Alkylene-C 3~6Cycloalkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, and -C 1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by R 4 is hydrogen, halogen, C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6 alkylene-4 to 6 membered heterocyclyl, wherein C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by where R 1 , R 2 , R 3 , and R 4 At least one of them is not hydrogen, R 5 is hydrogen, halogen, C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6 alkylene-4 to 6 membered heterocyclyl, wherein C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by R 6 is hydrogen, R 7 is hydrogen, R g is, for each occurrence, independently hydrogen, halogen, hydroxyl, cyano, nitro, oxo, -C(O)OH, R a R b N-, R a R b NC(O)-, R a R b N-SO w -, R a R b NC(O)-N(R a )-, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~6 Cycloalkyl, phenyl, C 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -(CO)-(NR a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, C 1~6 Alkoxy, C 3~6 Alkenyloxy, C 3~6 Alkynyloxy, C 3~6 Cycloalkoxy, C 1~6 Alkyl-C(O)-, C 1~6 Alkyl-OC(O)-, C 1~6 Alkyl-C(O)-O-, C 1~6 Alkyl-S(O) w -, C 1~6 Alkyl-N(R a)-, C 1~6 Alkyl-N(R a )-C(O)-, C 1~6 Alkyl-C(O)-N(R a ), C 1~6 Alkyl-N(R a )-C(O)-N(R a )-, C 1~6 Alkyl-N(R a )-SO w -, C 3~6 Cycloalkyl-N(R a )-SO w -, C 1~6 Alkyl-SO w -N(R a )-, C 3~6 Cycloalkyl-SO w -N(R a )-, 4-6 membered heterocyclyl-SO w -N(R a )-, C 1~6 Alkoxy-C(O)-N(R a )-, C 1~6 Alkyl-C(O)-N(R a )-C 1~6 Alkyl-, C 1~6 Alkyl-N(R a )-C(O)-C 1~6 Alkyl-, -P(O)(C 1~3 alkyl)2, and C 1~6 Alkoxy-C 1~6 alkyl-, wherein C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~6 Cycloalkyl, phenyl, C 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -(CO)-(NR a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, C 1~6 Alkoxy, C 3~6 Alkenyloxy, C 3~6 Alkynyloxy, C 3~6 Cycloalkoxy, C1~6 Alkyl-C(O)-, C 1~6 Alkyl-OC(O)-, C 1~6 Alkyl-C(O)-O-, C 1~6 Alkyl-S(O) w -, C 1~6 Alkyl-N(R a )-, C 1~6 Alkyl-N(R a )-C(O)-, C 1~6 Alkyl-C(O)-N(R a ), C 1~6 Alkyl-N(R a )-C(O)-N(R a )-, C 1~6 Alkyl-N(R a )-SO w -, C 3~6 Cycloalkyl-N(R a )-SO w -, C 1~6 Alkyl-SO w -N(R a )-, C 3~6 Cycloalkyl-SO w -N(R a )-, 4-6 membered heterocyclyl-SO w -N(R a )-, C 1~6 Alkoxy-C(O)-N(R a )-, C 1~6 Alkyl-C(O)-N(R a )-C 1~6 Alkyl-, C 1~6 Alkyl-N(R a )-C(O)-C 1~6 Alkyl-, -P(O)(C 1~3 alkyl)2, and C 1~6 Alkoxy-C 1~6 alkyl- is optionally independently R p and optionally substituted by one, two, three or more substituents selected from or two R on adjacent atoms g together with the atom to which they are attached form a 5- to 6-membered aryl or heteroaryl; R h For each occurrence, independently, C1~6 Alkyl, C 3~6 Alkenyl, C 3~6 Alkynyl, C 3~6 Cycloalkyl, -C 1~6 Alkyl-C 3~6 Cycloalkyl, C 1~6 Alkyl-S(O)2-, C 3~6 Cycloalkyl-S(O)2-, 4- to 6-membered heterocyclyl-S(O)2-, 4- to 6-membered heterocyclyl-C 1~6 Alkyl-S(O)2-, 5-6 membered heteroaryl-S(O)2-, phenyl-S(O)2-, phenyl-C 1~6 Alkyl-S(O)2-, C 1~6 Alkyl-C(O)-, C 1~6 Cycloalkyl-C(O)-, C 1~6 Alkoxy-C(O)-, R a R b NC(O)-, R a R b N-SO2- and -P(O)(C 1~3 alkyl)2, wherein C 1~6 Alkyl, C 3~6 Alkenyl, C 3~6 Alkynyl, C 3~6 Cycloalkyl, -C 1~6 Alkyl-C 3~6 Cycloalkyl, C 1~6 Alkyl-S(O)2-, C 3~6 Cycloalkyl-S(O)2-, 4- to 6-membered heterocyclyl-S(O)2-, 4- to 6-membered heterocyclyl-C 1~6 Alkyl-S(O)2-, 5-6 membered heteroaryl-S(O)2-, phenyl-S(O)2-, phenyl-C 1~6 Alkyl-S(O)2-, C 1~6 Alkyl-C(O)-, C 1~6 Cycloalkyl-C(O)-, C 1~6 Alkoxy-C(O)-, R a R b NC(O)-, R a R b N-SO2- and -P(O)(C 1~3 alkyl)2 optionally each independently represent R pand optionally substituted by one, two, three or more substituents selected from R p is, for each occurrence independently, halogen, hydroxyl, cyano, C 1~6 Alkyl, C 1~6 Alkoxy, C 3~6 Cycloalkyl, 4-6 membered heterocyclyl, R a R b N-, R a R b N-carbonyl-, R a R b N-SO2- and R a R b N-carbonyl-N(R a )-, R a and R b are, for each occurrence, independently, hydrogen, C 1~6 Alkyl, and C 3~6 cycloalkyl, wherein C 1~6 The alkyl is optionally selected from halogen, cyano, oxo, hydroxyl, and C 1~6 alkoxy (optionally substituted with 1, 2, or 3 fluorine atoms); Or, R a and R b together with the nitrogen to which they are attached form a 4- to 6-membered heterocyclyl, wherein the heterocyclyl is optionally substituted by one or more substituents each independently selected from the group consisting of halogen, cyano, oxo, and hydroxyl; w is 0, 1, or 2.

[0009] Also disclosed herein are compounds represented by formula (IIa) or a pharmaceutically acceptable salt thereof: TIFF2026004380000002.tif30128 formula, X is -O- and -N(R a )-, L is a linear or branched C 1~8 alkylene, where C 1~8 the alkylene is optionally substituted with one or more hydroxyl or one or more fluoro; R 2-IIa is hydrogen, cyano, -NR a R b , C 1~2 Alkoxy, C 3~6 Cycloalkyl-SO2-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 cycloalkyl, wherein C 1~2 Alkoxy, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 alkyl (optionally, -NR a R b , hydroxyl, or 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 optionally substituted by alkyl, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3Alkyl (optionally containing one or more halogens, cyano, or C 1~2 substituted by alkoxy).

[0010] Also disclosed herein is a compound represented by formula (IIb) or a pharmaceutically acceptable salt thereof: TIFF2026004380000003.tif30128 formula, X is -O- and -N(R a )-, L is a linear or branched C 1~6 is alkylene, R 2-IIb is hydrogen, cyano, -NR a R b , C 1~2 Alkoxy, C 3~6 Cycloalkyl-SO2-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 cycloalkyl, wherein phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 optionally substituted by alkyl, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl.

[0011] Also disclosed herein are compounds represented by formula (III) or a pharmaceutically acceptable salt thereof: TIFF2026004380000004.tif30128 formula, X III is a bond, -CH2-, -NR a selected from the group consisting of -, -O-, -O-CH2-, and -OCH2-CH2-; m is 1, 2, or 3; n is 1, 2, or 3; R 1-III represents hydrogen, halogen, hydroxyl, cyano, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2 alkoxy (optionally substituted with 1, 2, or 3 halogens); R 2-III is hydrogen, C 1~4 Alkyl, -C(O)-C 1~4 Alkyl, -C(O)-OC 1~4 Alkyl, -C(O)-N(R a )-C 1~4 Alkyl, -S(O)2-C 1~4 Alkyl, and -S(O)2-C 3~6 cycloalkyl, wherein C 1~4 Alkyl, -C(O)-C 1~4 Alkyl, -C(O)-OC 1~4 Alkyl, -C(O)-N(R a )-C 1~4 Alkyl, -S(O)2-C 1~4Alkyl, and -S(O)2-C 3~6 Cycloalkyl is optionally substituted with halogen, hydroxyl, cyano, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2 alkoxy (optionally substituted with 1, 2, or 3 halogens); R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl.

[0012] Also disclosed herein is a compound represented by formula (IV) or a pharmaceutically acceptable salt thereof: TIFF2026004380000005.tif31128 formula, X III -O- and -N(R a )-, L III is a linear or branched C 1~6 alkylene, where C 1~6 The alkylene is optionally substituted with hydroxyl or fluoro; R 3-III is hydrogen, -NR a R b , -N(R a )-C(O)-OC 1~6 Alkyl, hydroxyl, fluoro, C 1~2 Alkoxy, 4- to 6-membered heterocyclyl, and -C 3~6cycloalkyl, wherein 4- to 6-membered heterocyclyl and -C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 may be substituted by alkyl, or L III -R 3-III is hydrogen, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl.

[0013] Also disclosed herein are compounds represented by formula (V) or a pharmaceutically acceptable salt thereof: TIFF2026004380000006.tif30128 formula, X V is a bond, -O-, and -N(R a )-, L V is a bond or a linear or branched C 1~8 alkylene, where C 1~8 The alkylene is optionally substituted with one or more hydroxyl or fluoro; R 2-Vis hydrogen, halogen, cyano, -NR a R b , C 1~2 Alkoxy, C 3~6 Cycloalkyl-SO2-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 cycloalkyl, wherein phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 alkyl (optionally, -NR a R b , hydroxyl, or 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 optionally substituted by alkyl, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl.

[0014] In this specification, 5-{1-fluoro-3-hydroxy-7-[2-(morpholin-4-yl)ethoxy]naphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, Propan-2-ylcarbamic acid 8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ) 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl, 5-(9-fluoro-7-hydroxynaphtho[2,1-b]furan-8-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(azetidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-methoxy(4- 2 H) naphthalen-2-yl](4,4- 2 H2)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(methylamino)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-4-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-7-{[3-fluoro-1-(propan-2-yl)pyrrolidin-3-yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-7-[(3-fluoropyrrolidin-3-yl)methoxy]-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}pentanenitrile, 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(piperidin-4-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3,3-dimethylpentanenitrile, 5-{7-[(3,3-dimethylbutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1,4-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[( 2 H3) methyloxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-methoxyethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2-dimethylbutanenitrile, 5-{7-[2-(3-aminobicyclo[1.1.1]pentan-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[2-(dimethylamino)ethyl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)(4,4- 2 H2)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}ethyl)cyclopropanesulfonamide, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropanesulfonamide, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)azetidin-3-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanenitrile, [1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropyl]acetonitrile, 5-{7-[2-(dimethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1H-pyrazol-4-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-methylpropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxypropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(cyclopropylmethyl)-8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ) 6 ,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxamide, 5-[1-fluoro-3-hydroxy-7-(2-{[2-(trifluoromethoxy)ethyl]amino}ethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2-methoxyethyl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[3-(methylamino)propyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(ethylamino)propyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[5-(dimethylphosphoryl)thiophen-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclopropylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(methylamino)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(ethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(diethylphosphoryl)propoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3S)-3-hydroxybutoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1,4-difluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3R)-3-hydroxybutoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropyl-2-hydroxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4S)-4-hydroxypentyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3-oxopentyl)oxy]naphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-hydroxybutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-3-methylbutanamide, 5-[1-fluoro-3-hydroxy-7-(4,4,4-trifluorobutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 1-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropane-1-carbonitrile, 5-(1-fluoro-3-hydroxy-7-{2-[1-(methoxymethyl)cyclopropyl]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[(cyclopropylmethyl)amino]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2,2-difluoropropyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3,3-dimethyl-4-(methylamino)butoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-phenylethyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3-amino-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4,4,4-trifluorobutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(difluoromethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(dimethylphosphoryl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3,3,3-trifluoropropyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-methoxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylpropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-({2-[(propan-2-yl)oxy]ethyl}amino)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3-yl]methoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}butanenitrile, 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4-amino-3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[2-(azetidin-1-yl)ethyl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]oxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-methoxyethyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3,3,3-trifluoropropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}methyl)cyclopropane-1-carbonitrile, 5-[1-fluoro-3-hydroxy-7-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[3-(1H-pyrazol-1-yl)propoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(4-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(hydroxymethyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)piperidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(1H-pyrazol-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(piperidin-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(2,2-difluorocyclopropyl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(1-methylcyclopropyl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(3-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(2-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,2-difluoroethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2,2,2-trifluoroethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-7-(2-fluoroethoxy)-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropane-1-carbonitrile, 5-{1-fluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-methylpropyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(cyclopropylmethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetonitrile, 5-[1-fluoro-3-hydroxy-7-(3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1,8-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)azetidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)azetidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (2E)-3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]prop-2-enenitrile, 5-[7-(2-cyclopropylethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2,2-difluorocyclopropyl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclopropylmethoxy)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclobutyloxy)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)oxy]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3-ethoxypropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-tert-butoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[rac-(1R,2R)-2-ethylcyclopropyl]methoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-methylpentyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(2,2-dimethylpropyl)pyrrolidin-1-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(1-chloro-3-hydroxypropan-2-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)pyrrolidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(cyclopropyloxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2-cyclopropylethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-methyl-1H-imidazol-2-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(azetidin-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(5-methoxythiophen-2-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetonitrile, 5-[1-fluoro-3-hydroxy-7-(methoxymethyl)naphthalen-2-yl]-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3-methyloxetan-3-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3S)-pyrrolidin-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3R)-pyrrolidin-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(8-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3,3-difluorocyclobutyl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-cyclopropyl-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-(4-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(E)-2-cyclopropylethenyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1E)-4-methylpent-1-en-1-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(pentamethylphenyl)ethenyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(4-bromo-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(2-cyclopropylethyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1E)-3-methoxyprop-1-en-1-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-ethoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(1,1-dioxo-1λ 6 -thian-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(oxan-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methyl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methyl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[methyl(2-methylpropyl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxolan-2-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(oxolan-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)piperidin-4-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-2-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)piperidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(difluoromethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(pyrrolidin-3-yl)methyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,5-dihydrofuran-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,6-dihydro-2H-pyran-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,5-dihydro-1H-pyrrol-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyridin-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(azetidin-3-yl)methyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ] 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}acetamide, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-N-methylbutanamide, N-ethyl-N'-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)urea, 5-{1-fluoro-3-hydroxy-7-[(oxan-3-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(1-chloro-3-hydroxypropan-2-yl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxan-4-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxetan-3-yl)oxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyridin-4-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,7-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-propoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(propan-2-yl)oxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}acetic acid, N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ] 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetamide, N,N-diethyl-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetamide, 5-{1-fluoro-3-hydroxy-7-[2-oxo-2-(pyrrolidin-1-yl)ethoxy]naphthalen-2-yl}-1λ6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]oxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(oxolane-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2-methoxyethanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-Fluoro-3-hydroxy-7-{1-[(oxan-2-yl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(4,4,4-trifluorobutane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(butane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(1,4-dioxan-2-yl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-2,5-dihydro-1H-pyrrole-1-sulfonyl}pentanenitrile, 5-{1-fluoro-3-hydroxy-7-[1-(pentane-2-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(ethanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(propane-2-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)oxetane-3-sulfonamide, 5-[1-fluoro-3-hydroxy-7-(piperidin-4-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2-methylpropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-ethoxy-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,2-difluoroethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-1H-pyrazol-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[(3R)-1-(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-7-{[3-fluoro-1-(methanesulfonyl)pyrrolidin-3-yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(propane-2-sulfonyl)pyrrolidin-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)ethanesulfonamide, 5-{1-fluoro-7-[1-(furan-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-methylbutane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(thiophene-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(benzenesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclobutanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (2S)-2-amino-4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanoic acid methyl ester, 5-{7-[(3,5-dimethyl-1H-pyrazol-4-yl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,5-dimethyl-1H-pyrazol-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclohexylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-1H-imidazole-4-carbonitrile, 5-{1-fluoro-3-hydroxy-7-[2-(2,2,4-trimethyl-1,3-dioxolan-4-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,4-dihydroxy-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(4,4-difluorobutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[rac-(2R,4R)-2,4-dihydroxypentyl]oxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(2-oxoimidazolidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxybutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(6-amino-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{6-[(4,4-difluorobutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{6-[(cyclopropylmethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-6-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-6-[(3-hydroxy-3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-6-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-6-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (2-{[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1λ 6 tert-butyl 2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)carbamate, 5-[6-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[6-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-6-(3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[6-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3S)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-3,3-dimethylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-hydroxy-2,2-dimethylpropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(3-aminopropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (3R)-5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy-3-methylpentanenitrile, (3S)-5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy-3-methylpentanenitrile, 5-{7-[(5-amino-3,3-dimethylpentyl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{3-[(propan-2-yl)amino]propyl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxolan-3-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopentylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclobutylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(trifluoromethoxy)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,6-dihydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-ethyl-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3,6-dihydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclobutylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-butoxy-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopentylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4,4-difluorobutoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-3,6-dihydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2-dimethylbutanenitrile, 5-{1-fluoro-3,6-dihydroxy-7-[2-(oxolan-3-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-hydroxypropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-bromo-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(4-methylpentyl)naphthalen-2-yl]-1λ6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxetan-3-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[1-(hydroxymethyl)cyclobutyl]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(4,4-difluoro-5-hydroxypentyl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[3-(aminomethyl)bicyclo[1.1.1]pentan-1-yl]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[3-(2-hydroxyethyl)bicyclo[1.1.1]pentan-1-yl]methoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(bicyclo[1.1.1]pentan-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[1-(aminomethyl)cyclobutyl]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(3-hydroxy-3-methylazetidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2-methoxyethyl)(methyl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(1,3-dihydro-2H-isoindol-2-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3,6-dihydroxy-7-[2-(1-methylcyclopropyl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3,6-dihydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[ethyl(methyl)amino]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 3-[(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)(methyl)amino]propanenitrile, 5-(1-fluoro-3-hydroxy-7-{2-[(2,2,2-trifluoroethyl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, and pharmaceutically acceptable salts thereof Further disclosed is a compound selected from the group consisting of:

[0015] In some embodiments, a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V), is formulated as a pharmaceutically acceptable composition comprising a disclosed compound and a pharmaceutically acceptable carrier.

[0016] Also disclosed herein are methods for treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V), in combination with an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an immunotherapeutic agent. For example, in some embodiments, the immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody.

[0017] For example, disclosed herein is a method of treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0018] Further provided herein is a method for treating type 2 diabetes in a patient in need thereof, comprising administering to said patient an effective amount of a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0019] For example, disclosed herein are methods for treating and / or managing obesity in a patient in need thereof, comprising administering to said patient an effective amount of a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0020] For example, disclosed herein is a method for inhibiting further weight gain in an overweight or obese patient in need thereof, comprising administering to said patient an effective amount of a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0021] Further disclosed herein is a method for treating a metabolic disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0022] In some embodiments, the method comprises treating cancer. In some embodiments, the cancer comprises pancreatic cancer, breast cancer, multiple myeloma, melanoma, or cancer of secretory cells. In some embodiments, the method comprises treating a metabolic disease. In some embodiments, the metabolic disease comprises non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), liver fibrosis, obesity, type 2 diabetes, heart disease, atherosclerosis, arthritis, cystinosis, phenylketonuria, proliferative retinopathy, metabolic syndrome, or Kearns-Sayre disease.

[0023] Also disclosed herein are compositions for use in treating cancer in a patient in need thereof, comprising a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V), in combination with an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an immunotherapeutic agent. For example, in some embodiments, the immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody.

[0024] For example, disclosed herein are compositions for use in treating cancer in a patient in need thereof, comprising a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0025] Further provided herein are compositions for use in treating type 2 diabetes in a patient in need thereof, comprising a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0026] For example, disclosed herein are compositions for use in the treatment and / or management of obesity in a patient in need thereof, comprising a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0027] For example, disclosed herein are compositions for use in inhibiting further weight gain in an overweight or obese patient in need thereof, comprising a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0028] Further disclosed herein are compositions for use in treating metabolic disorders in a patient in need thereof, comprising a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V).

[0029] In some embodiments, the cancer comprises pancreatic cancer, breast cancer, multiple myeloma, melanoma, or cancer of secretory cells. In some embodiments, the metabolic disease comprises nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), liver fibrosis, obesity, type 2 diabetes, heart disease, atherosclerosis, arthritis, cystinosis, phenylketonuria, proliferative retinopathy, metabolic syndrome, or Kearns-Sayre disease. [The present invention 1001] A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: TIFF2026004380000007.tif31128 formula, R 1 is hydrogen, halogen, C 1~6 Alkyl, C 3~6 Cycloalkyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, and -C 1~6 alkylene-5-6 membered heterocyclyl, wherein C 1~6 Alkyl, C 3~6 Cycloalkyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, and -C 1~6 The alkylene-5- to 6-membered heterocyclyl may optionally be substituted with R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6 When the alkylene-5- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by R 2is hydrogen, halogen, hydroxyl, -CHF2, -CH2OH, -CH2CN, -CH2-OC 1~6 Alkyl, -CH2-N(R a )-C 1~6 Alkyl, C 2~6 Alkyl, C 2~6 Alkenyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, -OC(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-OC 1~6 Alkyl, -C 3~6 Cycloalkyl, -OC 3~6 Cycloalkyl, C 1~6 Alkylene-C 3~6 Cycloalkyl, -C 1~6 Alkenylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, -OC 1~6 alkylene-5-6 membered heteroaryl, -O-4-6 membered heterocyclyl, -N(R a )-4 to 6-membered heterocyclyl, -C 1~6 Alkylene-4 to 6-membered heterocyclyl, and -OC 1~6 alkylene-4 to 6 membered heterocyclyl, wherein -CH2-OC 1~6 Alkyl, -CH2-N(R a )-C 1~6 Alkyl, C 2~6 Alkyl, C 2~6 Alkenyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(Ra )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, -OC(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-OC 1~6 Alkyl, -C 3~6 Cycloalkyl, -OC 3~6 Cycloalkyl, -C 1~6 Alkylene-C 3~6 Cycloalkyl, -C 1~6 Alkenylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, 5-6 membered heteroaryl, -OC 1~6 alkylene-5-6 membered heteroaryl, 4-6 membered heterocyclyl, -O-4-6 membered heterocyclyl, -N(R a )-4 to 6-membered heterocyclyl, -C 1~6 Alkylene-4 to 6-membered heterocyclyl, and -OC 1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and may be substituted by one, two, three or more substituents selected from 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, -N(R a )-4 to 6-membered heterocyclyl, -C 1~6 Alkylene-4 to 6-membered heterocyclyl, or -OC 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by Or, R 1 and R 2 together with the atom to which they are attached form a 5-6 membered aryl or heteroaryl, wherein the aryl or heteroaryl is optionally selected from halogen, hydroxyl, cyano, C 1~6 Alkyl, and C 1~6and optionally substituted by one or more substituents each independently selected from the group consisting of alkoxy, wherein C 1~6 Alkyl and C 1~6 The alkoxy is optionally independently selected from R p and optionally substituted by one, two, three or more substituents selected from R 3 is hydrogen, halogen, hydroxyl, -NH2, -C 1~6 Alkyl, -OC 1~6 Alkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-N(R a )-C(O)-OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -N(R a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, and -C 1~6 alkylene-4 to 6 membered heterocyclyl, wherein -C 1~6 Alkyl, -OC 1~6 Alkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-N(R a )-C(O)-OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -N(R a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C1~6 Alkyl, and -C 1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by R 4 is hydrogen, halogen, C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6 alkylene-4 to 6 membered heterocyclyl, wherein C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by where R 1 , R 2 , R 3 , and R 4 At least one of them is not hydrogen, R 5 is hydrogen, halogen, C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6 alkylene-4 to 6 membered heterocyclyl, wherein C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by R 6 is hydrogen, R 7 is hydrogen, R g is, for each occurrence, independently hydrogen, halogen, hydroxyl, cyano, nitro, oxo, -C(O)OH, R a R b N-, R a R b NC(O)-, R a R b N-SO w -, R a R b NC(O)-N(R a )-, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~6 Cycloalkyl, phenyl, C 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -(CO)-(NR a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, C 1~6 Alkoxy, C 3~6 Alkenyloxy, C 3~6 Alkynyloxy, C 3~6 Cycloalkoxy, C 1~6 Alkyl-C(O)-, C 1~6 Alkyl-OC(O)-, C 1~6 Alkyl-C(O)-O-, C 1~6 Alkyl-S(O) w -, C 1~6 Alkyl-N(R a )-, C 1~6 Alkyl-N(R a )-C(O)-, C 1~6 Alkyl-C(O)-N(R a ), C 1~6 Alkyl-N(R a)-C(O)-N(R a )-, C 1~6 Alkyl-N(R a )-SO w -, C 3~6 Cycloalkyl-N(R a )-SO w -, C 1~6 Alkyl-SO w -N(R a )-, C 3~6 Cycloalkyl-SO w -N(R a )-, 4-6 membered heterocyclyl-SO w -N(R a )-, C 1~6 Alkoxy-C(O)-N(R a )-, C 1~6 Alkyl-C(O)-N(R a )-C 1~6 Alkyl-, C 1~6 Alkyl-N(R a )-C(O)-C 1~6 Alkyl-, -P(O)(C 1~3 alkyl)2, and C 1~6 Alkoxy-C 1~6 alkyl-, wherein C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~6 Cycloalkyl, phenyl, C 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -(CO)-(NR a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, C 1~6 Alkoxy, C 3~6 Alkenyloxy, C 3~6 Alkynyloxy, C 3~6 Cycloalkoxy, C 1~6 Alkyl-C(O)-, C 1~6 Alkyl-OC(O)-, C 1~6 Alkyl-C(O)-O-, C 1~6 Alkyl-S(O) w -, C1~6 Alkyl-N(R a )-, C 1~6 Alkyl-N(R a )-C(O)-, C 1~6 Alkyl-C(O)-N(R a ), C 1~6 Alkyl-N(R a )-C(O)-N(R a )-, C 1~6 Alkyl-N(R a )-SO w -, C 3~6 Cycloalkyl-N(R a )-SO w -, C 1~6 Alkyl-SO w -N(R a )-, C 3~6 Cycloalkyl-SO w -N(R a )-, 4-6 membered heterocyclyl-SO w -N(R a )-, C 1~6 Alkoxy-C(O)-N(R a )-, C 1~6 Alkyl-C(O)-N(R a )-C 1~6 Alkyl-, C 1~6 Alkyl-N(R a )-C(O)-C 1~6 Alkyl-, -P(O)(C 1~3 alkyl)2, and C 1~6 Alkoxy-C 1~6 alkyl- is optionally independently R p and optionally substituted by one, two, three or more substituents selected from or two R on adjacent atoms g together with the atom to which they are attached form a 5- to 6-membered aryl or heteroaryl; R h For each occurrence, independently, C 1~6 Alkyl, C 3~6 Alkenyl, C 3~6 Alkynyl, C 3~6 Cycloalkyl, -C 1~6 Alkyl-C 3~6Cycloalkyl, C 1~6 Alkyl-S(O)2-, C 3~6 Cycloalkyl-S(O)2-, 4- to 6-membered heterocyclyl-S(O)2-, 4- to 6-membered heterocyclyl-C 1~6 Alkyl-S(O)2-, 5-6 membered heteroaryl-S(O)2-, phenyl-S(O)2-, phenyl-C 1~6 Alkyl-S(O)2-, C 1~6 Alkyl-C(O)-, C 1~6 Cycloalkyl-C(O)-, C 1~6 Alkoxy-C(O)-, R a R b NC(O)-, R a R b N-SO2- and -P(O)(C 1~3 alkyl)2, wherein C 1~6 Alkyl, C 3~6 Alkenyl, C 3~6 Alkynyl, C 3~6 Cycloalkyl, -C 1~6 Alkyl-C 3~6 Cycloalkyl, C 1~6 Alkyl-S(O)2-, C 3~6 Cycloalkyl-S(O)2-, 4- to 6-membered heterocyclyl-S(O)2-, 4- to 6-membered heterocyclyl-C 1~6 Alkyl-S(O)2-, 5-6 membered heteroaryl-S(O)2-, phenyl-S(O)2-, phenyl-C 1~6 Alkyl-S(O)2-, C 1~6 Alkyl-C(O)-, C 1~6 Cycloalkyl-C(O)-, C 1~6 Alkoxy-C(O)-, R a R b NC(O)-, R a R b N-SO2- and -P(O)(C 1~3 alkyl)2 optionally each independently represent R p and optionally substituted by one, two, three or more substituents selected from R p is, for each occurrence independently, halogen, hydroxyl, cyano, C 1~6 Alkyl, C1~6 Alkoxy, C 3~6 Cycloalkyl, 4-6 membered heterocyclyl, R a R b N-, R a R b N-carbonyl-, R a R b N-SO2- and R a R b N-carbonyl-N(R a )-, R a and R b are, for each occurrence, independently, hydrogen, C 1~6 Alkyl, and C 3~6 cycloalkyl, wherein C 1~6 The alkyl is optionally selected from halogen, cyano, oxo, hydroxyl, and C 1~6 alkoxy (optionally substituted with 1, 2, or 3 fluorine atoms); Or, R a and R b together with the nitrogen to which they are attached form a 4- to 6-membered heterocyclyl, wherein the heterocyclyl is optionally substituted by one or more substituents each independently selected from the group consisting of halogen, cyano, oxo, and hydroxyl; w is 0, 1, or 2. [The present invention 1002] A compound of the present invention or a pharmaceutically acceptable salt thereof, wherein one, two, three, or more hydrogen atoms of said compound may optionally be deuterium atoms, and all other atoms of said compound are present in their naturally occurring isotopic abundance ratios. [The present invention 1003] 1, 2, 3, or more hydrogen atoms are optionally each independently R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , and R g1001 or 1002, or a pharmaceutically acceptable salt thereof, wherein the compound of the present invention is a compound of the present invention, wherein the compound of the present invention is a compound of the present invention, wherein the compound of the present invention is a compound of the present invention, [The present invention 1004] R 1 is selected from the group consisting of hydrogen, deuterium, chlorine, and fluorine, or a pharmaceutically acceptable salt thereof. [The present invention 1005] R 2 is a 4- to 6-membered heterocyclyl, where R 2 optionally, on one or more available carbons, each independently R g and when the 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted by one, two, or three substituents selected from R h The compound of any one of the present inventions 1001 to 1004 or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from: [The present invention 1006] R 2 is a 4- to 6-membered heterocyclyl, where R 2 optionally, on one or more available carbons, hydrogen and C 1~6 alkyl; R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally selected from hydrogen, C 1~6 alkyl (optionally substituted with 1, 2, or 3 fluorine atoms), -C 1~6 Alkyl-C 3~6 Cycloalkyl, C 1~6 Cycloalkyl-C(O)-, C 1~6 Alkyl-S(O)2- (optionally cyano, methoxy, hydroxyl, -NR a R b or substituted by 1, 2, or 3 fluorine atoms), C 3~6 Cycloalkyl-S(O)2-, 4- to 6-membered heterocyclyl-S(O)2-, 4- to 6-membered heterocyclyl-C 1~6Alkyl-S(O)2-, 5-6 membered heteroaryl-S(O)2-, phenyl-S(O)2-, phenyl-C 1~6 Alkyl-S(O)2- (optionally R a R b -P(O)(C 1~3 The compound of any one of the present inventions 1001 to 1005, or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from the group consisting of alkyl). [The present invention 1007] R 2 but, Any of the compounds of the present invention 1001 to 1006, or a pharmaceutically acceptable salt thereof, selected from the group consisting of TIFF2026004380000008.tif180161TIFF2026004380000009.tif133154. [The present invention 1008] R 2 is a 5-6 membered heteroaryl, where R 2 optionally, on one or more available carbons, each independently R g and R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be replaced by R h The compound of any one of the present inventions 1001 to 1004 or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from: [The present invention 1009] R 2 is a 5-6 membered heteroaryl, where R 2 optionally, on one or more available carbons, hydrogen, cyano, C 1~6 Alkyl, C 1~6 Alkoxy, and -P(O)(C 1~3 and R is optionally substituted by 1, 2, or 3 substituents independently selected from the group consisting of: 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be hydrogen, -C 1~6 Alkyl-C 3~6 Cycloalkyl, and C3~6 The compound of the present invention 1008 or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent selected from the group consisting of cycloalkyl-S(O)2-. [The present invention 1010] R 2 but, The compound of the present invention 1008 or 1009, or a pharmaceutically acceptable salt thereof, selected from the group consisting of TIFF2026004380000010.tif51156. [The present invention 1011] R 2 Ga-OC 1~6 alkylene-4 to 6-membered heterocyclyl, where R 2 optionally, on one or more available carbons, each independently R g and optionally substituted by 1, 2, or 3 substituents selected from two R on adjacent atoms. g together with the atom to which they are attached form a 5- to 6-membered aryl or heteroaryl), R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be replaced by R h The compound of any one of the present inventions 1001 to 1004 or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from: [The present invention 1012] R 2 Ga-OC 1~6 alkylene-4 to 6-membered heterocyclyl, where R 2 optionally, on one or more available carbons, hydrogen, halogen, hydroxyl, and C 1~6 alkyl (optionally substituted with 1, 2, or 3 fluorine atoms), and optionally R 2 The heterocycle of R may be substituted on two adjacent atoms, and the two substituents together with the atoms to which they are attached form a fused phenyl; 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally selected from hydrogen, C 1~6 Alkyl, and C1~6 The compound of the present invention or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent selected from the group consisting of alkyl-S(O)2-. [The present invention 1013] R 2 but, The compound of the present invention 1011 or 1012, or a pharmaceutically acceptable salt thereof, selected from the group consisting of TIFF2026004380000011.tif121160. [The present invention 1014] R 2 Ga-OC 1~6 The compound of any one of 1001 to 1004 of the present invention, which is alkylene-5-6-membered heteroaryl, or a pharmaceutically acceptable salt thereof. [The present invention 1015] R 2 but, 1014. A compound of the present invention or a pharmaceutically acceptable salt thereof selected from the group consisting of TIFF2026004380000012.tif21129. [The present invention 1016] R 2 But -C 2~6 Alkyl, C 2~6 Alkenyl, and C 3~6 cycloalkyl, wherein R 2 are optionally each independently R g The compound of any one of 1001 to 1004 of the present invention or a pharmaceutically acceptable salt thereof, optionally substituted by one, two, three or more substituents selected from: [The present invention 1017] R 2 But -C 2~6 Alkyl, C 2~6 Alkenyl, C 3~6 Cycloalkyl, -C 1~6 Alkylene-C 3~6 Cycloalkyl, and -C 1~6 Alkenylene-C 3~6 cycloalkyl, wherein R 2 is optionally cyano, chlorine, fluorine, hydroxyl, C 1~6Alkoxy, phenyl, and R a R b The compound of the present invention or a pharmaceutically acceptable salt thereof, optionally substituted with 1, 2, 3, or more substituents each independently selected from the group consisting of N-. [The present invention 1018] R 2 but, The compound of the present invention 1016 or 1017, or a pharmaceutically acceptable salt thereof, selected from the group consisting of TIFF2026004380000013.tif82160. [The present invention 1019] R 2 Ga-OC 1~6 alkyl, where R 2 are optionally each independently R g The compound of any one of 1001 to 1004 of the present invention or a pharmaceutically acceptable salt thereof, optionally substituted by one, two, three or more substituents selected from: [The present invention 1020] R 2 Ga-OC 1~6 alkyl, where R 2 is optionally cyano, deuterium, chlorine, fluorine, hydroxyl, oxo, C 1~6 Alkoxy (optionally substituted by 1, 2, or 3 fluorine atoms), C 3~6 Cycloalkoxy, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -(CO)-(NR a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, C 1~6 Alkyl-OC(O)-, R a R b N-(where R b is optionally substituted by -OCH3 or -OCF3), C 1~6 Alkyl-N(R a )-(where C 1~6 alkyl optionally substituted with fluoro, cyano, or -OCH3), R a Rb NC(O)-, -P(O)(C 1~3 Alkyl)2, C 1~6 Alkyl-N(R a )-C(O)-, C 1~6 Alkyl-N(R a )-C(O)-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, C 3~6 Cycloalkyl-SO2-N(R a )-, and 4- to 6-membered heterocyclyl-SO2-N(R a )-, or a pharmaceutically acceptable salt thereof, optionally substituted by 1, 2, 3, or more substituents independently selected from the group consisting of: [The present invention 1021] R 2 but, The compound of the present invention 1019 or 1020, or a pharmaceutically acceptable salt thereof, selected from the group consisting of TIFF2026004380000014.tif217161TIFF2026004380000015.tif62147. [The present invention 1022] R 2 Ga-OC 3~6 cycloalkyl or -O-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be replaced by R h The compound of any one of the present inventions 1001 to 1004 or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from: [The present invention 1023] R 2 Ga-OC 3~6 cycloalkyl or -O-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be C 1~6 Alkyl-SO2-N(R a )- and C 3~6 Cycloalkyl-SO2-N(R a)-Optionally substituted by a substituent selected from the group consisting of the compound of the present invention 1022 or a pharmaceutically acceptable salt thereof. [The present invention 1024] R 2 but, The compound of the present invention 1022 or 1023, or a pharmaceutically acceptable salt thereof, selected from the group consisting of TIFF2026004380000016.tif19128. [The present invention 1025] R 2 -N(R a )-C 1~6 alkyl, where R 2 are optionally each independently R g The compound of any one of 1001 to 1004 of the present invention or a pharmaceutically acceptable salt thereof, optionally substituted by 1, 2, or 3 substituents selected from: [The present invention 1026] R 2 -N(R a )-C 1~6 alkyl, where R 2 is optionally fluoro, —C(O)OH, cyano, oxo, R a R b N-, C 1~6 Alkoxy, phenyl, -C 3~6 Cycloalkyl, C 3~6 Cycloalkyl-SO2-N(R a )-, and -(CO)-(NR a )-C 1~6 Alkylene-C 3~6 The compound of the present invention 1025, or a pharmaceutically acceptable salt thereof, optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of cycloalkyl. [The present invention 1027] R 2 but, The compound of the present invention 1025 or 1026, or a pharmaceutically acceptable salt thereof, selected from the group consisting of TIFF2026004380000017.tif73163. [The present invention 1028] R 2Ga-OC 1~6 Alkylene-C 3~6 cycloalkyl, where R 2 are optionally each independently R g The compound of any one of 1001 to 1004 of the present invention or a pharmaceutically acceptable salt thereof, optionally substituted by 1, 2, or 3 substituents selected from: [The present invention 1029] R 2 Ga-OC 1~6 Alkylene-C 3~6 cycloalkyl, where R 2 is optionally fluoro, hydroxyl, R a R b N-, cyano, and C 1~3 and optionally substituted by 1, 2, or 3 substituents each independently selected from the group consisting of alkyl, wherein C 1~3 The alkyl may optionally be hydroxyl, R a R b N-, cyano and C 1~3 The compound of the present invention 1028 or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent selected from the group consisting of alkoxy. [The present invention 1030] R 2 but, The compound of the present invention 1028 or 1029, or a pharmaceutically acceptable salt thereof, selected from the group consisting of TIFF2026004380000018.tif103149. [The present invention 1031] R 2 -OC(O)-N(R a )-C 1~6 The compound of any one of 1001 to 1004 of the present invention, or a pharmaceutically acceptable salt thereof, wherein R is alkyl. [The present invention 1032] R 2 but, The compound of the present invention 1031 represented by TIFF2026004380000019.tif15128 or a pharmaceutically acceptable salt thereof. [The present invention 1033] R2 -N(R a )-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be replaced by R h The compound of any one of the present inventions 1001 to 1004 or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from: [The present invention 1034] R 2 -N(R a )-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be C 1~6 Alkyl-SO2-N(R a )- and C 3~6 Cycloalkyl-SO2-N(R a )-Optionally substituted by a substituent selected from the group consisting of the compound of the present invention 1033 or a pharmaceutically acceptable salt thereof. [This invention 1035] R 2 but, The compound of the present invention 1033 or 1034, or a pharmaceutically acceptable salt thereof, selected from the group consisting of TIFF2026004380000020.tif31128. [The present invention 1036] R 2 Ga-C 1~6 alkylene-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be replaced by R h The compound of any one of the present inventions 1001 to 1004 or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from: [This invention 1037] R 2 Ga-C 1~6 alkylene-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be C 1~6 Alkyl, C 1~6 Alkyl-SO2-N(R a)-, and C 3~6 Cycloalkyl-SO2-N(R a )-, wherein C 1~6 The compound of the present invention 1036, or a pharmaceutically acceptable salt thereof, wherein alkyl is optionally substituted with 1, 2, or 3 fluorine atoms. [The present invention 1038] R 2 but, The compound of the present invention 1036 or 1037, or a pharmaceutically acceptable salt thereof, selected from the group consisting of TIFF2026004380000021.tif52135. [This invention 1039] R 2 but, -CHF2, -CH2OH, -CH2OCH3, -CH2CN, -OH, Any of the compounds of the present invention 1001 to 1004 selected from the group consisting of TIFF2026004380000022.tif16128 or a pharmaceutically acceptable salt thereof. [The present invention 1040] R 2 is a halogen, and optionally R 2 is selected from the group consisting of fluoro, chloro, and bromo, and further optionally, R 2 The compound of any one of the present invention 1001 to 1004, or a pharmaceutically acceptable salt thereof, wherein is bromo. [The present invention 1041] R 1 and R 2 or a pharmaceutically acceptable salt thereof. 1001 Compounds of the present invention, wherein: together with the atom to which they are attached form a 5-membered heteroaryl; or a pharmaceutically acceptable salt thereof. [The present invention 1042] R 1 and R 2 together with the atom to which they are attached form a furanyl, or a pharmaceutically acceptable salt thereof. [This invention 1043] The compound of the present invention 1041 or 1042, or a pharmaceutically acceptable salt thereof, represented by TIFF2026004380000023.tif29128. [This invention 1044] R 3 The compound of any one of the present inventions 1001 to 1043, or a pharmaceutically acceptable salt thereof, wherein is hydrogen. [This invention 1045] R 3 is OH or -NH2, or a pharmaceutically acceptable salt thereof. [The present invention 1046] R 3 But -N(R a )-C 1~6 alkyl, and -N(R a )-C 1~6 The compound of any one of claims 1001 to 1043, or a pharmaceutically acceptable salt thereof, wherein alkyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of fluoro and hydroxyl. [This invention 1047] R 3 but, 1046. A compound of the present invention selected from the group consisting of TIFF2026004380000024.tif14128 or a pharmaceutically acceptable salt thereof. [This invention 1048] R 3 But -N(R a )-C 1~6 Alkylene-C 3~6 cycloalkyl, and —N(R a )-C 1~6 Alkylene-C 3~6 The compound of any one of claims 1001 to 1043, or a pharmaceutically acceptable salt thereof, of the present invention, wherein cycloalkyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of fluoro and hydroxyl. [This invention 1049] R 3 but, The compound of the present invention 1048 represented by TIFF2026004380000025.tif11128 or a pharmaceutically acceptable salt thereof. [The present invention 1050] R 3 But, -OC 1~6 alkyl, -OC 1~6 The alkyl may optionally contain fluorine, hydroxyl, and R a R b The compound of any one of claims 1001 to 1043 of the present invention, or a pharmaceutically acceptable salt thereof, optionally substituted by 1, 2, 3, or more substituents independently selected from the group consisting of N-. [This invention 1051] R 3 but, 1050. A compound of the present invention selected from the group consisting of TIFF2026004380000026.tif14142 or a pharmaceutically acceptable salt thereof. [This invention 1052] R 3 But, -OC 1~6 Alkylene-C 3~6 is cycloalkyl, -OC 1~6 Alkylene-C 3~6 The compound of any one of claims 1001 to 1043, or a pharmaceutically acceptable salt thereof, of the present invention, wherein cycloalkyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of fluoro and hydroxyl. [This invention 1053] R 3 but, The compound of the present invention 1052 represented by TIFF2026004380000027.tif10128 or a pharmaceutically acceptable salt thereof. [This invention 1054] R 3 But, -OC 1~6 Alkylene-N(R a )-C(O)-OC 1~6 The compound of any one of the present inventions 1001 to 1043, or a pharmaceutically acceptable salt thereof, wherein R is alkyl. [This invention 1055] R 3 but, The compound of the present invention 1054 represented by TIFF2026004380000028.tif13128 or a pharmaceutically acceptable salt thereof. [The present invention 1056] R 4 The compound of any one of the present inventions 1001 to 1055, or a pharmaceutically acceptable salt thereof, wherein is hydrogen. [This invention 1057] R 5 is selected from the group consisting of hydrogen, deuterium, bromine, chlorine, and fluorine, or a pharmaceutically acceptable salt thereof. [This invention 1058] R 6 is selected from the group consisting of hydrogen and deuterium, or a pharmaceutically acceptable salt thereof. [This invention 1059] R 7 is selected from the group consisting of hydrogen and deuterium, or a pharmaceutically acceptable salt thereof. [The present invention 1060] 1001-1059. A compound or a pharmaceutically acceptable salt thereof according to any one of the present inventions 1001-1059, wherein all atoms of said compound are present in their naturally occurring isotopic abundance ratios. [This invention 1061] A compound represented by formula (IIa) or a pharmaceutically acceptable salt thereof: TIFF2026004380000029.tif30128 formula, X is -O- and -N(R a )-, L is a linear or branched C 1~8 alkylene, where C 1~8 alkylene is optionally substituted with one or more hydroxyl or one or more fluoro; R 2-IIa is hydrogen, cyano, -NR a R b , C 1~2Alkoxy, C 3~6 Cycloalkyl-SO2-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 cycloalkyl, wherein C 1~2 Alkoxy, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 Alkyl (optionally -NR a R b , hydroxyl, or 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 optionally substituted by alkyl, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 Alkyl (optionally containing one or more halogens, cyano, or C 1~2 substituted by alkoxy). [This invention 1062] The compound of the present invention 1061, or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of -O-, -N(H)-, and -N(CH3)-. [This invention 1063] L, TIFF2026004380000030.tif51161 (where * and # represent R 2-II and X) The compound of the present invention 1061 or 1062, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: [This invention 1064] R 2-II are hydrogen, cyano, -NH2, -N(CH3)2, -N(H)CH2CF3, -N(CH3)(CH2CH3), -N(CH3)(CH2CH2OCH3), -N(CH3)(CH2CH2CN), -OCH3, -OCF3, Any of the compounds of the present invention 1061 to 1063 selected from the group consisting of TIFF2026004380000031.tif78161 or a pharmaceutically acceptable salt thereof. [This invention 1065] R 5 is selected from the group consisting of hydrogen, deuterium, and fluorine, or a pharmaceutically acceptable salt thereof. [The present invention 1066] A compound represented by formula (IIb) or a pharmaceutically acceptable salt thereof: TIFF2026004380000032.tif30128 formula, X is -O- and -N(R a )-, L is a linear or branched C 1~6 is alkylene, R 2-IIb is hydrogen, cyano, -NR a R b , C 1~2 Alkoxy, C 3~6 Cycloalkyl-SO2-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6cycloalkyl, wherein phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 optionally substituted by alkyl, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl. [This invention 1067] The compound of the present invention 1066, or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of -O-, -N(H)-, and -N(CH3)-. [The present invention 1068] L, TIFF2026004380000033.tif28149 (where * and # represent R 2-II and X) 1066 or 1067, a compound of the present invention, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [The present invention 1069] R 2-II However, hydrogen, cyano, -NH2, -N(CH3)2, -OCH3, Any of the compounds of the present invention 1066 to 1068 selected from the group consisting of TIFF2026004380000034.tif44160, or a pharmaceutically acceptable salt thereof. [The present invention 1070] R 5 is selected from the group consisting of hydrogen, deuterium, and fluorine, or a pharmaceutically acceptable salt thereof. [This invention 1071] A compound represented by formula (III) or a pharmaceutically acceptable salt thereof: TIFF2026004380000035.tif31128 formula, X III is a bond, -CH2-, -NR a selected from the group consisting of -, -O-, -O-CH2-, and -OCH2-CH2-; m is 1, 2, or 3; n is 1, 2, or 3; R 1-III represents hydrogen, halogen, hydroxyl, cyano, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2 alkoxy (optionally substituted with 1, 2, or 3 halogens); R 2-III is hydrogen, C 1~4 Alkyl, -C(O)-C 1~4 Alkyl, -C(O)-OC 1~4 Alkyl, -C(O)-N(R a )-C 1~4 Alkyl, -S(O)2-C 1~4 Alkyl, and -S(O)2-C 3~6 cycloalkyl, wherein C 1~4 Alkyl, -C(O)-C 1~4 Alkyl, -C(O)-OC 1~4 Alkyl, -C(O)-N(R a )-C 1~4 Alkyl, -S(O)2-C1~4 Alkyl, and -S(O)2-C 3~6 Cycloalkyl is optionally substituted with halogen, hydroxyl, cyano, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2 alkoxy (optionally substituted with 1, 2, or 3 halogens); R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl. [This invention 1072] X III is selected from the group consisting of a bond, -CH2-, -O-, -NH-, and -O-CH2-, or a pharmaceutically acceptable salt thereof. [This invention 1073] R 2-III is selected from the group consisting of hydrogen, isopropyl, -CH2CF3, -S(O)2-CH3, and -S(O)2-cyclopropyl, or a pharmaceutically acceptable salt thereof. [This invention 1074] R 5 is selected from the group consisting of hydrogen, deuterium, and fluorine, or a pharmaceutically acceptable salt thereof. [This invention 1075] A compound represented by formula (IV) or a pharmaceutically acceptable salt thereof: TIFF2026004380000036.tif31128 formula, X III -O- and -N(R a )-, L III is a linear or branched chain C 1~6 alkylene, where C 1~6 The alkylene is optionally substituted with hydroxyl or fluoro; R 3-III is hydrogen, -NR a R b , -N(R a )-C(O)-OC 1~6 Alkyl, hydroxyl, fluoro, C 1~2 Alkoxy, 4- to 6-membered heterocyclyl, and -C 3~6 cycloalkyl, wherein 4- to 6-membered heterocyclyl and -C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 may be substituted by alkyl, or L III -R 3-III is hydrogen, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl. [This invention 1076] A compound represented by formula (V) or a pharmaceutically acceptable salt thereof: TIFF2026004380000037.tif30128 formula, X V is a bond, -O-, and -N(R a )-, L V is a bond or a linear or branched C 1~8 alkylene, where C 1~8 The alkylene is optionally substituted with one or more hydroxyl or fluoro; R 2-V is hydrogen, halogen, cyano, -NR a R b , C 1~2 Alkoxy, C 3~6 Cycloalkyl-SO2-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 cycloalkyl, wherein phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 alkyl (optionally, -NR a R b , hydroxyl, or 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 optionally substituted by alkyl, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl. [This invention 1077] X V is a bond or -O-, or a pharmaceutically acceptable salt thereof. [This invention 1078] L V But the bond, TIFF2026004380000038.tif30164 (where * and # represent R 2-V and X V (represents the point of covalent attachment to 1076 or 1077, a compound of the present invention, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [This invention 1079] R 2-V But hydrogen, bromo, cyano, -OCH3, Any of the compounds of the present invention 1076 to 1078 selected from the group consisting of TIFF2026004380000039.tif12128 or a pharmaceutically acceptable salt thereof. [The present invention 1080] R 5 , R 6 , and R 7 and n is 0 or 1. The compound of any one of claims 1076 to 1079 of the present invention, or a pharmaceutically acceptable salt thereof, wherein each of [This invention 1081] 5-{1-fluoro-3-hydroxy-7-[2-(morpholin-4-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, Propan-2-ylcarbamic acid 8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ) 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl, 5-(9-fluoro-7-hydroxynaphtho[2,1-b]furan-8-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(azetidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-methoxy(4- 2 H) naphthalen-2-yl](4,4- 2 H2)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(methylamino)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-4-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-7-{[3-fluoro-1-(propan-2-yl)pyrrolidin-3-yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-7-[(3-fluoropyrrolidin-3-yl)methoxy]-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}pentanenitrile, 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(piperidin-4-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3,3-dimethylpentanenitrile, 5-{7-[(3,3-dimethylbutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1,4-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[( 2 H3) methyloxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-methoxyethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2-dimethylbutanenitrile, 5-{7-[2-(3-aminobicyclo[1.1.1]pentan-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[2-(dimethylamino)ethyl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)(4,4- 2 H2)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}ethyl)cyclopropanesulfonamide, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropanesulfonamide, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)azetidin-3-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanenitrile, [1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropyl]acetonitrile, 5-{7-[2-(dimethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1H-pyrazol-4-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-methylpropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxypropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(cyclopropylmethyl)-8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ) 6 ,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxamide, 5-[1-fluoro-3-hydroxy-7-(2-{[2-(trifluoromethoxy)ethyl]amino}ethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2-methoxyethyl)amino]ethoxy}naphthalen-2-yl)-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[3-(methylamino)propyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(ethylamino)propyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[5-(dimethylphosphoryl)thiophen-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclopropylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(methylamino)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(ethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(diethylphosphoryl)propoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3S)-3-hydroxybutoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1,4-difluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3R)-3-hydroxybutoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropyl-2-hydroxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4S)-4-hydroxypentyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3-oxopentyl)oxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-hydroxybutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-3-methylbutanamide, 5-[1-fluoro-3-hydroxy-7-(4,4,4-trifluorobutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 1-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropane-1-carbonitrile, 5-(1-fluoro-3-hydroxy-7-{2-[1-(methoxymethyl)cyclopropyl]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[(cyclopropylmethyl)amino]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2,2-difluoropropyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3,3-dimethyl-4-(methylamino)butoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-phenylethyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3-amino-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4,4,4-trifluorobutyl)amino]naphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(difluoromethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(dimethylphosphoryl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3,3,3-trifluoropropyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-methoxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylpropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-({2-[(propan-2-yl)oxy]ethyl}amino)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3-yl]methoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}butanenitrile, 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4-amino-3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[2-(azetidin-1-yl)ethyl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]oxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-methoxyethyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3,3,3-trifluoropropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}methyl)cyclopropane-1-carbonitrile, 5-[1-fluoro-3-hydroxy-7-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[3-(1H-pyrazol-1-yl)propoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(4-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(hydroxymethyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)piperidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(1H-pyrazol-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(piperidin-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(2,2-difluorocyclopropyl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(1-methylcyclopropyl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(3-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(2-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,2-difluoroethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2,2,2-trifluoroethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-7-(2-fluoroethoxy)-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropane-1-carbonitrile, 5-{1-fluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-methylpropyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(cyclopropylmethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetonitrile, 5-[1-fluoro-3-hydroxy-7-(3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1,8-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)azetidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)azetidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (2E)-3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]prop-2-enenitrile, 5-[7-(2-cyclopropylethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2,2-difluorocyclopropyl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclopropylmethoxy)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclobutyloxy)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)oxy]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3-ethoxypropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-tert-butoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[rac-(1R,2R)-2-ethylcyclopropyl]methoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-methylpentyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(2,2-dimethylpropyl)pyrrolidin-1-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(1-chloro-3-hydroxypropan-2-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)pyrrolidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(cyclopropyloxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2-cyclopropylethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-methyl-1H-imidazol-2-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(azetidin-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(5-methoxythiophen-2-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetonitrile, 5-[1-fluoro-3-hydroxy-7-(methoxymethyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3-methyloxetan-3-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3S)-pyrrolidin-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3R)-pyrrolidin-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(8-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3,3-difluorocyclobutyl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-cyclopropyl-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(4-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(E)-2-cyclopropylethenyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1E)-4-methylpent-1-en-1-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(pentamethylphenyl)ethenyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(4-bromo-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(2-cyclopropylethyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1E)-3-methoxyprop-1-en-1-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-ethoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(1,1-dioxo-1λ 6 -thian-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(oxan-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methyl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methyl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[methyl(2-methylpropyl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxolan-2-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(oxolan-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)piperidin-4-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-2-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)piperidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(difluoromethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(pyrrolidin-3-yl)methyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,5-dihydrofuran-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,6-dihydro-2H-pyran-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,5-dihydro-1H-pyrrol-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyridin-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(azetidin-3-yl)methyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ] 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}acetamide, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-N-methylbutanamide, N-ethyl-N'-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)urea, 5-{1-fluoro-3-hydroxy-7-[(oxan-3-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(1-chloro-3-hydroxypropan-2-yl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxan-4-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxetan-3-yl)oxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyridin-4-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,7-dihydroxynaphthalen-2-yl)-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-propoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(propan-2-yl)oxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}acetic acid, N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ] 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetamide, N,N-diethyl-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetamide, 5-{1-fluoro-3-hydroxy-7-[2-oxo-2-(pyrrolidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]oxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(oxolane-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2-methoxyethanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-Fluoro-3-hydroxy-7-{1-[(oxan-2-yl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(4,4,4-trifluorobutane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(butane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(1,4-dioxan-2-yl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-2,5-dihydro-1H-pyrrole-1-sulfonyl}pentanenitrile, 5-{1-fluoro-3-hydroxy-7-[1-(pentane-2-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(ethanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(propane-2-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)oxetane-3-sulfonamide, 5-[1-fluoro-3-hydroxy-7-(piperidin-4-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2-methylpropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-ethoxy-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,2-difluoroethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-1H-pyrazol-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[(3R)-1-(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-7-{[3-fluoro-1-(methanesulfonyl)pyrrolidin-3-yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(propane-2-sulfonyl)pyrrolidin-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)ethanesulfonamide, 5-{1-fluoro-7-[1-(furan-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-methylbutane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(thiophene-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(benzenesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclobutanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (2S)-2-amino-4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanoic acid methyl ester, 5-{7-[(3,5-dimethyl-1H-pyrazol-4-yl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,5-dimethyl-1H-pyrazol-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclohexylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-1H-imidazole-4-carbonitrile, 5-{1-fluoro-3-hydroxy-7-[2-(2,2,4-trimethyl-1,3-dioxolan-4-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,4-dihydroxy-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(4,4-difluorobutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[rac-(2R,4R)-2,4-dihydroxypentyl]oxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(2-oxoimidazolidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxybutoxy)naphthalen-2-yl]-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(6-amino-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{6-[(4,4-difluorobutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{6-[(cyclopropylmethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-6-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-6-[(3-hydroxy-3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-6-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-6-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (2-{[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1λ 6 tert-butyl 2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)carbamate, 5-[6-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[6-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-6-(3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[6-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3S)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-3,3-dimethylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-hydroxy-2,2-dimethylpropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(3-aminopropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (3R)-5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy-3-methylpentanenitrile, (3S)-5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy-3-methylpentanenitrile, 5-{7-[(5-amino-3,3-dimethylpentyl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{3-[(propan-2-yl)amino]propyl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxolan-3-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopentylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclobutylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(trifluoromethoxy)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,6-dihydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-ethyl-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3,6-dihydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclobutylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-butoxy-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopentylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4,4-difluorobutoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-3,6-dihydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2-dimethylbutanenitrile, 5-{1-fluoro-3,6-dihydroxy-7-[2-(oxolan-3-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-hydroxypropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-bromo-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(4-methylpentyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxetan-3-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[1-(hydroxymethyl)cyclobutyl]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(4,4-difluoro-5-hydroxypentyl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[3-(aminomethyl)bicyclo[1.1.1]pentan-1-yl]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[3-(2-hydroxyethyl)bicyclo[1.1.1]pentan-1-yl]methoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(bicyclo[1.1.1]pentan-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[1-(aminomethyl)cyclobutyl]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(3-hydroxy-3-methylazetidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2-methoxyethyl)(methyl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(1,3-dihydro-2H-isoindol-2-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3,6-dihydroxy-7-[2-(1-methylcyclopropyl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3,6-dihydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[ethyl(methyl)amino]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 3-[(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)(methyl)amino]propanenitrile, 5-(1-fluoro-3-hydroxy-7-{2-[(2,2,2-trifluoroethyl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, and pharmaceutically acceptable salts thereof A compound selected from the group consisting of: [This invention 1082] A pharmaceutically acceptable composition comprising any one of the compounds of the present invention 1001 to 1081 and a pharmaceutically acceptable carrier. [This invention 1083] A composition of the present invention 1082 formulated for oral administration. [This invention 1084] A method for treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of any of the compounds of the present inventions 1001 to 1081 in combination with an additional therapeutic agent. [This invention 1085] A method for treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of a pharmaceutically acceptable composition of 1082 or 1083 of the present invention in combination with an additional therapeutic agent. [The present invention 1086] 1086. The method of any one of claims 1084 to 1085, wherein said additional therapeutic agent is an immunotherapeutic agent. [This invention 1087] 1086. The method of claim 1086, wherein said immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody. [This invention 1088] A method for treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of any of the compounds of present inventions 1001 to 1081. [This invention 1089] A method for treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of a pharmaceutically acceptable composition of 1082 or 1083 of the present invention. [The present invention 1090] A method for treating type 2 diabetes in a patient in need thereof, comprising administering to the patient an effective amount of any of the compounds of the present inventions 1001 to 1081 or the composition of the present invention 1082 or 1083. [This invention 1091] A method for the treatment and / or management of obesity in a patient in need thereof, comprising administering to said patient an effective amount of any of the compounds of the present inventions 1001 to 1081 or the composition of the present invention 1082 or 1083. [This invention 1092] A method for suppressing further weight gain in an overweight or obese patient in need thereof, comprising administering to the patient an effective amount of any of the compounds of the present inventions 1001 to 1081 or the composition of the present invention 1082 or 1083. [This invention 1093] A method for treating a metabolic disease in a patient in need thereof, comprising administering to the patient an effective amount of any of the compounds of the present inventions 1001 to 1081 or the composition of the present invention 1082 or 1083.

[0030] Brief description of the sequence listing The sequence listing entitled "CLS-021WO SEQ ID List_ST25," including SEQ ID NOs: 1 to 3, which contain the amino acid sequences disclosed herein, is incorporated herein by reference in its entirety. The sequence listing has been submitted herewith via EFS in ASCII text format. The sequence listing was first created on December 15, 2020, and is 7,279 bytes in size. DETAILED DESCRIPTION OF THE INVENTION

[0031] Detailed Description The present disclosure relates, at least in part, to compounds, compositions, and methods for inhibiting protein tyrosine phosphatases, such as non-receptor type 2 protein tyrosine phosphatase (PTPN2) and / or non-receptor type 1 protein tyrosine phosphatase (PTPN1), also known as protein tyrosine phosphatase-1B (PTP1B)).

[0032] Definition of Terms Chemical term definitions Definitions of specific functional groups and chemical terms are explained in more detail below. Chemical elements are listed in the Periodic Table of the Elements, CAS edition, Handbook of Chemistry and Physics, 75 th Ed., endpapers, and specific functional groups are generally defined as described in the above handbook. Further, general principles of organic chemistry, as well as specific functional moieties and reactivities, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5 th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987.

[0033] Abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulas set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.

[0034] The compounds described herein may contain one or more asymmetric centers and therefore may exist in various isomeric forms, e.g., enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of individual enantiomers, diastereomers, or geometric isomers, or may be in the form of mixtures of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts, or preferred isomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (EL Eliel, Ed., University of Notre Dame Press, Notre Dame, IN 1972). The present disclosure further encompasses the compounds described herein as individual isomers substantially free of other isomers or as mixtures of various isomers.

[0035] As used herein, a pure enantiomer of a compound is substantially free of other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, the "S" form of the compound is substantially free of the "R" form of the compound and is thus in enantiomeric excess of the "R" form. The term "enantiomerically pure" or "pure enantiomer" means that the compound contains more than 75%, more than 80%, more than 85%, more than 90%, more than 91%, more than 92%, more than 93%, more than 94%, more than 95%, more than 96%, more than 97%, more than 98%, more than 99%, more than 99.5%, or more than 99.9% by weight of the enantiomer. In certain embodiments, the weights are based on the total weight of all enantiomers or stereoisomers of the compound.

[0036] In the compositions provided herein, the enantiomerically pure compound may be present together with other active or inactive ingredients. For example, a pharmaceutical composition containing an enantiomerically pure R compound may contain, for example, about 90% excipients and about 10% enantiomerically pure R compound. In certain embodiments, the enantiomerically pure R compound in such a composition may contain, for example, at least about 95% by weight of the R compound and up to about 5% by weight of the S compound, based on the total weight of the compound. For example, a pharmaceutical composition containing an enantiomerically pure S compound may contain, for example, about 90% excipients and about 10% of the enantiomerically pure S compound. In certain embodiments, the enantiomerically pure S compound in such a composition may contain, for example, at least about 95% by weight of the S compound and up to about 5% by weight of the R compound, based on the total weight of the compound. In certain embodiments, the active ingredient may be formulated with little or no excipients or carriers.

[0037] As used herein, "isotopically enriched variants" refer to disclosed compounds having one or more isotopic substitutions, in which one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number normally occurring in nature. Examples of isotopes that can be incorporated into compounds of the present disclosure include:2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F, and 36 These include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as Cl. For example, hydrogen (H) is: 1 H, 2 H (D or deuterium), and 3 H (T or tritium) and carbon (C) can be in any isotopic form. 12 C. 13 C, and 14 C may be in any isotopic form, including oxygen (O) 16 O and 18 It may be in any isotopic form, including O, etc. For example, in the isotopically enriched variants disclosed herein, one or more hydrogen atoms may be replaced with deuterium.

[0038] The articles "a" and "an" may be used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an analogue" means one analogue or more than one analogue.

[0039] When a range of numerical values ​​is recited, it is intended that the range encompass each numerical value and subrange within the range. For example, "C1-C6 alkyl" is intended to include C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6 alkyl.

[0040] The following terms are intended to have the meanings indicated below and are helpful in understanding the description and intended scope of the present disclosure.

[0041] "Alkyl" means a radical of a linear or branched saturated hydrocarbon group having 1 to 20 carbon atoms ("C 1~20 Alkyl" or "C1-C 20 In some embodiments, an alkyl group has 1 to 12 carbon atoms ("C 1~12 Alkyl" or "C1-C 12 In some embodiments, the alkyl group has 1 to 8 carbon atoms ("C 1~8 In some embodiments, an alkyl group has 1 to 6 carbon atoms ("C alkyl" or "C 1~6 In some embodiments, an alkyl group has 1 to 5 carbon atoms ("C alkyl" or "C1-C6 alkyl"). 1~5 In some embodiments, an alkyl group has 1 to 4 carbon atoms ("C alkyl" or "C1-C5 alkyl"). 1~4 In some embodiments, an alkyl group has 1 to 3 carbon atoms ("C alkyl" or "C1-C4 alkyl"). 1~3 In some embodiments, an alkyl group has 1 to 2 carbon atoms ("C alkyl" or "C 1~2In some embodiments, an alkyl group has 1 carbon atom ("C1 alkyl"), and in some embodiments, an alkyl group has 2 to 6 carbon atoms ("C2-6 alkyl"). Examples of C1-C6 alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (C6). Further examples of alkyl groups include n-heptyl (C7), n-octyl (C8), and the like. Each instance of an alkyl group can be independently optionally substituted with one or more substituents, e.g., 1 to 5 substituents, 1 to 3 substituents, or 1 substituent, i.e., unsubstituted (an "unsubstituted alkyl") or substituted with the above substituents (a "substituted alkyl"). In certain embodiments, the alkyl group can be an unsubstituted C1 to C2 alkyl group. 10 Alkyl (e.g., -CH). In certain embodiments, the alkyl group is a substituted C1-6 alkyl. Common abbreviations for alkyl include Me(-CH3), Et(-CH2CH3), iPr(-CH(CH3)2), nPr(-CH2CH2CH3), n-Bu(-CH2CH2CH2CH3), or i-Bu(-CH2CH(CH3)2).

[0042] The term "alkylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from alkyl, for example, but not limited to, -CHCHCHCH-. Generally, an alkyl (or alkylene) group has from 1 to 24 carbon atoms, with alkyl (or alkylene) groups having 10 or fewer carbon atoms being preferred in this disclosure. The term "alkenylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene. An alkylene group may be described, for example, as a C1-C6 membered alkylene, where the term "membered" refers to a non-hydrogen atom in the moiety.

[0043] "Alkenyl" means a radical of a straight-chain or branched-chain hydrocarbon group having 2 to 20 carbon atoms, one or more carbon-carbon double bonds, and no triple bonds ("C 2~20 alkenyl" or "C2-C 20 In some embodiments, an alkenyl group has 2 to 10 carbon atoms ("C 2~10 alkenyl" or "C2-C 10 In some embodiments, the alkenyl group has 2 to 8 carbon atoms ("C 2~8 In some embodiments, an alkenyl group has 2 to 6 carbon atoms ("C alkenyl" or "C2-C8 alkenyl"). 2~6 In some embodiments, an alkenyl group has 2 to 5 carbon atoms ("C alkenyl" or "C2-C6 alkenyl"). 2~5 In some embodiments, the alkenyl group has 2 to 4 carbon atoms ("C alkenyl" or "C-C alkenyl"). 2~4 In some embodiments, the alkenyl group has 2 to 3 carbon atoms ("C alkenyl" or "C-C alkenyl"). 2~3In some embodiments, the alkenyl group has two carbon atoms ("C2 alkenyl"). The one or more carbon-carbon double bonds can be internal (e.g., 2-butenyl) or terminal (e.g., 1-butenyl). Examples of C2-C4 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-C6 alkenyl groups include the aforementioned C 2~4 Alkenyl groups include pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Further examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Each instance of an alkenyl group independently may be optionally substituted with one or more substituents, e.g., 1 to 5 substituents, 1 to 3 substituents, or 1 substituent, e.g., unsubstituted ("unsubstituted alkenyl") or substituted with the above-mentioned substituents ("substituted alkenyl"). In certain embodiments, the alkenyl group is an unsubstituted C 2~10 In certain embodiments, the alkenyl group is a substituted C 2~6 It is alkenyl.

[0044] "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a cyclic array) having 6 to 14 ring carbon atoms associated with said aromatic ring system and no heteroatoms ("C6-C 14 In some embodiments, an aryl group has 6 ring carbon atoms ("C aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C 10 Aryl"; e.g., naphthyl, such as 1-naphthyl and 2-naphthyl). In some embodiments, the aryl group has 14 ring carbon atoms ("C 14 Aryl"; for example, anthracyl). The aryl group is, for example, C6-C10 aryl, where the term "membered" refers to a non-hydrogen ring atom in the moiety. Aryl groups include, but are not limited to, phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Each instance of an aryl group may independently be optionally substituted with one or more substituents, e.g., unsubstituted ("unsubstituted aryl") or substituted ("substituted aryl") with the substituents described above. In certain embodiments, the aryl group is an unsubstituted C6-C 14 In certain embodiments, the aryl group is a substituted C-C 14 It is aryl.

[0045] In certain embodiments, the aryl group is substituted with one or more groups selected from halo, C1-C8 alkyl, halo-C1-C8 alkyl, halooxy-C1-C8 alkyl, cyano, hydroxy, alkoxy-C1-C8 alkyl, and amino.

[0046] Representative examples of substituted aryl are as follows: TIFF2026004380000040.tif19128, in which R 56 and R 57 may be hydrogen, and R 56 and R 57 At least one of the groups independently represents C1-C8 alkyl, halo-C1-C8 alkyl, 4- to 10-membered heterocyclyl, alkanoyl, alkoxy-C1-C8 alkyl, heteroaryloxy, alkylamino, arylamino, heteroarylamino, or NR 58 COR 59 , N.R. 58 SOR 59 , N.R. 58 SO2R 59 , C(O)O alkyl, C(O)O aryl, CONR 58 R 59 ,CONR 58 OR 59 , N.R. 58 R 59 , SO2NR 58 R 59, S-alkyl, S(O)-alkyl, S(O)2-alkyl, S-aryl, S(O)-aryl, S(O2)-aryl, or R 56 and R 57 may be linked to form a cyclic ring (saturated or unsaturated) of 5 to 8 atoms, optionally containing one or more heteroatom groups selected from the groups N, O, S, S(O), or S(O)2.

[0047] Other representative aryl groups having a fused heterocyclyl group include the following: TIFF2026004380000041.tif13128, wherein each W′ is C(R 66 )2, NR 66 , O, and S; each Y' is selected from carbonyl, NR 66 , O, and S; R 66 are independently hydrogen, C1-C8 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 aryl, and 5- to 10-membered heteroaryl.

[0048] The terms "arylene" and "heteroarylene," alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. Non-limiting examples of heteroaryl groups include pyridinyl, pyrimidinyl, thiophenyl, thienyl, furanyl, indolyl, benzoxadiazolyl, benzodioxolyl, benzodioxanyl, thianaphthalenyl, pyrrolopyridinyl, indazolyl, quinolinyl, quinoxalinyl, pyridopyrazinyl, quinazolinonyl, benzisoxazolyl, imidazopyridinyl, benzofuranyl, benzothienyl, benzothiophenyl, phenyl, naphthyl, biphenyl, and pyrrolopyridinyl. Examples of heteroaryl include aryl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furylthienyl, pyridyl, pyrimidyl, benzothiazolyl, purinyl, benzimidazolyl, isoquinolyl, thiadiazolyl, oxadiazolyl, pyrrolyl, diazolyl, triazolyl, tetrazolyl, benzothiadiazolyl, isothiazolyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, benzotriazolyl, benzoxazolyl, and quinolyl. The above examples may be substituted or unsubstituted, and the divalent radical of each of the above heteroaryl examples is a non-limiting example of heteroarylene.

[0049] "Halo" or "halogen," independently or as part of another substituent, means, unless otherwise stated, a fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) atom. The term "halide," by itself or as part of another substituent, refers to a fluoride, chloride, bromide, or iodide atom. In certain embodiments, the halo group is either fluorine or chlorine.

[0050] Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo-C1-C6 alkyl" includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0051] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, an acyclic, stable, straight or branched chain, or combination thereof, containing at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, wherein the nitrogen and sulfur atoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. The heteroatom(s) O, N, P, S, and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Exemplary heteroalkyl groups include, but are not limited to, -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -S(O)-CH3, -S(O)-CH3, -CH2-CH2-S(O)-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, -O-CH3, and O-CH2-CH3. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. The term "heteroalkyl" followed by -CHO-CH3, -NR B R C When specific heteroalkyl groups such as -CH2O-CH3 or -NR B R C It will be understood that the terms "heteroalkyl" and "heteroalkyl-" are not redundant or mutually exclusive. Rather, specific heteroalkyl groups are recited for clarity. Thus, as used herein, the term "heteroalkyl" refers to groups such as -CH2O-CH3, -NR B R C The term should not be construed as excluding specific heteroalkyl groups such as:

[0052] Similarly, the term "heteroalkylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, for example, but not limited to, -CHO- and -CHCHO-. A heteroalkylene group may be described, for example, as a 2- to 7-membered heteroalkylene, where the term "member" refers to a non-hydrogen atom within the moiety. For heteroalkylene groups, heteroatoms can occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). Furthermore, for alkylene and heteroalkylene linking groups, no directionality of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)R'- can represent both -C(O)R'- and -R'C(O)-.

[0053] "Heteroaryl" refers to a radical of a 5- to 10-membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic array) having ring carbon atoms and 1 to 4 heteroatoms, each heteroatom independently selected from nitrogen, oxygen, and sulfur ("5- to 10-membered heteroaryl"). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be at a carbon or nitrogen atom, valence permitting. Heteroaryl bicyclic ring systems may contain one or more heteroatoms in one or both rings. "Heteroaryl" also encompasses ring systems in which a heteroaryl ring, as defined above, is fused to one or more aryl groups, and the point of attachment is on either the aryl or heteroaryl ring; in such cases, the number of ring members refers to the number of ring members in the fused (aryl / heteroaryl) ring system. In bicyclic heteroaryl groups in which one ring does not contain heteroatoms (e.g., indolyl, quinolinyl, carbazolyl, etc.), the point of attachment can be on either ring, i.e., on the ring containing the heteroatom (e.g., 2-indolyl) or on the ring without the heteroatom (e.g., 5-indolyl). Heteroaryl groups may be described, for example, as 6- to 10-membered heteroaryl, where the term "member" refers to the non-hydrogen ring atoms in the moiety.

[0054] In some embodiments, a heteroaryl group is a 5- to 10-membered aromatic ring system having the given ring carbon atoms and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, oxygen, and sulfur ("5- to 10-membered heteroaryl"). In some embodiments, a heteroaryl group is a 5- to 8-membered aromatic ring system having the given ring carbon atoms and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, oxygen, and sulfur ("5- to 8-membered heteroaryl"). In some embodiments, a heteroaryl group is a 5- to 6-membered aromatic ring system having the given ring carbon atoms and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, oxygen, and sulfur ("5- to 6-membered heteroaryl"). In some embodiments, the 5- to 6-membered heteroaryl has 1 to 3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5- to 6-membered heteroaryl has 1 to 2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5- to 6-membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Each instance of a heteroaryl group independently may be optionally substituted with one or more substituents, i.e., unsubstituted ("unsubstituted heteroaryl") or substituted ("substituted heteroaryl") with the substituents described above. In certain embodiments, the heteroaryl group is an unsubstituted 5- to 14-membered heteroaryl. In certain embodiments, the heteroaryl group is a substituted 5- to 14-membered heteroaryl.

[0055] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0056] Representative examples of heteroaryls include those of the formula: TIFF2026004380000042.tif69128, wherein each Y is a carbonyl, N, NR 65 , O, and S; R 65are independently hydrogen, C1-C8 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 aryl, and 5- to 10-membered heteroaryl.

[0057] "Cycloalkyl" means a non-aromatic cyclic hydrocarbon group having 3 to 10 ring carbon atoms ("C3-C 10 "Cycloalkyl" refers to a radical of any of the above hydrocarbon groups that has no heteroatoms in the non-aromatic ring system. In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C3-C8 cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C3-C6 cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C3-C6 cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ("C5-C 10 Cycloalkyl groups may be described, for example, as C4-C7 membered cycloalkyl, where the term "membered" refers to a non-hydrogen ring atom in the moiety. Exemplary C3-C6 cycloalkyl groups include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3-C8 cycloalkyl groups include, but are not limited to, the C3-C6 cycloalkyl groups described above, as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), cubanyl (C8), bicyclo[1.1.1]pentanyl (C5), bicyclo[2.2.2]octanyl (C8), bicyclo[2.1.1]hexanyl (C6), bicyclo[3.1.1]heptanyl (C7), and the like. 10The cycloalkyl group includes, but is not limited to, the above-mentioned C3 to C8 cycloalkyl groups, as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10 As the examples above illustrate, in certain embodiments, the cycloalkyl group is either monocyclic ("monocyclic cycloalkyl") or includes fused, bridged, or spiro ring systems, such as bicyclic systems ("bicyclic cycloalkyl"), and may be saturated or partially unsaturated. "Cycloalkyl" also encompasses ring systems in which a cycloalkyl ring, as defined above, is fused to one or more aryl groups and the point of attachment is on the cycloalkyl ring; in such cases, the carbon number continues to refer to the carbon number of the cycloalkyl ring system. Each instance of a cycloalkyl group may independently be optionally substituted with one or more substituents, e.g., unsubstituted ("unsubstituted cycloalkyl") or substituted ("substituted cycloalkyl") with the substituents described above. In certain embodiments, the cycloalkyl group is an unsubstituted C3-C6 10 In certain embodiments, the cycloalkyl group is a substituted C3-C 10 It is cycloalkyl.

[0058] In some embodiments, "cycloalkyl" refers to a monocyclic saturated cycloalkyl group having 3 to 10 ring carbon atoms ("C 10 In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C3-C8 cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C3-C6 cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("C5-C6 cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ("C5-C 10Examples of C5-C6 cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C6). Examples of C3-C6 cycloalkyl groups include the C5-C6 cycloalkyl groups mentioned above as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-C8 cycloalkyl groups include the C3-C6 cycloalkyl groups mentioned above as well as cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an "unsubstituted cycloalkyl") or substituted with one or more substituents (a "substituted cycloalkyl"). In certain embodiments, the cycloalkyl group is an unsubstituted C3-C 10 In certain embodiments, the cycloalkyl group is a substituted C3-C 10 It is cycloalkyl.

[0059] "Heterocyclyl" or "heterocyclic" refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatom groups, each heteroatom group independently selected from nitrogen, oxygen, sulfur and oxidized forms of sulfur (e.g., S, S(O), and S(O)), boron, phosphorus, and silicon ("3- to 10-membered heterocyclyl"). In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment may be at a carbon or nitrogen atom, valence permitting. Heterocyclyl groups may be monocyclic ("monocyclic heterocyclyl") or fused, bridged, or spiro ring systems, such as bicyclic systems ("bicyclic heterocyclyl"), and may be saturated or partially unsaturated. Heterocyclyl bicyclic ring systems may contain one or more heteroatoms in one or both rings. "Heterocyclyl" also encompasses ring systems in which a heterocyclyl ring, as defined above, is fused to one or more cycloalkyl groups and the point of attachment is on either the cycloalkyl ring or the heterocyclyl ring, or in which a heterocyclyl ring, as defined above, is fused to one or more aryl or heteroaryl groups and the point of attachment is on the heterocyclyl ring; in such cases, the number of ring members continues to refer to the number of ring members in the heterocyclyl ring system. Heterocyclyl groups may be described, for example, as 3- to 7-membered heterocyclyls, where the term "members" refers to the non-hydrogen ring atoms in the moiety, i.e., carbon, nitrogen, oxygen, sulfur and oxidized forms of sulfur (e.g., S, S(O), and S(O)), boron, phosphorus, and silicon. Each instance of heterocyclyl may independently be optionally substituted with one or more substituents, e.g., unsubstituted ("unsubstituted heterocyclyl") or substituted ("substituted heterocyclyl") with the substituents described above. In certain embodiments, the heterocyclyl group is an unsubstituted 3- to 10-membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 3- to 10-membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 4- to 6-membered heterocyclyl.

[0060] In some embodiments, a heterocyclyl group is a 5- to 10-membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, each heteroatom being independently selected from nitrogen, oxygen, sulfur, and oxidized forms of sulfur (e.g., S, S(O), and S(O)2), boron, phosphorus, and silicon ("5- to 10-membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5- to 8-membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, each heteroatom being independently selected from nitrogen, oxygen, sulfur, and oxidized forms of sulfur (e.g., S, S(O), and S(O)2) ("5- to 8-membered heterocyclyl"). In some embodiments, the heterocyclyl group is a 5- to 6-membered non-aromatic ring system having ring carbon atoms and one to four ring heteroatom groups, each heteroatom group independently selected from nitrogen, oxygen, sulfur, and oxidized forms of sulfur (e.g., S, S(O), and S(O)2) ("5- to 6-membered heterocyclyl"). In some embodiments, the 5- to 6-membered heterocyclyl has one to three ring heteroatoms selected from nitrogen, oxygen, sulfur, and oxidized forms of sulfur (e.g., S, S(O), and S(O)2). In some embodiments, the 5- to 6-membered heterocyclyl has one to two ring heteroatoms selected from nitrogen, oxygen, sulfur, and oxidized forms of sulfur (e.g., S, S(O), and S(O)2). In some embodiments, the 5- to 6-membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, sulfur, and oxidized forms of sulfur (e.g., S, S(O), and S(O)2).

[0061] Exemplary 3-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azirdinyl, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, triazinanyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azocanyl, oxecanyl, and thiocanyl. Exemplary 5-membered heterocyclyl groups (also referred to herein as 5,6-bicyclic heterocyclic rings) fused to a C6 aryl ring include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, etc. Exemplary 6-membered heterocyclyl groups (also referred to herein as 6,6-bicyclic heterocyclic rings) fused to an aryl ring include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc.

[0062] Specific examples of heterocyclyl groups are illustrated below: TIFF2026004380000043.tif46128, where each W" is the CR 67 , C(R 67 )2, NR 67 , O, and S, and each Y is selected from NR 67 , O, and S; R 67 are independently hydrogen, C1-C8 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 and aryl and 5- to 10-membered heteroaryl. These heterocyclyl rings may be optionally substituted with one or more groups selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl (e.g., amido), aminocarbonylamino, aminosulfonyl, sulfonylamino, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, halogen, hydroxy, keto, nitro, thiol, -S-alkyl, -S-aryl, -S(O)-alkyl, -S(O)-aryl, -S(O)2-alkyl, and -S(O)2-aryl. Substituents include, for example, carbonyl or thiocarbonyl, which give lactam and urea derivatives.

[0063] A "nitrogen-containing heterocyclyl" group refers to a 4- to 7-membered non-aromatic cyclic group containing at least one nitrogen atom, including, but not limited to, morpholine, piperidine (e.g., 2-piperidinyl, 3-piperidinyl, and 4-piperidinyl), pyrrolidine (e.g., 2-pyrrolidinyl and 3-pyrrolidinyl), azetidine, pyrrolidone, imidazoline, imidazolidinone, 2-pyrazoline, pyrazolidine, piperazine, and N-alkylpiperazines such as N-methylpiperazine. Specific examples include azetidine, piperidone, and piperazone.

[0064] "Amino" means the radical -NR 70 R 71 wherein R70 and R 71 are each independently hydrogen, C1-C8 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C6-C 10 In some embodiments, amino refers to NH2.

[0065] "Cyano" refers to the radical --CN.

[0066] "Hydroxy" or "hydroxyl" refers to the radical --OH.

[0067] In some embodiments, one or more nitrogen atoms of the disclosed compounds, if present, are oxidized to the corresponding N-oxide.

[0068] Alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups defined herein are optionally substituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl, "substituted" or "unsubstituted" cycloalkyl, "substituted" or "unsubstituted" heterocyclyl, "substituted" or "unsubstituted" aryl, or "substituted" or "unsubstituted" heteroaryl group). In general, the term "substituted," whether preceded by the term "optionally," means that at least one hydrogen present on the group (e.g., a carbon or nitrogen atom) is replaced with an acceptable substituent, e.g., a substituent that, upon substitution, results in a stable compound, e.g., a compound that does not spontaneously change, such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise specified, a "substituted" group has a substituent at one or more substitutable positions of the group; when multiple positions in any given structure are substituted, the substituents are either the same or different at each position. The term "substituted" is intended to include substitution with all permissible substituents of organic compounds, including any substituents described herein, that result in the formation of stable compounds. The present disclosure contemplates any and all such combinations in order to arrive at stable compounds. For purposes of this disclosure, heteroatoms such as nitrogen may have hydrogen substituents and / or any and all suitable substituents described herein that satisfy the valence of the heteroatom and result in the formation of a stable moiety.

[0069] Two or more substituents may optionally be bonded to form an aryl, heteroaryl, cycloalkyl, or heterocyclyl group. Such so-called ring-forming substituents are typically, but not necessarily, attached to a cyclic base structure. In one embodiment, the ring-forming substituents are bonded to adjacent atoms of the base structure. For example, two ring-forming substituents attached to adjacent atoms of a cyclic base structure form a fused ring structure. In another embodiment, the ring-forming substituents are bonded to a single atom of the base structure. For example, two ring-forming substituents attached to a single atom of a cyclic base structure form a spiro ring structure. In yet another embodiment, the ring-forming substituents are bonded to non-adjacent atoms of the base structure.

[0070] A "counterion" or "anionic counterion" is a negatively charged group attached to a cationic quaternary amino group to maintain electronic neutrality. Exemplary counterions include halide ions (e.g., F - , Cl - , Br - , I - ), NO3 - , ClO4 - , O.H. - , H2PO4 - , HSO4 - , sulfonate ions (e.g., methanesulfonate ion, trifluoromethanesulfonate ion, p-toluenesulfonate ion, benzenesulfonate ion, 10-camphorsulfonate ion, naphthalene-2-sulfonate ion, naphthalene-1-sulfonic acid-5-sulfonate ion, ethane-1-sulfonic acid-2-sulfonate ion, etc.), and carboxylate ions (e.g., acetate ion, ethanoate ion, propanoate ion, benzoate ion, glycerate ion, lactate ion, tartrate ion, glycolate ion, etc.).

[0071] The term "pharmaceutically acceptable salt" is intended to include salts of the active compounds prepared using relatively non-toxic acids or bases, depending on the specific substituents present on the compounds described herein.When a compound of the present disclosure contains a relatively acidic functional group, a base addition salt can be obtained by contacting the neutral form of such a compound with a sufficient amount of the desired base, either neat or in an appropriate inert solvent.Examples of pharmaceutically acceptable base addition salts include sodium salts, potassium salts, calcium salts, ammonium salts, organic amino salts, or magnesium salts, or similar salts.When a compound of the present disclosure contains a relatively basic functional group, an acid addition salt can be obtained by contacting the neutral form of such a compound with a sufficient amount of the desired acid, either neat or in an appropriate inert solvent. Examples of pharmaceutically acceptable acid addition salts include acid addition salts derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphate, dihydrogenphosphate, sulfuric acid, monohydrogensulfuric acid, hydroiodic acid, or phosphorous acid, as well as salts derived from relatively non-toxic organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, methanesulfonic acid, etc. Also included are salts of amino acids such as alginate, and salts of organic acids such as glucuronic acid or galacturonic acid (see, for example, Berge et al., Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain compounds of the present disclosure contain both basic and acidic functional groups, which allow the compounds to be converted into either base or acid addition salts. Other pharmaceutically acceptable carriers known to those skilled in the art are suitable for this disclosure. Salts tend to be more soluble in aqueous or other protic solvents than the corresponding free base forms. In other cases, the formulation may be a lyophilized powder in a first buffer solution, e.g., 1 mM to 50 mM histidine, 0.1% to 2% sucrose, 2% to 7% mannitol, pH range 4.5 to 5.5, which is mixed with a second buffer solution prior to use.

[0072] Therefore, the compounds of the present disclosure may exist as salts, such as salts with pharmaceutically acceptable acids. The present disclosure includes such salts. Examples of such salts include hydrochloride, hydrobromide, sulfate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate (e.g., (+)-tartrate, (-)-tartrate, or a mixture thereof, including a racemic mixture), succinate, benzoate, and salts with amino acids such as glutamic acid. These salts can be prepared by methods known to those skilled in the art.

[0073] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent forms of the compounds differ from the various salt forms in certain physical properties, such as solubility in polar solvents.

[0074] In addition to salt forms, the present disclosure also provides compounds in prodrug form. Prodrugs of the compounds described herein are compounds that easily undergo chemical changes under physiological conditions to yield the compounds of the present disclosure. Furthermore, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present disclosure when placed in a transdermal patch reservoir with an appropriate enzyme or chemical reactant.

[0075] Certain compounds of the present disclosure may exist in solvated forms, including hydrated forms, as well as unsolvated forms. Generally, the solvated forms are equivalent to the unsolvated forms and are included within the scope of the present disclosure. Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. Generally, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.

[0076] As used herein, the term "salt" refers to an acid or base salt of a compound used in the method of the present disclosure. Illustrative examples of acceptable salts include mineral acid salts (such as hydrochloric acid, hydrobromic acid, phosphoric acid, etc.), organic acid salts (such as acetic acid, propionic acid, glutamic acid, citric acid, etc.), and quaternary ammonium salts (such as methyl iodide, ethyl iodide, etc.).

[0077] Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomers that can be specified in terms of absolute stereochemistry as (R)- or (S)-, or, for amino acids, as (D)- or (L)-, and individual isomers are encompassed within the scope of the present disclosure. The compounds of the present disclosure do not include compounds known in the art to be excessively unstable and therefore unable to be synthesized and / or isolated. The present disclosure is intended to encompass compounds in racemic and optically pure form. Optically active (R)- and (S)-, or (D)- and (L)-isomers can be prepared using chiral starting materials or chiral reactants, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, unless otherwise specified, the compounds are intended to encompass both E and Z geometric isomers.

[0078] As used herein, the term "isomers" refers to compounds that have the same number and kind of atoms, and hence the same molecular weight, but differ with respect to the structural arrangement or configuration of the atoms.

[0079] As used herein, the term "tautomer" refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another.

[0080] It will be apparent to one skilled in the art that certain compounds of the present disclosure may exist in tautomeric forms, and all such tautomeric forms of the compounds are within the scope of the present disclosure.

[0081] Other term definitions "Treating" or "treatment" includes preventing or delaying the onset of symptoms, complications, or biochemical manifestations of a disease, alleviating or ameliorating such symptoms, or preventing or inhibiting further development of a disease, condition, or disorder. "Treating" or "treatment" includes any effect that leads to the improvement of a condition, disease, disorder, or the like, e.g., attenuating, alleviating, modulating, or elimination. For example, certain methods herein treat cancer by reducing, alleviating, or preventing the onset, growth, metastasis, or progression of cancer, or by reducing the symptoms of cancer. The term "treatment" and its conjugations include prevention of an injury, condition, state, or disease (e.g., preventing the onset of one or more symptoms of a disease, disorder, or condition described herein).

[0082] An "effective amount" is an amount sufficient to achieve a stated purpose (e.g., achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, or alleviate one or more symptoms of a disease or condition). An example of an "effective amount" is an amount sufficient to contribute to the treatment, prevention, or alleviation of one or more symptoms of a disease, and this amount is also referred to as a "therapeutically effective amount." A "prophylactically effective amount" of a drug is an amount of drug that, when administered to a subject, will exhibit the intended prophylactic effect, such as preventing or delaying the onset (or recurrence) of an injury, disease, condition, or pathology, or reducing the likelihood of the onset (or recurrence) of an injury, disease, condition, or pathology, or a symptom thereof. A complete prophylactic effect does not necessarily occur with a single administration, but may occur only after a series of administrations. Thus, a prophylactically effective amount may be administered in one or more administrations. The precise amount will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

[0083] "Alleviation" (and grammatical equivalents of this phrase) of one or more symptoms means a decrease in the severity or frequency of the symptom(s) or the elimination of said symptom(s).

[0084] "Control" or "control experiment" is used according to its plain and ordinary meaning to refer to an experiment in which the experimental subjects or agents are treated as in a parallel experiment, except for the omission of an experimental procedure, agent, or variable. In some cases, the control is used as a standard of comparison in evaluating the effectiveness of the experiment.

[0085] "Contacting" is used according to its plain and ordinary meaning to refer to the process of bringing at least two different species (e.g., compounds, including biomolecules or cells) into sufficient proximity to react, interact, or come into physical contact. However, it should be understood that the resulting reaction product may be generated directly from the reaction between the added reactants or from an intermediate derived from one or more added reactants that may be generated in the reaction mixture. The term "contacting" may encompass reacting, interacting, or physically contacting two species, where the two species may be a compound described herein and a protein or enzyme, e.g., a protein tyrosine phosphatase, e.g., non-receptor type 2 protein tyrosine phosphatase (PTPN2) or non-receptor type 1 protein tyrosine phosphatase (PTP1B).

[0086] As defined herein, the terms "inhibition," "inhibit," "inhibiting," and the like, in reference to protein-inhibitor (e.g., antagonist) interaction, refer to negatively affecting (e.g., decreasing) the activity or function of a protein compared to the activity or function of the protein in the absence of the inhibitor. In some embodiments, inhibition refers to the alleviation of a disease or disease symptom. In some embodiments, inhibition refers to the reduction of the activity of a signal transduction pathway or signaling pathway. Thus, inhibition includes at least partially, partially, or completely blocking a stimulus, reducing, preventing, or delaying activation, or inactivating, desensitizing, or downregulating signal transduction or enzymatic activity or the amount of a protein. In some embodiments, inhibition refers to the reduction of the activity of a protein tyrosine phosphatase, e.g., non-receptor type 2 protein tyrosine phosphatase (PTPN2) or non-receptor type 1 protein tyrosine phosphatase (PTP1B). Thus, inhibiting may include at least partially, partially, or completely reducing stimulation, reducing or decreasing activation, or inactivating, desensitizing, or downregulating signaling or enzymatic activity or the amount of a protein tyrosine phosphatase, e.g., non-receptor type 2 protein tyrosine phosphatase (PTPN2) or non-receptor type 1 protein tyrosine phosphatase (PTP1B).

[0087] A "patient" or "subject" in need thereof refers to an organism suffering from or susceptible to a disease or condition that can be treated by administration of a compound or pharmaceutical composition provided herein. Non-limiting examples include humans, other mammals, bovine animals, rats, mice, dogs, monkeys, goats, sheep, cows, deer, and other non-mammals. In some embodiments, the patient is a human. In some embodiments, the patient is a domestic animal. In some embodiments, the patient is a dog. In some embodiments, the patient is a parrot. In some embodiments, the patient is a livestock animal. In some embodiments, the patient is a mammal. In some embodiments, the patient is a cat. In some embodiments, the patient is a horse. In some embodiments, the patient is a bovine animal. In some embodiments, the patient is a canine animal. In some embodiments, the patient is a feline animal. In some embodiments, the patient is an ape. In some embodiments, the patient is a monkey. In some embodiments, the patient is a mouse. In some embodiments, the patient is a laboratory animal. In some embodiments, the patient is a rat. In some embodiments, the patient is a hamster. In some embodiments, the patient is a test animal. In some embodiments, the patient is a newborn animal. In some embodiments, the patient is a human neonate. In some embodiments, the patient is a newborn mammal. In some embodiments, the patient is an elderly animal. In some embodiments, the patient is an elderly human. In some embodiments, the patient is an elderly mammal. In some embodiments, the patient is a geriatric patient.

[0088] A "disease," "disorder," or "condition" refers to a physical condition or state of health of a patient or subject that can be treated with the compounds, pharmaceutical compositions, or methods provided herein. In some embodiments, the compounds and methods described herein include the reduction or elimination of one or more symptoms of the disease, disorder, or condition, e.g., by administration of a compound disclosed herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0089] As used herein, the term "signal transduction pathway" refers to a series of interactions between cellular and optionally extracellular components (e.g., proteins, nucleic acids, small molecules, ions, lipids) that transmit a change in one component to one or more other components, which in turn may transmit the change to additional components, which are optionally propagated to components of other signal transduction pathways.

[0090] "Pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to substances that aid in the administration and absorption of an active agent by a subject and can be included in the compositions of the present disclosure without causing significant adverse toxicological effects to the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline, lactated Ringer's solution, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coating agents, sweeteners, flavorings, salt solutions (such as Ringer's solution), alcohols, oils, gelatin, carbohydrates such as lactose, amylose, or starch, fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidine, and coloring agents. Such formulations may be sterilized and, if necessary, mixed with auxiliary substances such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring agents, and / or flavoring agents that do not adversely react with the compounds of the present disclosure. Those of skill in the art will recognize that other pharmaceutical excipients are useful in the present disclosure.

[0091] The term "formulation" is intended to encompass formulations of active compounds with an encapsulating material as a carrier, providing a capsule, in which the active ingredient is surrounded by a carrier, with or without other carriers, thus uniting the carrier with the active ingredient. Cachets and lozenges are also encompassed. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0092] As used herein, the term "administering" refers to oral administration, administration as a suppository, topical contact, intravenous administration, parenteral administration, intraperitoneal administration, intramuscular administration, intralesional administration, intrathecal administration, intracranial administration, intranasal administration, or subcutaneous administration, or implantation of a sustained-release device, such as a mini-osmotic pump, into a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, and the like. "Co-administering" means that a compound or composition described herein is administered simultaneously with, immediately before, or immediately after the administration of one or more additional therapeutic agents (e.g., anti-cancer, chemotherapeutic, or immunotherapeutic agents). The compounds or compositions described herein can be administered to patients alone or simultaneously. Simultaneous administration is intended to include simultaneous or sequential administration of the compounds or compositions individually or in combination (multiple compounds or drugs). Thus, the above formulations can also be combined with other active substances (e.g., to reduce metabolic degradation) if desired.

[0093] As used herein, the term "PTPN2" refers to non-receptor type 2 protein tyrosine phosphatase. The term "PTPN1" refers to non-receptor type 1 protein tyrosine phosphatase (PTPN1), also known as protein tyrosine phosphatase-1B (PTP1B).

[0094] compound Disclosed herein, for example, are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof: TIFF2026004380000044.tif30128 formula, R 1 is hydrogen, halogen, C 1~6 Alkyl, C 3~6 Cycloalkyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, and -C 1~6 alkylene-5-6 membered heterocyclyl, wherein C 1~6 Alkyl, C 3~6 Cycloalkyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, and -C 1~6 The alkylene-5- to 6-membered heterocyclyl may optionally be substituted with R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6 When the alkylene-5- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by R 2 is hydrogen, halogen, hydroxyl, -CHF2, -CH2OH, -CH2CN, -CH2-OC 1~6 Alkyl, -CH2-N(R a )-C 1~6 Alkyl, C 2~6 Alkyl, C 2~6 Alkenyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, -OC(O)-N(R a )-C 1~6Alkyl, -N(R a )-C(O)-OC 1~6 Alkyl, -C 3~6 Cycloalkyl, -OC 3~6 Cycloalkyl, C 1~6 Alkylene-C 3~6 Cycloalkyl, -C 1~6 Alkenylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, -OC 1~6 alkylene-5-6 membered heteroaryl, -O-4-6 membered heterocyclyl, -N(R a )-4 to 6-membered heterocyclyl, -C 1~6 Alkylene-4 to 6-membered heterocyclyl, and -OC 1~6 alkylene-4 to 6 membered heterocyclyl, wherein -CH2-OC 1~6 Alkyl, -CH2-N(R a )-C 1~6 Alkyl, C 2~6 Alkyl, C 2~6 Alkenyl, -OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, -OC(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-OC 1~6 Alkyl, -C 3~6 Cycloalkyl, -OC 3~6 Cycloalkyl, -C 1~6 Alkylene-C 3~6 Cycloalkyl, -C 1~6 Alkenylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, 5-6 membered heteroaryl, -OC1~6 alkylene-5-6 membered heteroaryl, 4-6 membered heterocyclyl, -O-4-6 membered heterocyclyl, -N(R a )-4 to 6-membered heterocyclyl, -C 1~6 Alkylene-4 to 6-membered heterocyclyl, and -OC 1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and may be substituted by one, two, three or more substituents selected from 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, -N(R a )-4 to 6-membered heterocyclyl, -C 1~6 Alkylene-4 to 6-membered heterocyclyl, or -OC 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by Or, R 1 and R 2 together with the atom to which they are attached form a 5-6 membered aryl or heteroaryl, wherein the aryl or heteroaryl is optionally selected from halogen, hydroxyl, cyano, C 1~6 Alkyl, and C 1~6 and optionally substituted by one or more substituents each independently selected from the group consisting of alkoxy, wherein C 1~6 Alkyl and C 1~6 The alkoxy is optionally independently selected from R p and optionally substituted by one, two, three or more substituents selected from R 3 is hydrogen, halogen, hydroxyl, -NH2, -C 1~6 Alkyl, -OC 1~6 Alkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-N(R a )-C(O)-OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -N(Ra )-C 1~6 Alkylene-C 3~6 Cycloalkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, and -C 1~6 alkylene-4 to 6 membered heterocyclyl, wherein -C 1~6 Alkyl, -OC 1~6 Alkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-N(R a )-C(O)-OC 1~6 Alkyl, -N(R a )-C 1~6 Alkyl, -N(R a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, -S(O) w -C 1~6 Alkyl, -C(O)-N(R a )-C 1~6 Alkyl, -N(R a )-C(O)-C 1~6 Alkyl, and -C 1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by R 4 is hydrogen, halogen, C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6 alkylene-4 to 6 membered heterocyclyl, wherein C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by where R 1 , R 2 , R 3 , and R 4 At least one of them is not hydrogen, R 5 is hydrogen, halogen, C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6 alkylene-4 to 6 membered heterocyclyl, wherein C 1~6 Alkyl, C 3~6 Cycloalkyl, and -C 1~6 The alkylene-4- to 6-membered heterocyclyl may optionally be independently R on one or more available carbons. g and optionally substituted by one, two, three or more substituents selected from -C 1~6 When alkylene-4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R h and optionally substituted by R 6 is hydrogen, R 7 is hydrogen, R g is, for each occurrence, independently hydrogen, halogen, hydroxyl, cyano, nitro, oxo, -C(O)OH, R a R b N-, R a R b NC(O)-, R a R b N-SO w -, R a R b NC(O)-N(R a )-, C 1~6Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~6 Cycloalkyl, phenyl, C 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -(CO)-(NR a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, C 1~6 Alkoxy, C 3~6 Alkenyloxy, C 3~6 Alkynyloxy, C 3~6 Cycloalkoxy, C 1~6 Alkyl-C(O)-, C 1~6 Alkyl-OC(O)-, C 1~6 Alkyl-C(O)-O-, C 1~6 Alkyl-S(O) w -, C 1~6 Alkyl-N(R a )-, C 1~6 Alkyl-N(R a )-C(O)-, C 1~6 Alkyl-C(O)-N(R a ), C 1~6 Alkyl-N(R a )-C(O)-N(R a )-, C 1~6 Alkyl-N(R a )-SO w -, C 3~6 Cycloalkyl-N(R a )-SO w -, C 1~6 Alkyl-SO w -N(R a )-, C 3~6 Cycloalkyl-SO w -N(R a )-, 4-6 membered heterocyclyl-SO w -N(R a )-, C 1~6 Alkoxy-C(O)-N(R a )-, C 1~6 Alkyl-C(O)-N(R a )-C 1~6 Alkyl-, C1~6 Alkyl-N(R a )-C(O)-C 1~6 Alkyl-, -P(O)(C 1~3 alkyl)2, and C 1~6 Alkoxy-C 1~6 alkyl-, wherein C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~6 Cycloalkyl, phenyl, C 1~6 Alkylene-C 3~6 Cycloalkyl, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -(CO)-(NR a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, C 1~6 Alkoxy, C 3~6 Alkenyloxy, C 3~6 Alkynyloxy, C 3~6 Cycloalkoxy, C 1~6 Alkyl-C(O)-, C 1~6 Alkyl-OC(O)-, C 1~6 Alkyl-C(O)-O-, C 1~6 Alkyl-S(O) w -, C 1~6 Alkyl-N(R a )-, C 1~6 Alkyl-N(R a )-C(O)-, C 1~6 Alkyl-C(O)-N(R a ), C 1~6 Alkyl-N(R a )-C(O)-N(R a )-, C 1~6 Alkyl-N(R a )-SO w -, C 3~6 Cycloalkyl-N(R a )-SO w -, C 1~6 Alkyl-SO w -N(R a )-, C 3~6 Cycloalkyl-SO w -N(R a)-, 4-6 membered heterocyclyl-SO w -N(R a )-, C 1~6 Alkoxy-C(O)-N(R a )-, C 1~6 Alkyl-C(O)-N(R a )-C 1~6 Alkyl-, C 1~6 Alkyl-N(R a )-C(O)-C 1~6 Alkyl-, -P(O)(C 1~3 alkyl)2, and C 1~6 Alkoxy-C 1~6 alkyl- is optionally independently R p and optionally substituted by one, two, three or more substituents selected from or two R on adjacent atoms g together with the atom to which they are attached form a 5- to 6-membered aryl or heteroaryl; R h For each occurrence, independently, C 1~6 Alkyl, C 3~6 Alkenyl, C 3~6 Alkynyl, C 3~6 Cycloalkyl, -C 1~6 Alkyl-C 3~6 Cycloalkyl, C 1~6 Alkyl-S(O)2-, C 3~6 Cycloalkyl-S(O)2-, 4- to 6-membered heterocyclyl-S(O)2-, 4- to 6-membered heterocyclyl-C 1~6 Alkyl-S(O)2-, 5-6 membered heteroaryl-S(O)2-, phenyl-S(O)2-, phenyl-C 1~6 Alkyl-S(O)2-, C 1~6 Alkyl-C(O)-, C 1~6 Cycloalkyl-C(O)-, C 1~6 Alkoxy-C(O)-, R a R b NC(O)-, R a R b N-SO2- and -P(O)(C 1~3 alkyl)2, wherein C 1~6 Alkyl, C3~6 Alkenyl, C 3~6 Alkynyl, C 3~6 Cycloalkyl, -C 1~6 Alkyl-C 3~6 Cycloalkyl, C 1~6 Alkyl-S(O)2-, C 3~6 Cycloalkyl-S(O)2-, 4- to 6-membered heterocyclyl-S(O)2-, 4- to 6-membered heterocyclyl-C 1~6 Alkyl-S(O)2-, 5-6 membered heteroaryl-S(O)2-, phenyl-S(O)2-, phenyl-C 1~6 Alkyl-S(O)2-, C 1~6 Alkyl-C(O)-, C 1~6 Cycloalkyl-C(O)-, C 1~6 Alkoxy-C(O)-, R a R b NC(O)-, R a R b N-SO2- and -P(O)(C 1~3 alkyl)2 optionally each independently represent R p and optionally substituted by one, two, three or more substituents selected from R p is, for each occurrence independently, halogen, hydroxyl, cyano, C 1~6 Alkyl, C 1~6 Alkoxy, C 3~6 Cycloalkyl, 4-6 membered heterocyclyl, R a R b N-, R a R b N-carbonyl-, R a R b N-SO2- and R a R b N-carbonyl-N(R a )-, R a and R b are, for each occurrence, independently, hydrogen, C 1~6 Alkyl, and C 3~6 cycloalkyl, wherein C 1~6 The alkyl is optionally selected from halogen, cyano, oxo, hydroxyl, and C1~6 alkoxy (optionally substituted with 1, 2, or 3 fluorine atoms); Or, R a and R b together with the nitrogen to which they are attached form a 4- to 6-membered heterocyclyl, wherein the heterocyclyl is optionally substituted by one or more substituents each independently selected from the group consisting of halogen, cyano, oxo, and hydroxyl; w is 0, 1, or 2.

[0095] In some embodiments, one, two, three, or more hydrogen atoms of the compound or pharmaceutically acceptable salt thereof may optionally be deuterium atoms, and all other atoms of the compound are present in their naturally occurring isotopic abundance. For example, in some embodiments, one, two, three, or more hydrogen atoms are optionally each independently selected from R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , and R g may be deuterium atoms in one, two, three or more groups selected from:

[0096] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 1 is, for example, selected from the group consisting of hydrogen, deuterium, chlorine, and fluorine.

[0097] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2 is a 4- to 6-membered heterocyclyl, where R 2 optionally, on one or more available carbons, each independently R g and when the 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted by one, two, or three substituents selected from Rh For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from 2 is a 4- to 6-membered heterocyclyl, where R 2 optionally, on one or more available carbons, hydrogen and C 1~6 alkyl; R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally selected from hydrogen, C 1~6 alkyl (optionally substituted with 1, 2, or 3 fluorine atoms), -C 1~6 Alkyl-C 3~6 Cycloalkyl, C 1~6 Cycloalkyl-C(O)-, C 1~6 Alkyl-S(O)2- (optionally cyano, methoxy, hydroxyl, -NR a R b or substituted by 1, 2, or 3 fluorine atoms), C 3~6 Cycloalkyl-S(O)2-, 4- to 6-membered heterocyclyl-S(O)2-, 4- to 6-membered heterocyclyl-C 1~6 Alkyl-S(O)2-, 5-6 membered heteroaryl-S(O)2-, phenyl-S(O)2-, phenyl-C 1~6 Alkyl-S(O)2- (optionally R a R b -P(O)(C 1~3 For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from the group consisting of: 2 For example, TIFF2026004380000045.tif150162TIFF2026004380000046.tif165152.

[0098] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2 is a 5-6 membered heteroaryl, where R2 optionally, on one or more available carbons, each independently R g and R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be replaced by R h For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from 2 is a 5-6 membered heteroaryl, where R 2 optionally, on one or more available carbons, hydrogen, cyano, C 1~6 Alkyl, C 1~6 Alkoxy, and -P(O)(C 1~3 and R is optionally substituted by 1, 2, or 3 substituents independently selected from the group consisting of: 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be hydrogen, -C 1~6 Alkyl-C 3~6 Cycloalkyl, and C 3~6 For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is optionally substituted with a substituent selected from the group consisting of cycloalkyl-S(O)-. 2 For example, TIFF2026004380000047.tif53154.

[0099] In a further embodiment, R of the above compound or a pharmaceutically acceptable salt thereof 2 Ha-OC 1~6 alkylene-4 to 6-membered heterocyclyl, where R 2 optionally, on one or more available carbons, each independently R g and optionally substituted by 1, 2, or 3 substituents selected from two R on adjacent atoms. g together with the atom to which they are attached form a 5- to 6-membered aryl or heteroaryl), R 2When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be replaced by R h For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from 2 Ha-OC 1~6 alkylene-4 to 6-membered heterocyclyl, where R 2 optionally, on one or more available carbons, hydrogen, halogen, hydroxyl, and C 1~6 alkyl (optionally substituted with 1, 2, or 3 fluorine atoms), and optionally R 2 The heterocycle of R may be substituted on two adjacent atoms, and the two substituents together with the atoms to which they are attached form a fused phenyl; 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally selected from hydrogen, C 1~6 Alkyl, and C 1~6 For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from the group consisting of alkyl-S(O)-. 2 For example, TIFF2026004380000048.tif121160.

[0100] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2 Ha-OC 1~6 For example, in some embodiments, R of the following compound or a pharmaceutically acceptable salt thereof is: 2 For example, TIFF2026004380000049.tif21130.

[0101] In a further embodiment, R of the above compound or a pharmaceutically acceptable salt thereof 2 Ha-C 2~6 Alkyl, C 2~6Alkenyl, and C 3~6 cycloalkyl, wherein R 2 are optionally each independently R g For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with one, two, three, or more substituents selected from 2 -C 2~6 Alkyl, C 2~6 Alkenyl, C 3~6 Cycloalkyl, -C 1~6 Alkylene-C 3~6 Cycloalkyl, and -C 1~6 Alkenylene-C 3~6 cycloalkyl, wherein R 2 is optionally cyano, chlorine, fluorine, hydroxyl, C 1~6 Alkoxy, phenyl, and R a R b For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is optionally substituted with one, two, three, or more substituents each independently selected from the group consisting of: 2 For example, TIFF2026004380000050.tif84158.

[0102] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2 Ha-OC 1~6 alkyl, where R 2 are optionally each independently R g For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with one, two, three, or more substituents selected from 2 -OC 1~6 alkyl, where R 2 is optionally cyano, deuterium, chlorine, fluorine, hydroxyl, oxo, C 1~6 Alkoxy (optionally substituted by 1, 2, or 3 fluorine atoms), C3~6 Cycloalkoxy, -OC 1~6 Alkylene-C 3~6 Cycloalkyl, -(CO)-(NR a )-C 1~6 Alkylene-C 3~6 Cycloalkyl, C 1~6 Alkyl-OC(O)-, R a R b N-(where R b is optionally substituted by -OCH3 or -OCF3), C 1~6 Alkyl-N(R a )-(where C 1~6 alkyl optionally substituted with fluoro, cyano, or -OCH3), R a R b NC(O)-, -P(O)(C 1~3 Alkyl)2, C 1~6 Alkyl-N(R a )-C(O)-, C 1~6 Alkyl-N(R a )-C(O)-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, C 3~6 Cycloalkyl-SO2-N(R a )-, and 4- to 6-membered heterocyclyl-SO2-N(R a )-. For example, in some embodiments, R 2 For example, TIFF2026004380000051.tif53154TIFF2026004380000052.tif226160.

[0103] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2 Ha-OC 3~6 cycloalkyl or -O-4 to 6-membered heterocyclyl, where R 2When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be replaced by R h For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from 2 Ha-OC 3~6 cycloalkyl or -O-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be C 1~6 Alkyl-SO2-N(R a )- and C 3~6 Cycloalkyl-SO2-N(R a For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from the group consisting of: 2 For example, TIFF2026004380000053.tif20128.

[0104] In still further embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is 2 -N(R a )-C 1~6 alkyl, where R 2 are optionally each independently R g For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with 1, 2, or 3 substituents selected from 2 -N(R a )-C 1~6 alkyl, where R 2 is optionally fluoro, —C(O)OH, cyano, oxo, R a R b N-, C 1~6 Alkoxy, phenyl, -C 3~6 Cycloalkyl, C 3~6 Cycloalkyl-SO2-N(R a )-, and -(CO)-(NR a )-C 1~6 Alkylene-C 3~6For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is optionally substituted by 1, 2, or 3 substituents each independently selected from the group consisting of: cycloalkyl; 2 For example, TIFF2026004380000054.tif73164.

[0105] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2 Ha-OC 1~6 Alkylene-C 3~6 cycloalkyl, where R 2 are optionally each independently R g For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with 1, 2, or 3 substituents selected from 2 Ha-OC 1~6 Alkylene-C 3~6 cycloalkyl, where R 2 is optionally fluoro, hydroxyl, R a R b N-, cyano, and C 1~3 and optionally substituted by 1, 2, or 3 substituents each independently selected from the group consisting of alkyl, wherein C 1~3 The alkyl may optionally be hydroxyl, R a R b N-, cyano, and C 1~3 For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from the group consisting of alkoxy. 2 For example, TIFF2026004380000055.tif92163.

[0106] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2 -OC(O)-N(R a )-C 1~6For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is alkyl. 2 For example, Represented by TIFF2026004380000056.tif14128.

[0107] In a further embodiment, R of the above compound or a pharmaceutically acceptable salt thereof 2 -N(R a )-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be replaced by R h For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from 2 -N(R a )-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be C 1~6 Alkyl-SO2-N(R a )- and C 3~6 Cycloalkyl-SO2-N(R a For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from the group consisting of: 2 For example, TIFF2026004380000057.tif30128.

[0108] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2 Ha-C 1~6 alkylene-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be replaced by R h For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof may be substituted with a substituent selected from 2 Ha-C 1~6alkylene-4 to 6-membered heterocyclyl, where R 2 When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be C 1~6 Alkyl, C 1~6 Alkyl-SO2-N(R a )-, and C 3~6 Cycloalkyl-SO2-N(R a )-, wherein C 1~6 The alkyl may be optionally substituted with 1, 2, or 3 fluorine atoms. For example, in some embodiments, R 2 For example, TIFF2026004380000058.tif51134.

[0109] In some embodiments, R 2 For example, R of the above compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of: 2 is.

[0110] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2 is halogen. For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2 is, for example, selected from the group consisting of fluoro, chloro, and bromo. For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is 2 is bromo.

[0111] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 1 and R 2 together with the atom to which they are attached form a 5-membered heteroaryl. For example, in some embodiments, R 1 and R 2together with the atom to which they are attached form, for example, furanyl. For example, in some embodiments, the compound of formula (I) is Represented by TIFF2026004380000060.tif29128.

[0112] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 3 In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is hydrogen. 3 is selected from the group consisting of OH and —NH. In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is 3 -N(R a )-C 1~6 alkyl, where -N(R a )-C 1~6 The alkyl may be optionally substituted with one, two, or three substituents, each independently selected from the group consisting of fluoro and hydroxyl. For example, in some embodiments, R 3 teeth, TIFF2026004380000061.tif14128.

[0113] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 3 Ha-(NR a )-C 1~6 Alkylene-C 3~6 cycloalkyl, where —(NR a )-C 1~6 Alkylene-C 3~6 Cycloalkyl can be optionally substituted with one, two, or three substituents, each independently selected from the group consisting of fluoro and hydroxyl. For example, in some embodiments, R 3 teeth Represented by TIFF2026004380000062.tif10128.

[0114] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 3 Ha-OC 1~6 alkyl, where -OC 1~6 The alkyl optionally contains fluorine, hydroxyl, and R a R b For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is optionally substituted with one, two, three, or more substituents each independently selected from the group consisting of N-, ... 3 teeth, TIFF2026004380000063.tif14142.

[0115] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 3 Ha-OC 1~6 Alkylene-C 3~6 cycloalkyl, where -OC 1~6 Alkylene-C 3~6 Cycloalkyl can be optionally substituted with one, two, or three substituents, each independently selected from the group consisting of fluoro and hydroxyl. For example, in some embodiments, R 3 teeth The file is TIFF2026004380000064.tif11128.

[0116] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 3 Ha-OC 1~6 Alkylene-N(R a )-C(O)-OC 1~6 For example, in some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is alkyl. 3 teeth The file is TIFF2026004380000065.tif14128.

[0117] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 4 In a further embodiment, R of the above compound or a pharmaceutically acceptable salt thereof is hydrogen. 5 is selected from the group consisting of hydrogen, deuterium, bromine, chlorine, and fluorine. In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is 6 is selected from the group consisting of hydrogen and deuterium. In further embodiments, R of the above compound or a pharmaceutically acceptable salt thereof is 7 is selected from the group consisting of hydrogen and deuterium. In some embodiments, all atoms of a compound of Formula (I) or a pharmaceutically acceptable salt thereof are present in their naturally occurring isotopic abundance.

[0118] Also disclosed herein are compounds represented by formula (IIa) or a pharmaceutically acceptable salt thereof: TIFF2026004380000066.tif30128 formula, X is -O- and -N(R a )-, L is a linear or branched C 1~8 alkylene, where C 1~8 The alkylene is optionally substituted with one or more hydroxyl or one or more fluoro; R 2-IIa is hydrogen, cyano, -NR a R b , C 1~2 Alkoxy, C 3~6 Cycloalkyl-SO2-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 cycloalkyl, wherein C 1~2 Alkoxy, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR aR b , C 1~2 alkyl (optionally, -NR a R b , hydroxyl, or 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 optionally substituted by alkyl, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 Alkyl (optionally containing one or more halogens, cyano, or C 1~2 substituted by alkoxy).

[0119] In some embodiments, X of the above compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of -O-, -N(H)-, and -N(CH3)-.

[0120] In other embodiments, L of the above compound or a pharmaceutically acceptable salt thereof is TIFF2026004380000067.tif50161 (where * and # represent R 2-II and represents the point of covalent attachment to X).

[0121] In a further embodiment, R of the above compound or a pharmaceutically acceptable salt thereof 2-IIis hydrogen, cyano, -NH2, -N(CH3)2, -N(H)CH2CF3, -N(CH3)(CH2CH3), -N(CH3)(CH2CH2OCH3), -N(CH3)(CH2CH2CN), -OCH3, -OCF3, TIFF2026004380000068.tif78161.

[0122] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 5 is selected from the group consisting of hydrogen, deuterium, and fluorine.

[0123] Also disclosed herein is a compound represented by formula (IIb) or a pharmaceutically acceptable salt thereof: TIFF2026004380000069.tif30128 formula, X is -O- and -N(R a )-, L is a linear or branched C 1~6 is alkylene, R 2-IIb is hydrogen, cyano, -NR a R b , C 1~2 Alkoxy, C 3~6 Cycloalkyl-SO2-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 cycloalkyl, wherein phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 optionally substituted by alkyl, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl.

[0124] In some embodiments, X of the above compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of -O-, -N(H)-, and -N(CH3)-.

[0125] In other embodiments, L of the above compound or a pharmaceutically acceptable salt thereof is TIFF2026004380000070.tif26148 (where * and # represent R 2-II and represents the point of covalent attachment to X).

[0126] In a further embodiment, R of the above compound or a pharmaceutically acceptable salt thereof 2-II is hydrogen, cyano, -NH2, -N(CH3)2, -OCH3, TIFF2026004380000071.tif45158.

[0127] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 5 is selected from the group consisting of hydrogen, deuterium, and fluorine.

[0128] Also disclosed herein are compounds represented by formula (III) or a pharmaceutically acceptable salt thereof: TIFF2026004380000072.tif30128 formula, X III is a bond, -CH2-, -NR a selected from the group consisting of -, -O-, -O-CH2-, and -OCH2-CH2-; m is 1, 2, or 3; n is 1, 2, or 3; R 1-III represents hydrogen, halogen, hydroxyl, cyano, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2 alkoxy (optionally substituted with 1, 2, or 3 halogens); R 2-III is hydrogen, C 1~4 Alkyl, -C(O)-C 1~4 Alkyl, -C(O)-OC 1~4 Alkyl, -C(O)-N(R a )-C 1~4 Alkyl, -S(O)2-C 1~4 Alkyl, and -S(O)2-C 3~6 cycloalkyl, wherein C 1~4 Alkyl, -C(O)-C 1~4 Alkyl, -C(O)-OC 1~4 Alkyl, -C(O)-N(R a )-C 1~4 Alkyl, -S(O)2-C 1~4 Alkyl, and -S(O)2-C 3~6 Cycloalkyl is optionally substituted with halogen, hydroxyl, cyano, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2alkoxy (optionally substituted with 1, 2, or 3 halogens); R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl.

[0129] In some embodiments, X of the above compound or a pharmaceutically acceptable salt thereof III is selected from the group consisting of a bond, —CH2—, —O—, —NH—, and —O—CH2—.

[0130] In other embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2-III is selected from the group consisting of hydrogen, isopropyl, —CH2CF3, —S(O)2—CH3, and —S(O)2-cyclopropyl.

[0131] In a further embodiment, R of the above compound or a pharmaceutically acceptable salt thereof 5 is selected from the group consisting of hydrogen, deuterium, and fluorine.

[0132] Further disclosed herein is a compound represented by formula (IV) or a pharmaceutically acceptable salt thereof: TIFF2026004380000073.tif31128 formula, X III -O- and -N(R a )-, L III is a linear or branched chain C 1~6 alkylene, where C 1~6The alkylene is optionally substituted with hydroxyl or fluoro; R 3-III is hydrogen, -NR a R b , -N(R a )-C(O)-OC 1~6 Alkyl, hydroxyl, fluoro, C 1~2 Alkoxy, 4- to 6-membered heterocyclyl, and C 3~6 cycloalkyl, wherein 4- to 6-membered heterocyclyl and C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 alkyl (optionally substituted with 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 may be substituted by alkyl, or L III -R 3-III is hydrogen, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; R a and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl.

[0133] Further disclosed herein are compounds represented by formula (V) or a pharmaceutically acceptable salt thereof: TIFF2026004380000074.tif30128 formula, XV is a bond, -O-, and -N(R a )-, L V is a bond or a linear or branched C 1~8 alkylene, where C 1~8 The alkylene is optionally substituted with one or more hydroxyl or fluoro; R 2-V is hydrogen, halogen, cyano, -NR a R b , C 1~2 Alkoxy, C 3~6 Cycloalkyl-SO2-N(R a )-, C 1~6 Alkyl-SO2-N(R a )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 cycloalkyl, wherein phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C 3~6 Cycloalkyl optionally has a halogen, hydroxyl, -NR a R b , C 1~2 alkyl (optionally, -NR a R b , hydroxyl, or 1, 2, or 3 halogens), and C 1~2 and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C 1~3 optionally substituted by alkyl, R 5 is selected from the group consisting of hydrogen, deuterium, and halogen; R 6 is selected from the group consisting of hydrogen and deuterium; R 7 is selected from the group consisting of hydrogen and deuterium; Ra and R b is, for each occurrence, independently hydrogen and C 1~3 alkyl.

[0134] In some embodiments, X of the above compound or a pharmaceutically acceptable salt thereof V is selected from the group consisting of a bond and —O—.

[0135] In some embodiments, L of the above compound or a pharmaceutically acceptable salt thereof V is a bond, TIFF2026004380000075.tif43156 (where * and # represent R 2-V and X V represents the point of covalent attachment to

[0136] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 2-V is hydrogen, bromo, cyano, -OCH3, TIFF2026004380000076.tif12128.

[0137] In some embodiments, R of the above compound or a pharmaceutically acceptable salt thereof 5 , R 6 , and R 7 are hydrogen atoms.

[0138] In this specification, 5-{1-fluoro-3-hydroxy-7-[2-(morpholin-4-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, Propan-2-ylcarbamic acid 8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ) 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl, 5-(9-fluoro-7-hydroxynaphtho[2,1-b]furan-8-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(azetidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-methoxy(4- 2 H) naphthalen-2-yl](4,4- 2 H2)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(methylamino)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-4-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-7-{[3-fluoro-1-(propan-2-yl)pyrrolidin-3-yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-7-[(3-fluoropyrrolidin-3-yl)methoxy]-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}pentanenitrile, 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(piperidin-4-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3,3-dimethylpentanenitrile, 5-{7-[(3,3-dimethylbutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1,4-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[( 2 H3) methyloxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-methoxyethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2-dimethylbutanenitrile, 5-{7-[2-(3-aminobicyclo[1.1.1]pentan-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[2-(dimethylamino)ethyl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)(4,4- 2 H2)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}ethyl)cyclopropanesulfonamide, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropanesulfonamide, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)azetidin-3-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanenitrile, [1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropyl]acetonitrile, 5-{7-[2-(dimethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1H-pyrazol-4-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-methylpropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxypropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(cyclopropylmethyl)-8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ) 6 ,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxamide, 5-[1-fluoro-3-hydroxy-7-(2-{[2-(trifluoromethoxy)ethyl]amino}ethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2-methoxyethyl)amino]ethoxy}naphthalen-2-yl)-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[3-(methylamino)propyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(ethylamino)propyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[5-(dimethylphosphoryl)thiophen-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclopropylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(methylamino)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(ethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(diethylphosphoryl)propoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3S)-3-hydroxybutoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1,4-difluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3R)-3-hydroxybutoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropyl-2-hydroxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4S)-4-hydroxypentyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3-oxopentyl)oxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-hydroxybutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-3-methylbutanamide, 5-[1-fluoro-3-hydroxy-7-(4,4,4-trifluorobutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 1-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropane-1-carbonitrile, 5-(1-fluoro-3-hydroxy-7-{2-[1-(methoxymethyl)cyclopropyl]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[(cyclopropylmethyl)amino]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2,2-difluoropropyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3,3-dimethyl-4-(methylamino)butoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-phenylethyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3-amino-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4,4,4-trifluorobutyl)amino]naphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(difluoromethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(dimethylphosphoryl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3,3,3-trifluoropropyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-methoxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylpropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-({2-[(propan-2-yl)oxy]ethyl}amino)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3-yl]methoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}butanenitrile, 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4-amino-3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[2-(azetidin-1-yl)ethyl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]oxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-methoxyethyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3,3,3-trifluoropropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}methyl)cyclopropane-1-carbonitrile, 5-[1-fluoro-3-hydroxy-7-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[3-(1H-pyrazol-1-yl)propoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(4-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(hydroxymethyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)piperidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(1H-pyrazol-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(piperidin-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(2,2-difluorocyclopropyl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(1-methylcyclopropyl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(3-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(2-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,2-difluoroethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2,2,2-trifluoroethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-7-(2-fluoroethoxy)-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropane-1-carbonitrile, 5-{1-fluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-methylpropyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(cyclopropylmethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetonitrile, 5-[1-fluoro-3-hydroxy-7-(3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1,8-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)azetidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)azetidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (2E)-3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]prop-2-enenitrile, 5-[7-(2-cyclopropylethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2,2-difluorocyclopropyl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclopropylmethoxy)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclobutyloxy)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)oxy]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3-ethoxypropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-tert-butoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[rac-(1R,2R)-2-ethylcyclopropyl]methoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-methylpentyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(2,2-dimethylpropyl)pyrrolidin-1-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(1-chloro-3-hydroxypropan-2-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)pyrrolidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(cyclopropyloxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2-cyclopropylethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-methyl-1H-imidazol-2-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(azetidin-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(5-methoxythiophen-2-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetonitrile, 5-[1-fluoro-3-hydroxy-7-(methoxymethyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3-methyloxetan-3-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3S)-pyrrolidin-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3R)-pyrrolidin-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(8-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3,3-difluorocyclobutyl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-cyclopropyl-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(4-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(E)-2-cyclopropylethenyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1E)-4-methylpent-1-en-1-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(pentamethylphenyl)ethenyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(4-bromo-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(2-cyclopropylethyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1E)-3-methoxyprop-1-en-1-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-ethoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(1,1-dioxo-1λ 6 -thian-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(oxan-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methyl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methyl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[methyl(2-methylpropyl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxolan-2-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(oxolan-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)piperidin-4-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-2-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)piperidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(difluoromethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(pyrrolidin-3-yl)methyl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,5-dihydrofuran-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,6-dihydro-2H-pyran-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,5-dihydro-1H-pyrrol-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyridin-3-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(azetidin-3-yl)methyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ] 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}acetamide, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-N-methylbutanamide, N-ethyl-N'-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)urea, 5-{1-fluoro-3-hydroxy-7-[(oxan-3-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(1-chloro-3-hydroxypropan-2-yl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxan-4-yl)methoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxetan-3-yl)oxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyridin-4-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,7-dihydroxynaphthalen-2-yl)-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-propoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(propan-2-yl)oxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}acetic acid, N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ] 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetamide, N,N-diethyl-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetamide, 5-{1-fluoro-3-hydroxy-7-[2-oxo-2-(pyrrolidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]oxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(oxolane-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2-methoxyethanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-Fluoro-3-hydroxy-7-{1-[(oxan-2-yl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(4,4,4-trifluorobutane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(butane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(1,4-dioxan-2-yl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-2,5-dihydro-1H-pyrrole-1-sulfonyl}pentanenitrile, 5-{1-fluoro-3-hydroxy-7-[1-(pentane-2-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(ethanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(propane-2-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)oxetane-3-sulfonamide, 5-[1-fluoro-3-hydroxy-7-(piperidin-4-yl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2-methylpropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-ethoxy-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,2-difluoroethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-1H-pyrazol-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[(3R)-1-(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]amino}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-7-{[3-fluoro-1-(methanesulfonyl)pyrrolidin-3-yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(propane-2-sulfonyl)pyrrolidin-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6 ,2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)ethanesulfonamide, 5-{1-fluoro-7-[1-(furan-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-methylbutane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(thiophene-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(benzenesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclobutanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (2S)-2-amino-4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanoic acid methyl ester, 5-{7-[(3,5-dimethyl-1H-pyrazol-4-yl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,5-dimethyl-1H-pyrazol-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclohexylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-1H-imidazole-4-carbonitrile, 5-{1-fluoro-3-hydroxy-7-[2-(2,2,4-trimethyl-1,3-dioxolan-4-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,4-dihydroxy-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(4,4-difluorobutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[rac-(2R,4R)-2,4-dihydroxypentyl]oxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(2-oxoimidazolidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxybutoxy)naphthalen-2-yl]-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(6-amino-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{6-[(4,4-difluorobutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{6-[(cyclopropylmethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-6-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-6-[(3-hydroxy-3-methylbutyl)amino]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-6-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-6-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (2-{[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1λ 6 tert-butyl 2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)carbamate, 5-[6-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[6-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-6-(3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[6-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3S)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-3,3-dimethylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-hydroxy-2,2-dimethylpropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(3-aminopropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, (3R)-5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy-3-methylpentanenitrile, (3S)-5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy-3-methylpentanenitrile, 5-{7-[(5-amino-3,3-dimethylpentyl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{3-[(propan-2-yl)amino]propyl}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxolan-3-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopentylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclobutylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(trifluoromethoxy)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,6-dihydroxy-7-methoxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-ethyl-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3,6-dihydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-methylbutoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclobutylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-butoxy-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopentylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4,4-difluorobutoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ 6,2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-3,6-dihydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2-dimethylbutanenitrile, 5-{1-fluoro-3,6-dihydroxy-7-[2-(oxolan-3-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-hydroxypropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-bromo-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(4-methylpentyl)naphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxetan-3-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[1-(hydroxymethyl)cyclobutyl]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(4,4-difluoro-5-hydroxypentyl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[3-(aminomethyl)bicyclo[1.1.1]pentan-1-yl]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[3-(2-hydroxyethyl)bicyclo[1.1.1]pentan-1-yl]methoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(bicyclo[1.1.1]pentan-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[1-(aminomethyl)cyclobutyl]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(3-hydroxy-3-methylazetidin-1-yl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2-methoxyethyl)(methyl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(1,3-dihydro-2H-isoindol-2-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3,6-dihydroxy-7-[2-(1-methylcyclopropyl)ethoxy]naphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3,6-dihydroxynaphthalen-2-yl}-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[ethyl(methyl)amino]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, 3-[(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ 6 ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)(methyl)amino]propanenitrile, 5-(1-fluoro-3-hydroxy-7-{2-[(2,2,2-trifluoroethyl)amino]ethoxy}naphthalen-2-yl)-1λ 6 ,2,5-thiadiazolidine-1,1,3-trione, and pharmaceutically acceptable salts thereof Further disclosed is a compound selected from the group consisting of:

[0139] In some embodiments, a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V), is formulated as a pharmaceutically acceptable composition comprising a disclosed compound and a pharmaceutically acceptable carrier.

[0140] In some embodiments, a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V), is selected from the compounds set forth in Table 1.

[0141] Table 1: Exemplary compounds of the present disclosure TIFF2026004380000077.tif57170TIFF2026004380000078.tif225170TIFF2026004380000079.tif227170TIFF2026004380000080.tif240170 TIFF2026004380000081.tif242170TIFF2026004380000082.tif235170TIFF2026004380000083.tif245170TIFF2026004380000084.tif238170 TIFF2026004380000085.tif238170TIFF2026004380000086.tif227170TIFF2026004380000087.tif248170TIFF2026004380000088.tif245170 TIFF2026004380000089.tif234170TIFF2026004380000090.tif242170TIFF2026004380000091.tif240170TIFF2026004380000092.tif232170

[0142] Exemplary Compound Preparation Methods The compounds of the present disclosure may be better understood in connection with the following synthetic schemes and methods, which illustrate the means by which such compounds may be prepared. The compounds of the present disclosure may be prepared by a variety of synthetic procedures. Representative synthetic procedures are shown in Schemes 1-13, but are not limited thereto. The variable R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 is defined as detailed herein, i.e., in the Summary of the Invention.

[0143] Scheme 1: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 1 of TIFF2026004380000093.tif206170, compounds of formula (1-9), formula (1-10), formula (1-11), and formula (1-12) can be prepared from compounds of formula (1-1). Compounds of formula (1-1) can be alkylated with optionally substituted benzyl bromides (e.g., benzyl bromide, 4-methoxybenzyl bromide, or 3,4-dimethoxybenzyl bromide) in a solvent such as N,N-dimethylformamide in the presence of a base such as cesium carbonate. Under these conditions, the carboxylic acid group also reacts to form a benzyl ester. This benzyl ester can be hydrolyzed with a base such as lithium hydroxide or sodium hydroxide in methanol or a mixture of methanol and water to give compounds of formula (1-2). Compounds of formula (1-2) can be reacted under Curtius reaction conditions (diphenylphosphoryl azide, tert-butanol, triethylamine in heated toluene) to give compounds of formula (1-3). The tert-butoxycarbonyl moiety can be removed from compounds of formula (1-3) by treatment with heated diethylenetriamine to give compounds of formula (1-4). Compounds of formula (1-4) can be reacted with 2-bromoacetic acid esters of formula (1-5) in the presence of a base such as potassium carbonate in a warm solvent, such as, but not limited to, a mixture of N,N-dimethylformamide and water, to give compounds of formula (1-6). Compounds of formula (1-6) can then be fluorinated with a reagent such as N-fluorobenzenesulfonimide (NFSI) in a solvent such as tetrahydrofuran or Selectfluor® in optionally warmed N,N-dimethylformamide to give compounds of formula (1-7). Compounds of formula (1-7) can be reacted with chlorosulfonyl isocyanate and tert-butanol in the presence of a tertiary amine base such as triethylamine in a cold solvent such as dichloromethane, followed by treatment under acidic conditions such as trifluoroacetic acid in dichloromethane to remove the tert-butoxycarbonyl group to give compounds of formula (1-8).Compounds of formula (1-8) can be reacted with an alkoxide base, such as sodium methoxide in optionally warmed methanol or a mixture of methanol and water, or potassium tert-butoxide in tetrahydrofuran, followed by quenching with an acid such as 1 M hydrochloric acid, to give compounds of formula (1-9) or (1-10). Compounds of formula (1-9) can be converted to compounds of formula (1-11) using water under cross-coupling reaction conditions, such as water in the presence of a precatalyst, RockPhos Pd G3, a base, cesium carbonate, and a warm solvent, N,N-dimethylformamide. The optionally substituted benzyl ether of compounds of formula (1-10) can be removed using conditions known to those skilled in the art and dependent on the particular benzyl ether. For example, the unsubstituted benzyl ether can be removed by treatment with boron trichloride in dichloromethane in the presence of 1,2,3,4,5-pentamethylbenzene at −60 to −80° C. to give the compound of formula (1-12), which is a representative compound of formula (I).

[0144] Scheme 2: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 2 of TIFF2026004380000094.tif160137, compounds of formula (2-2), formula (2-4), formula (2-6), and formula (2-8) can be prepared from compounds of formula (1-9). Compounds of formula (1-9) can be reacted under C-cross-coupling reaction conditions. For example, using Suzuki reaction conditions, compounds of formula (1-9) can be coupled with compounds of formula (2-1), where A represents an alkene moiety, a cyclopropyl, or an aromatic or partially unsaturated ring. Reaction conditions for coupling a compound of formula (1-9) with a compound of formula (2-1) may include a catalyst (tetrakis(triphenylphosphine)palladium(0), 1,1-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex, or [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride) and a base (sodium carbonate, potassium carbonate, or cesium carbonate) in heated dioxane, a mixture of dioxane and water, or a mixture of tetrahydrofuran and water. The optionally substituted benzyl ether protecting group can then be removed using conditions known to those skilled in the art and dependent on the particular benzyl ether. For example, the unsubstituted benzyl ether can be removed by treatment with boron trichloride in dichloromethane in the presence of 1,2,3,4,5-pentamethylbenzene at −60 to −80° C. to afford a compound of formula (2-2). Alternatively, unsubstituted benzyl ethers can be removed by treatment with hydrogen and a palladium catalyst in a solvent such as dioxane or tetrahydrofuran. Compounds of formula (2-2) or protected precursors may be further modified as known to those skilled in the art and as illustrated in the examples.

[0145] Compounds of formula (1-9) can be reacted under N-cross-coupling reaction conditions. For example, compounds of formula (1-9) can be coupled with compounds of formula (2-3) using Buchwald-Hartwig reaction conditions. For example, compounds of formula (1-9) and compounds of formula (2-3) can be coupled in a solvent such as heated dioxane, N,N-dimethylacetamide, or tert-amyl alcohol in the presence of a precatalyst (BrettPhos Pd G3 or RuPhos Pd G3) or catalyst (palladium(II) acetate), ligand (BrettPhos, RuPhos, or Xantphos), and base (sodium tert-butoxide or cesium carbonate). Subsequently, the optionally substituted benzyl ether protecting group is removed as described above to give compounds of formula (2-4) (wherein NR 2-1 R 2-2 is R 2 Compounds of formula (2-4) or protected precursors may be further modified as known to those skilled in the art and as illustrated in the examples.

[0146] Compounds of formula (1-9) can be reacted under O-cross-coupling reaction conditions. For example, compounds of formula (1-9) can be coupled with compounds of formula (2-5) using cross-coupling reaction conditions. For example, compounds of formula (1-9) and (2-5) can be coupled in a solvent such as heated N,N-dimethylformamide in the presence of a pre-catalyst, RockPhos Pd G3, and a base, cesium carbonate. The optionally substituted benzyl ether protecting group can then be removed as described above to give compounds of formula (2-6), where OR 2-3 is R 2 Compounds of formula (2-6) or protected precursors may be further modified as known to those skilled in the art and as illustrated in the examples.

[0147] Compounds of formula (1-9) can be reacted under C-cross-coupling reaction conditions. For example, compounds of formula (1-9) can be reacted with compounds of formula (2-7) (wherein R 2-4 is R beyond the allylic portion. 2 (representing the remaining moiety of the formula). Reaction conditions for coupling a compound of formula (1-9) with a compound of formula (2-7) may include a catalyst such as palladium(II) acetate, a phosphine ligand such as 2-(di-tert-butylphosphino)biphenyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, or 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, and a base such as a tertiary amine base, e.g., triethylamine, or cesium carbonate, in a solvent such as heated N,N-dimethylformamide or dioxane. The optionally substituted benzyl ether protecting group can then be removed as described above to provide a compound of formula (2-8). The compound of formula (2-8) or its protected precursor may be further modified as known to those skilled in the art and as illustrated in the examples.

[0148] The compounds of formula (2-2), formula (2-4), formula (2-6), or formula (2-8) are representative of compounds of formula (I) or are precursors of compounds of formula (I).

[0149] Scheme 3: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 3, compounds of formula (3-1) and formula (3-2) can be prepared from compounds of formula (1-11). 3-1 -LG 1 (In the formula, LG 1 is a leaving group such as chloro, bromo, iodo, or sulfonate, and R 3-1is an optionally substituted alkyl, an optionally substituted heterocyclyl, or an optionally substituted cycloalkyl. Alkylation conditions may include treatment with a base, such as, but not limited to, cesium carbonate or sodium hydride, in a solvent such as N,N-dimethylformamide, optionally heated. The optionally substituted benzyl ether protecting group can then be removed using conditions known to those skilled in the art and dependent on the particular benzyl ether. For example, the unsubstituted benzyl ether can be removed by treatment with boron trichloride in the presence of 1,2,3,4,5-pentamethylbenzene in dichloromethane at −60 to −80° C. to give a compound of formula (3-1). The unsubstituted benzyl ether can also be removed by reduction with hydrogen in the presence of a palladium-on-carbon catalyst in a solvent such as tetrahydrofuran at or near ambient temperature. The compound of formula (3-1) or the corresponding protected precursor may be further modified as known to those skilled in the art and as illustrated in the Examples. Base OR 3-1 is R 2 represents the ether portion of

[0150] An alternative preparation of compounds of formula (3-1) is to react compounds of formula (1-11) with compounds of formula R under Mitsunobu reaction conditions. 3-1 -OH(in the formula, R 3-1 is optionally substituted alkyl or optionally substituted cycloalkyl. Thus, a compound of formula (1-11) and a compound of formula R 3-1 Compounds of formula (3-1) can be treated with (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone) and tri-n-butylphosphine in a solvent such as warm tetrahydrofuran. Subsequent removal of the benzyl protecting group as described above provides compounds of formula (3-1). Compounds of formula (3-1) or the corresponding protected precursors can be further modified as known to those skilled in the art and as shown in the examples.

[0151] Compounds of formula (1-11) can also be converted to compounds of formula (3-2). Compounds of formula (1-11) can be converted to compounds of formula (3-2) by addition of R 3-2 -NCO (wherein R 3-2 is optionally replaced by C 1~6 The benzyl protecting group can then be removed as described above to give compounds of formula (3-2). 3-2 is R 2 The compound of formula (3-2) or the corresponding protected precursor may be further modified as known to those skilled in the art and as shown in the examples.

[0152] The compounds of formula (3-1) and formula (3-2) are representative of the compounds of formula (I) or are precursors of the compounds of formula (I).

[0153] Scheme 4: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 4, a compound of formula (4-4) can be prepared from a compound of formula (1-9). Compound (1-9) can be prepared by coupling one R B is another R B The compound of formula (1-9) can be reacted with a boron reagent of formula (4-1), such as bis(pinacolato)diboron, which is bonded to the boron group, to give a compound of formula (4-2). Reaction conditions for coupling a compound of formula (1-9) with a compound of formula (4-1) can include a catalyst ([1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex) and a base (potassium acetate or potassium carbonate) in heated dioxane. Subsequently, the compound of formula (4-2) can be converted to a compound of formula (4-3), where R 2-C represents an aromatic ring or a partially unsaturated ring, an alkyl group, or an alkylene group; LG 2is a leaving group such as iodine, bromine, or chlorine. Reaction conditions for coupling a compound of formula (4-2) with a compound of formula (4-3) may include a catalyst (tetrakis(triphenylphosphine)palladium(0), XPhos Pd G2, or meCgPPh Pd G3) and a base (sodium carbonate, potassium phosphate, or potassium carbonate) in a heated mixture of toluene and ethanol, or dioxane and water, or N-methyl-2-pyrrolidinone. The optionally substituted benzyl ether protecting group can then be removed using conditions known to those skilled in the art and dependent on the particular benzyl ether. For example, the unsubstituted benzyl ether can be removed by treatment with boron trichloride in dichloromethane in the presence of 1,2,3,4,5-pentamethylbenzene at −60 to −80° C. to give a compound of formula (4-4). Compounds of formula (4-4) or the corresponding protected precursors may be further modified as known to those skilled in the art and as shown in the examples.

[0154] The compound of formula (4-4) is representative of the compound of formula (I) or is a precursor of the compound of formula (I).

[0155] Scheme 5: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 5 of TIFF2026004380000097.tif92136, compounds of formula (5-3) can be prepared from compounds of formula (1-9). Compounds of formula (1-9) can be converted to compounds of formula (5-1) (wherein R PRis potassium trifluoroborate or a carboxylic acid moiety, and B represents an optionally substituted heterocyclyl or an optionally substituted alkyl. Conditions for coupling compounds of formula (1-9) with compounds of formula (5-1) include treatment with NiCl-dimethoxyethane adduct, a ligand (4,4'-di-tert-butyl-2,2'-dipyridyl), a base (cesium carbonate), and bis[3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridyl]phenyl]iridium(1+); 2-(2-pyridyl)pyridine; and hexafluorophosphate in a solvent such as dioxane, optionally containing N,N-dimethylacetamide, in a 450 nm LED photoreactor. The optionally substituted benzyl ether protecting group can then be removed using conditions known to those skilled in the art and dependent on the particular benzyl ether. For example, the unsubstituted benzyl ether can be removed by hydrogenation in the presence of a palladium on carbon catalyst in tetrahydrofuran to give compounds of formula (5-3).

[0156] Alternatively, the compound of formula (5-1) can be converted to the compound of formula (5-2) (wherein PG 3 is (2-methoxyethoxy)methyl). One or both protecting groups can be deprotected by treatment with hydrochloric acid in dioxane to give compounds of formula (5-3).

[0157] Compounds of formula (5-3) or the corresponding protected precursors may be further modified as known to those skilled in the art and as shown in the examples.

[0158] Compounds of formula (5-3) are representative of compounds of formula (I) or are precursors of compounds of formula (I).

[0159] Scheme 6: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 6, a compound of formula (6-3) can be prepared from a compound of formula (6-1). 1 is a protecting group such as (2-methoxyethoxy)methyl, and PG 2 is an optionally substituted benzyl group or (2-methoxyethoxy)methyl) in a compound of formula (6-2) 6-1 is an optionally substituted alkyl group, an optionally substituted cycloalkyl group, or an optionally substituted heterocyclyl group. Conditions for coupling a compound of formula (6-1) with a compound of formula (6-2) are treatment with a catalyst (Pd SPhos G4) in heated N,N-dimethylacetamide. Optionally substituted benzyl ether protecting groups, if present, can be removed using conditions known to those skilled in the art and dependent on the particular benzyl ether. For example, the unsubstituted benzyl ether (PG 2 ) can be removed by hydrogenation in the presence of a palladium on carbon catalyst or by treatment with boron trichloride in dichloromethane to give compounds of formula (6-3). PG 1 or PG 2 When either of is a (2-methoxyethoxy)methyl group, either or both can be removed by treatment with an acid such as hydrochloric acid in dioxane to give compounds of formula (6-3). Compounds of formula (6-3) or the corresponding protected precursors may be further modified as known to those skilled in the art and as shown in the examples.

[0160] Compounds of formula (6-3) are representative of compounds of formula (I) or are precursors of compounds of formula (I).

[0161] Scheme 7: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 7, compounds of formula (2-2) can be prepared from compounds of formula (1-9) by the reverse synthetic sequence described in Scheme 2. In the first step, the optionally substituted benzyl moiety can be removed using conditions known to those skilled in the art and dependent on the particular benzyl ether. For example, unsubstituted benzyl ethers can be removed by treatment with boron trichloride in the presence of 1,2,3,4,5-pentamethylbenzene in dichloromethane at −60 to −80°C to give compounds of formula (7-1). Compounds of formula (7-1) can be reacted under C-cross-coupling reaction conditions. For example, Suzuki reaction conditions can be used to couple compounds of formula (7-1) with compounds of formula (2-1), where A represents an alkene moiety, a cyclopropyl group, or an aromatic or partially unsaturated ring. The corresponding boronic acid of the compound of formula (2-1) is also suitable for the cross-coupling reaction. Reaction conditions for coupling the compound of formula (7-1) with the compound of formula (2-1) may include a catalyst (1,1'-bis(di-tert-butylphosphino)ferrocene palladium dichloride) and a base (sodium carbonate or potassium carbonate) in heated dioxane or a mixture of dioxane and water. The compound of formula (2-2) or the corresponding protected precursor may be further modified as known to those skilled in the art and as shown in the examples.

[0162] The compound of formula (2-2) is a representative of the compound of formula (I) or a precursor of the compound of formula (I).

[0163] Scheme 8: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 8 of TIFF2026004380000100.tif148166, compounds of formula (8-7) and formula (8-8) can be prepared from compounds of formula (8-1). Compounds of formula (8-1) can be brominated with bromine in chloroform at ambient temperature to give compounds of formula (8-2). Compounds of formula (8-2) can be selectively debrominated with tin in the presence of an acid, such as a heated solution of concentrated hydrochloric acid in ethanol, to give compounds of formula (8-3). Compounds of formula (8-3) can be fluorinated by treatment with a solution of N-fluoro-N-(phenylsulfonyl)benzenesulfonamide in tetrahydrofuran, a solution of N-fluorobenzenesulfonimide (NFSI) in a solvent such as tetrahydrofuran, or a solution of Selectfluor® in N,N-dimethylformamide, optionally at elevated temperature, to give compounds of formula (8-4). Compounds of formula (8-4) can be reacted with 2-bromoacetic acid esters of formula (1-5) in the presence of a base such as N,N-diisopropylethylamine or potassium carbonate in a warm solvent, such as, but not limited to, a mixture of N,N-dimethylformamide and water, to give compounds of formula (8-5). Compounds of formula (8-5) can be reacted with sulfurisocyanatidic chloride and tert-butanol in the presence of a tertiary amine base, such as triethylamine, in a cooled solvent, such as dichloromethane. Subsequent removal of the tert-butoxycarbonyl group by treatment under acidic conditions, such as trifluoroacetic acid in dichloromethane, gives compounds of formula (8-6). Compounds of formula (8-6) can be reacted with an alkoxide base, such as sodium methoxide in optionally warmed methanol or a mixture of methanol and water, or potassium tert-butoxide in tetrahydrofuran, followed by quenching with an acid such as 1 M hydrochloric acid, to give compounds of formula (8-7).Compounds of formula (8-7) can be converted to compounds of formula (8-8) with water under cross-coupling reaction conditions, such as water in the presence of a precatalyst (RockPhos Pd G3), a ligand (RockPhos), a base (cesium carbonate), and a warm solvent (N,N-dimethylacetamide).

[0164] Scheme 9: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 9 of TIFF2026004380000101.tif78143, a compound of formula (8-7) can be reacted under N-cross-coupling reaction conditions. For example, a compound of formula (8-7) can be coupled with a compound of formula (9-1) using Buchwald-Hartwig reaction conditions. For example, a compound of formula (8-7) can be coupled with a compound of formula (9-1) in a heated solvent such as dioxane, tert-amyl alcohol, or N,N-dimethylformamide in the presence of a precatalyst (BrettPhos Pd G3 or RuPhos PdG3) or a catalyst (palladium(II) acetate), a ligand (BrettPhos, RuPhos, or Xantphos), and a base (sodium tert-butoxide or cesium carbonate). Subsequently, the optionally substituted benzyl ether protecting group can be removed as described above to afford a compound of formula (9-2) (wherein NR 9-1 R 9-2 is R 3(representing a cyclic or acyclic moiety of the formula:) can be obtained. The optionally substituted benzyl ether protecting group can then be removed using conditions known to those skilled in the art and dependent on the particular benzyl ether. For example, the unsubstituted benzyl ether can be removed by treatment with boron trichloride in the presence of 1,2,3,4,5-pentamethylbenzene in dichloromethane at −60 to −80°C, followed by warming to 0°C, to give compounds of formula (9-2). The unsubstituted benzyl ether can also be removed by reduction with hydrogen in the presence of a palladium-on-carbon catalyst in a solvent such as tetrahydrofuran at or near ambient temperature. An alternative method involves the removal of the unsubstituted benzyl ether by transfer hydrogenation using a palladium-on-carbon catalyst in the presence of ammonium formate in ethanol, optionally at elevated temperatures. The compound of formula (9-2) or the protected precursor can be further modified as known to those skilled in the art and as illustrated in the Examples. Compounds of formula (9-2) are representative of compounds of formula (I) or are precursors of compounds of formula (I).

[0165] A compound of formula (8-7) can be reacted under O-cross-coupling reaction conditions. For example, a compound of formula (8-7) can be coupled with a compound of formula (9-3) using cross-coupling reaction conditions. For example, a compound of formula (8-7) can be coupled with a compound of formula (9-3) in a heated solvent such as N,N-dimethylformamide or N,N-dimethylacetamide in the presence of a precatalyst (RockPhos Pd G3) or catalyst (tris(dibenzylideneacetone)dipalladium(0)), an optional catalyst (di-tert-butyl(2',4',6'-triisopropyl-3,6-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine), and a base (cesium carbonate). The optionally substituted benzyl ether protecting group can then be removed as described above to give a compound of formula (9-4), which is represented by OR in the scheme. 9-3 is R 3The compound of formula (9-4) or its protected precursor can be further modified as known to those skilled in the art and as shown in the Examples. The compound of formula (9-4) is representative of or a precursor to the compound of formula (I).

[0166] Scheme 10: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 10, a compound of formula (10-1) can be prepared from a compound of formula (8-8). 10-1 -LG 1 (In the formula, LG 1 is a leaving group such as chloro, bromo, iodo, or sulfonate, and R 10-1 is an optionally substituted alkyl). Alkylation conditions can include treatment with a base such as, but not limited to, cesium carbonate, potassium phosphate, or sodium hydride, optionally in the presence of tetrabutylammonium bromide, in a solvent such as N,N-dimethylformamide or N,N-dimethylacetamide, optionally heated. The optionally substituted benzyl ether protecting group can then be removed using conditions known to those skilled in the art and dependent on the particular benzyl ether. For example, the unsubstituted benzyl ether can be removed by treatment with boron trichloride in the presence of 1,2,3,4,5-pentamethylbenzene in dichloromethane, or by catalytic or transfer hydrogenation as described in Scheme 9, to give a compound of formula (10-1). Compounds of formula (10-1) or the corresponding protected precursors can be further modified as known to those skilled in the art and as shown in the Examples. The group OR 10-1 is R 3 The compound of formula (10-1) is a representative of the compound of formula (I) or a precursor of the compound of formula (I).

[0167] Scheme 11: Representative scheme for the synthesis of exemplary compounds of the present disclosureAs shown in Scheme 11 of TIFF2026004380000103.tif106168, compounds of formula (11-6) can be prepared from compounds of formula (11-1). Compounds of formula (11-1) can be fluorinated by treatment with a solution of N-fluoro-N-(phenylsulfonyl)benzenesulfonamide in tetrahydrofuran, a solution of N-fluorobenzenesulfonimide (NFSI) in a solvent such as tetrahydrofuran, or a solution of Selectfluor® in N,N-dimethylformamide, optionally at elevated temperature, to give compounds of formula (11-2). Compounds of formula (11-2) can be reacted with trifluoroacetic anhydride in a solvent such as acetonitrile. Subsequent reaction with the 2-bromoacetic acid ester of formula (1-5) in the presence of a base such as N,N-diisopropylethylamine or potassium carbonate in a warm solvent, such as, but not limited to, N,N-dimethylformamide or a mixture of N,N-dimethylformamide and water, provides compounds of formula (11-3). Compounds of formula (11-3) can be converted to compounds of formula (11-4) in a two-step process. Compounds of formula (11-3) can be reacted with sodium methoxide, optionally in warm methanol, to remove the trifluoroacetyl group. Compounds of formula (11-4) can then be obtained by reaction with chlorosulfonyl isocyanate and tert-butanol in the presence of a tertiary amine base such as triethylamine in a cooled solvent, such as dichloromethane. Compounds of formula (11-4) can then be converted to compounds of formula (11-5) in another two-step sequence. Treatment under acidic conditions, such as trifluoroacetic acid in dichloromethane, removes the tert-butoxycarbonyl group. Subsequent reaction with an alkoxide base, such as sodium methoxide in optionally warmed methanol or a mixture of methanol and water, or potassium tert-butoxide in tetrahydrofuran, followed by quenching with an acid such as 1 M hydrochloric acid, provides compounds of formula (11-5). Compounds of formula (11-5) can be converted to compounds of formula (11-6).Compounds of formula (11-5) are cross-coupled under cross-coupling reaction conditions described in Scheme 1, Scheme 2, Scheme 4, Scheme 5, Scheme 6, or Scheme 7 to afford R. 2 A moiety representing the formula (11-6) can be introduced. Removal of the two phenol protecting groups under conditions known to those skilled in the art provides compounds of formula (11-6), which are representative of compounds of formula (I).

[0168] Scheme 12: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 12, compounds of formula (12-3) can be prepared from compounds of formula (11-5). Compounds of formula (11-5) can be cross-coupled with water to give compounds of formula (12-1). Compounds of formula (12-1) can be reacted with R 12-2 -LG 1 (In the formula, LG 1 is a leaving group such as chloro, bromo, iodo, or sulfonate, and R 12-2 is optionally substituted alkyl, optionally substituted -C 1~6 Alkylene-C 3~6 Cycloalkyl, optionally substituted heterocyclyl, optionally substituted -C 1~6 alkylene-5-6 membered heteroaryl, optionally substituted -C 1~6 The compound of formula (12-2) can be alkylated with alkylene-4-6 membered heterocyclyl, or optionally substituted cycloalkyl. Alkylation conditions can include treatment with a solution of a base, such as, but not limited to, cesium carbonate or sodium hydride, in a solvent such as N,N-dimethylformamide, optionally heated. Compounds of formula (12-2) can be further modified as known to those skilled in the art and as shown in the examples. Removal of the two phenol protecting groups under conditions known to those skilled in the art provides compounds of formula (12-3). Compounds of formula (12-3) are representative of compounds of formula (I).

[0169] Scheme 13: Representative scheme for the synthesis of exemplary compounds of the present disclosure As shown in Scheme 13, compounds of formula (13-4) can be prepared from compounds of formula (1-11). Compounds of formula (13-1) can be obtained by alkylating compounds of formula (1-11) with 2-bromo-1,1-dimethoxyethane and then hydrolyzing them under acidic conditions. Compounds of formula (13-1) can be converted to compounds of formula (13-2) (wherein R 13-2 is independently in each occurrence hydrogen, optionally substituted C 1~6 Alkyl or optionally substituted C 3~6 Compounds of formula (13-2) can be reductively alkylated with cycloalkyl (wherein 13-2 is an optionally substituted 4- to 6-membered heterocyclyl) to give compounds of formula (13-3). Compounds of formula (13-3) can be further modified as known to those skilled in the art and as shown in the examples. Removal of the phenol protecting group under conditions known to those skilled in the art gives compounds of formula (13-4). Compounds of formula (13-4) are representative of compounds of formula (I).

[0170] Pharmaceutical Composition The present disclosure provides pharmaceutical compositions comprising a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V). In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. In some embodiments, the compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V), is provided in the pharmaceutical composition in an effective amount. In some embodiments, the effective amount is a therapeutically effective amount. In certain embodiments, the effective amount is a prophylactically effective amount.

[0171] The pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. Generally, such preparation methods include the step of bringing the disclosed compound ("active ingredient") into association with a carrier and / or one or more other accessory ingredients, and then, if necessary and / or desirable, shaping and / or packaging the product into a desired single- or multi-dosage unit. Pharmaceutical compositions may be formulated, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single-unit doses. As used herein, a "unit dose" is a discrete amount of a pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient to be administered to a subject, and / or a manageable fraction of such a dosage, e.g., one-half or one-third of such a dosage.

[0172] The relative amounts of a compound disclosed herein, e.g., a compound of Formula (I), Formula (IIa), Formula (IIb), Formula (III), Formula (IV), or Formula (V), pharmaceutically acceptable excipient, and / or any additional components in a pharmaceutical composition of the present disclosure will vary depending on the identity, size, and / or condition of the subject being treated, as well as the route by which the composition is administered. By way of example, the composition may contain from 0.1% to 100% (w / w) of a compound disclosed herein.

[0173] The term "pharmaceutically acceptable excipient" refers to a non-toxic carrier, adjuvant, diluent, or vehicle that does not impair the pharmacological activity of the compound being formulated. Pharmaceutically acceptable excipients useful in preparing the pharmaceutical compositions of the present disclosure are any pharmaceutically acceptable excipients well known in the art of pharmaceutical formulation, including inert diluents, dispersing and / or granulating agents, surfactants and / or emulsifying agents, disintegrating agents, binders, preservatives, buffers, lubricants, and / or oils. Pharmaceutically acceptable excipients useful in preparing pharmaceutical compositions of the present disclosure include, but are not limited to, ion exchangers; alumina; aluminum stearate; lecithin; serum proteins such as human serum albumin; buffer substances such as phosphoric acid, glycine, sorbic acid, potassium sorbate, and the like; partial glyceride mixtures of saturated vegetable fatty acids; water; salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, and the like; colloidal silica; magnesium trisilicate; polyvinylpyrrolidone; cellulosic substances; polyethylene glycol; sodium carboxymethylcellulose; polyacrylic acid esters; waxes; polyethylene-polyoxypropylene block polymers; polyethylene glycol; and wool fat.

[0174] Compositions of the present disclosure can be administered orally, parenterally (including subcutaneously, intramuscularly, intravenously, and intradermally), by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. In some embodiments, provided compounds or compositions can be administered intravenously and / or orally.

[0175] As used herein, the term "parenteral" includes subcutaneous, intravenous, intramuscular, intraocular, intravitreal, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intraperitoneal, intralesional, and intracranial injection or infusion techniques. The compositions are preferably administered orally, subcutaneously, intraperitoneally, or intravenously. Sterile injectable forms of the compositions of the present disclosure may be aqueous or oily suspensions. These suspensions can be formulated using suitable dispersing or wetting agents and suspending agents according to techniques known in the art. The sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution, and isotonic sodium chloride solution. Additionally, sterile, fixed oils are conventionally used as solvents or suspending media.

[0176] The pharmaceutically acceptable compositions of the present disclosure may be orally administered in any orally acceptable dosage form, including, but not limited to, capsules, tablets, aqueous suspensions, or solutions. For tablets for oral use, commonly used carriers include lactose and cornstarch. Lubricants, such as magnesium stearate, are also commonly added. For oral administration in capsule form, useful diluents include lactose and dried cornstarch. When an aqueous suspension is required for oral use, the active ingredient is mixed with emulsifying and suspending agents. If desired, certain sweeteners, flavorings, or coloring agents may also be added. In some embodiments, the provided oral formulations are formulated for immediate release or sustained / delayed release. In some embodiments, the compositions are suitable for buccal or sublingual administration, including tablets, lozenges, and pastilles. The compounds disclosed herein may also be in microencapsulated form.

[0177] The compositions of the present disclosure may be formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols for topical delivery via transdermal administration. Oral formulations include tablets, pills, powders, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, and the like, suitable for ingestion by the patient. Solid formulations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid formulations include solutions, suspensions, and emulsions, such as water or water / propylene glycol solutions. The compositions of the present disclosure may further contain components for sustained release and / or comfort. Such components include high molecular weight anionic mucomimetic polymers, gelling polysaccharides, and finely divided drug carrier matrices. These components are discussed in more detail in U.S. Patent Nos. 4,911,920, 5,403,841, 5,212,162, and 4,861,760, the entire contents of which are incorporated herein by reference for all purposes. The compositions of the present disclosure may also be delivered as microspheres for sustained release in the body. For example, microspheres may be administered via intradermal injection of drug-containing microspheres that release the drug subcutaneously (see, e.g., Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995); as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995); or as oral microspheres (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997). In another embodiment, the formulations of the compositions of the present disclosure may be delivered using liposomes that fuse with or are endocytosed by, for example, using a receptor ligand bound to the liposome that binds to a cell's surface membrane protein receptor, resulting in endocytosis.Liposomes, particularly those that have target cell-specific receptor ligands on their surface or that otherwise preferentially target specific organs, can be used to target the delivery of the compositions of the present disclosure in vivo (see, for example, Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, J. Hosp. Pharm. 46: 1576-1587, 1989). The compositions of the present disclosure can also be delivered as nanoparticles.

[0178] Alternatively, the pharmaceutically acceptable compositions of the present disclosure may be administered in the form of suppositories for rectal administration.The pharmaceutically acceptable compositions of the present disclosure may also be administered topically, especially when the target of treatment includes areas or organs that are easily accessible by topical application, including diseases of the eye, skin, or lower intestinal tract.Suitable topical formulations for each of these areas or organs are easily prepared.

[0179] In some embodiments, to prolong the effect of a drug, it is often desirable to delay the absorption of th...

Claims

1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: During the ceremony, R １ is hydrogen, halogen, C １～６ Alkyl, C ３～６ Cycloalkyl, —O—C １～６ Alkyl, —N(R ａ )-C １～６ Alkyl, and -C １～６ alkylene-5- to 6-membered heterocyclyl, wherein C １～６ Alkyl, C ３～６ Cycloalkyl, —O—C １～６ Alkyl, —N(R ａ )-C １～６ Alkyl, and -C １～６ The alkylene-5- to 6-membered heterocyclyl may optionally have, independently on one or more available carbons, R ｇ and optionally substituted by one, two, three or more substituents selected from -C １～６ When the alkylene-5- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R ｈ and optionally substituted by R ２ is hydrogen, halogen, hydroxyl, -CHF ２ , -CH ２ OH, -CH ２ CN, -CH ２ -O-C １～６ Alkyl, —CH ２ -N(R ａ )-C １～６ Alkyl, C ２～６ Alkyl, C ２～６ Alkenyl, —O—C １～６ Alkyl, —N(R ａ )-C １～６ Alkyl, —S(O) ｗ -C １～６ Alkyl, —C(O)—N(R ａ )-C １～６ Alkyl, —N(R ａ )-C(O)-C １～６ Alkyl, —O—C(O)—N(R ａ )-C １～６ Alkyl, —N(R ａ )-C(O)-OC １～６ Alkyl, -C ３～６ Cycloalkyl, —O—C ３～６ Cycloalkyl, C １～６ Alkylene-C ３～６ Cycloalkyl, —C １～６ Alkenylene-C ３～６ Cycloalkyl, —O—C １～６ Alkylene-C ３～６ cycloalkyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, —O—C １～６ alkylene-5 to 6-membered heteroaryl, —O-4 to 6-membered heterocyclyl, —N(R ａ )-4 to 6-membered heterocyclyl, —C １～６ alkylene-4 to 6-membered heterocyclyl, and —O—C １～６ alkylene-4 to 6 membered heterocyclyl, wherein -CH ２ -O-C １～６ Alkyl, —CH ２ -N(R ａ )-C １～６ Alkyl, C ２～６ Alkyl, C ２～６ Alkenyl, —O—C １～６ Alkyl, —N(R ａ )-C １～６ Alkyl, —S(O) ｗ -C １～６ Alkyl, —C(O)—N(R ａ )-C １～６ Alkyl, —N(R ａ )-C(O)-C １～６ Alkyl, —O—C(O)—N(R ａ )-C １～６ Alkyl, —N(R ａ )-C(O)-OC １～６ Alkyl, —C ３～６ Cycloalkyl, —O—C ３～６ Cycloalkyl, —C １～６ Alkylene-C ３～６ Cycloalkyl, —C １～６ Alkenylene-C ３～６ Cycloalkyl, —O—C １～６ Alkylene-C ３～６ cycloalkyl, 5- to 6-membered heteroaryl, —O—C １～６ alkylene-5 to 6-membered heteroaryl, 4 to 6-membered heterocyclyl, —O-4 to 6-membered heterocyclyl, —N(R ａ )-4 to 6-membered heterocyclyl, —C １～６ alkylene-4 to 6-membered heterocyclyl, and —O—C １～６ The alkylene-4 to 6-membered heterocyclyl may optionally have, independently on one or more available carbons, R ｇ and optionally substituted by one, two, three or more substituents selected from 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, —N(R ａ )-4 to 6-membered heterocyclyl, —C １～６ alkylene-4 to 6-membered heterocyclyl, or —O—C １～６ When the alkylene-4 to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R ｈ and optionally substituted by Or, R １ and R ２ together with the atom to which they are attached form a 5-6 membered aryl or heteroaryl, wherein the aryl or heteroaryl is optionally selected from halogen, hydroxyl, cyano, C １～６ Alkyl, and C １～６ and optionally substituted by one or more substituents each independently selected from the group consisting of alkoxy, wherein C １～６ Alkyl and C １～６ The alkoxy may optionally be independently selected from R ｐ and optionally substituted by one, two, three or more substituents selected from R ３ is hydrogen, halogen, hydroxyl, -NH ２ , -C １～６ Alkyl, —O—C １～６ Alkyl, —O—C １～６ Alkylene-C ３～６ Cycloalkyl, —O—C １～６ Alkylene-N(R ａ )-C(O)-OC １～６ Alkyl, —N(R ａ )-C １～６ Alkyl, —N(R ａ )-C １～６ Alkylene-C ３～６ Cycloalkyl, —S(O) ｗ -C １～６ Alkyl, —C(O)—N(R ａ )-C １～６ Alkyl, —N(R ａ )-C(O)-C １～６ Alkyl, and -C １～６ alkylene-4 to 6 membered heterocyclyl, wherein -C １～６ Alkyl, —O—C １～６ Alkyl, —O—C １～６ Alkylene-C ３～６ Cycloalkyl, —O—C １～６ Alkylene-N(R ａ )-C(O)-OC １～６ Alkyl, —N(R ａ )-C １～６ Alkyl, —N(R ａ )-C １～６ Alkylene-C ３～６ Cycloalkyl, —S(O) ｗ -C １～６ Alkyl, —C(O)—N(R ａ )-C １～６ Alkyl, —N(R ａ )-C(O)-C １～６ Alkyl, and -C １～６ The alkylene-4 to 6-membered heterocyclyl may optionally have, independently on one or more available carbons, R ｇ and optionally substituted by one, two, three or more substituents selected from -C １～６ When the alkylene-4 to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R ｈ and optionally substituted by R ４ is hydrogen, halogen, C １～６ Alkyl, C ３～６ cycloalkyl, and —C １～６ alkylene-4 to 6 membered heterocyclyl, wherein C １～６ Alkyl, C ３～６ cycloalkyl, and —C １～６ The alkylene-4 to 6-membered heterocyclyl may optionally have, independently on one or more available carbons, R ｇ and optionally substituted by one, two, three or more substituents selected from -C １～６ When the alkylene-4 to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R ｈ and optionally substituted by Here, R １ , R ２ , R ３ , and R ４ At least one of them is not hydrogen, R ５ is hydrogen, halogen, C １～６ Alkyl, C ３～６ cycloalkyl, and —C １～６ alkylene-4 to 6 membered heterocyclyl, wherein C １～６ Alkyl, C ３～６ cycloalkyl, and —C １～６ The alkylene-4 to 6-membered heterocyclyl may optionally have, independently on one or more available carbons, R ｇ and optionally substituted by one, two, three or more substituents selected from -C １～６ When the alkylene-4 to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom can optionally be R ｈ and optionally substituted by R ６ is hydrogen, R ７ is hydrogen, R ｇ is, for each occurrence, independently hydrogen, halogen, hydroxyl, cyano, nitro, oxo, —C(O)OH, R ａ R ｂ N-, R ａ R ｂ N—C(O)—, R ａ R ｂ N-SO ｗ -, R ａ R ｂ NC(O)-N(R ａ ) -, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～６ Cycloalkyl, phenyl, C １～６ Alkylene-C ３～６ Cycloalkyl, —O—C １～６ Alkylene-C ３～６ cycloalkyl, —(CO)—(NR ａ )-C １～６ Alkylene-C ３～６ Cycloalkyl, C １～６ Alkoxy, C ３～６ Alkenyloxy, C ３～６ Alkynyloxy, C ３～６ Cycloalkoxy, C １～６ Alkyl-C(O)-, C １～６ Alkyl-O—C(O)—, C １～６ Alkyl-C(O)—O—, C １～６ Alkyl-S(O) ｗ -, C １～６ Alkyl-N(R ａ ) -, C １～６ Alkyl-N(R ａ )-C(O)-, C １～６ Alkyl-C(O)—N(R ａ ), C １～６ Alkyl-N(R ａ )-C(O)-N(R ａ ) -, C １～６ Alkyl-N(R ａ )-SO ｗ -, C ３～６ Cycloalkyl-N(R ａ )-SO ｗ -, C １～６ Alkyl-SO ｗ -N(R ａ ) -, C ３～６ Cycloalkyl-SO ｗ -N(R ａ )-, 4- to 6-membered heterocyclyl-SO ｗ -N(R ａ ) -, C １～６ Alkoxy-C(O)-N(R ａ ) -, C １～６ Alkyl-C(O)—N(R ａ )-C １～６ Alkyl-, C １～６ Alkyl-N(R ａ )-C(O)-C １～６ Alkyl-, -P(O)(C １～３ alkyl) ２ , and C １～６ Alkoxy-C １～６ alkyl-, wherein C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～６ Cycloalkyl, phenyl, C １～６ Alkylene-C ３～６ Cycloalkyl, —O—C １～６ Alkylene-C ３～６ cycloalkyl, —(CO)—(NR ａ )-C １～６ Alkylene-C ３～６ Cycloalkyl, C １～６ Alkoxy, C ３～６ Alkenyloxy, C ３～６ Alkynyloxy, C ３～６ Cycloalkoxy, C １～６ Alkyl-C(O)-, C １～６ Alkyl-O—C(O)—, C １～６ Alkyl-C(O)—O—, C １～６ Alkyl-S(O) ｗ -, C １～６ Alkyl-N(R ａ ) -, C １～６ Alkyl-N(R ａ )-C(O)-, C １～６ Alkyl-C(O)—N(R ａ ), C １～６ Alkyl-N(R ａ )-C(O)-N(R ａ ) -, C １～６ Alkyl-N(R ａ )-SO ｗ -, C ３～６ Cycloalkyl-N(R ａ )-SO ｗ -, C １～６ Alkyl-SO ｗ -N(R ａ ) -, C ３～６ Cycloalkyl-SO ｗ -N(R ａ )-, 4- to 6-membered heterocyclyl-SO ｗ -N(R ａ ) -, C １～６ Alkoxy-C(O)-N(R ａ ) -, C １～６ Alkyl-C(O)—N(R ａ )-C １～６ Alkyl-, C １～６ Alkyl-N(R ａ )-C(O)-C １～６ Alkyl-, -P(O)(C １～３ alkyl) ２ , and C １～６ Alkoxy-C １～６ The alkyl- is optionally independently selected from R ｐ and optionally substituted by one, two, three or more substituents selected from or two R on adjacent atoms ｇ together with the atom to which they are attached form a 5- to 6-membered aryl or heteroaryl; R ｈ is, for each occurrence, independently, C １～６ Alkyl, C ３～６ Alkenyl, C ３～６ Alkynyl, C ３～６ Cycloalkyl, —C １～６ Alkyl-C ３～６ Cycloalkyl, C １～６ Alkyl-S(O) ２ -, C ３～６ Cycloalkyl-S(O) ２ -, 4- to 6-membered heterocyclyl-S(O) ２ -, 4- to 6-membered heterocyclyl-C １～６ Alkyl-S(O) ２ -, 5- to 6-membered heteroaryl-S(O) ２ -, phenyl-S(O) ２ -, phenyl-C １～６ Alkyl-S(O) ２ -, C １～６ Alkyl-C(O)-, C １～６ Cycloalkyl-C(O)-, C １～６ Alkoxy-C(O)-, R ａ R ｂ N—C(O)—, R ａ R ｂ N-SO ２ -, and -P(O)(C １～３ alkyl) ２ wherein C is selected from the group consisting of １～６ Alkyl, C ３～６ Alkenyl, C ３～６ Alkynyl, C ３～６ Cycloalkyl, —C １～６ Alkyl-C ３～６ Cycloalkyl, C １～６ Alkyl-S(O) ２ -, C ３～６ Cycloalkyl-S(O) ２ -, 4- to 6-membered heterocyclyl-S(O) ２ -, 4- to 6-membered heterocyclyl-C １～６ Alkyl-S(O) ２ -, 5- to 6-membered heteroaryl-S(O) ２ -, phenyl-S(O) ２ -, phenyl-C １～６ Alkyl-S(O) ２ -, C １～６ Alkyl-C(O)-, C １～６ Cycloalkyl-C(O)-, C １～６ Alkoxy-C(O)-, R ａ R ｂ N—C(O)—, R ａ R ｂ N-SO ２ -, and -P(O)(C １～３ alkyl) ２ are optionally each independently R ｐ and optionally substituted by one, two, three or more substituents selected from R ｐ is, for each occurrence, independently, halogen, hydroxyl, cyano, C １～６ Alkyl, C １～６ Alkoxy, C ３～６ cycloalkyl, 4- to 6-membered heterocyclyl, R ａ R ｂ N-, R ａ R ｂ N-carbonyl-, R ａ R ｂ N-SO ２ - and R ａ R ｂ N-carbonyl-N(R ａ )- is selected from the group consisting of R ａ and R ｂ is, for each occurrence, independently, hydrogen, C １～６ Alkyl, and C ３～６ cycloalkyl, wherein C １～６ Alkyl is optionally substituted with halogen, cyano, oxo, hydroxyl, and C １～６ alkoxy (optionally substituted with 1, 2, or 3 fluorine atoms); Or, R ａ and R ｂ together with the nitrogen to which they are attached form a 4- to 6-membered heterocyclyl, which is optionally substituted by one or more substituents each independently selected from the group consisting of halogen, cyano, oxo, and hydroxyl; w is 0, 1, or 2.

2. 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein one, two, three, or more hydrogen atoms of said compound may optionally be deuterium atoms, and all other atoms of said compound are present in their naturally occurring isotopic abundance ratios.

3. 1, 2, 3, or more hydrogen atoms are optionally each independently R １ , R ２ , R ４ , R ５ , R ６ , R ７ , and R ｇ 3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the deuterium atoms are optionally present in one, two, three, or more groups selected from:

4. R １ The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein is selected from the group consisting of hydrogen, deuterium, chlorine, and fluorine.

5. R ２ is a 4- to 6-membered heterocyclyl, where R ２ optionally, on one or more available carbons, each independently R ｇ and when a 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted by 1, 2, or 3 substituents selected from R ｈ The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from:

6. R ２ is a 4- to 6-membered heterocyclyl, where R ２ optionally, on one or more available carbons, hydrogen and C １～６ alkyl; R ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be hydrogen, C １～６ alkyl (optionally substituted with 1, 2, or 3 fluorine atoms), —C １～６ Alkyl-C ３～６ Cycloalkyl, C １～６ Cycloalkyl-C(O)-, C １～６ Alkyl-S(O) ２ -(optionally cyano, methoxy, hydroxyl, -NR ａ R ｂ or substituted by 1, 2 or 3 fluorine atoms), C ３～６ Cycloalkyl-S(O) ２ -, 4- to 6-membered heterocyclyl-S(O) ２ -, 4- to 6-membered heterocyclyl-C １～６ Alkyl-S(O) ２ -, 5- to 6-membered heteroaryl-S(O) ２ -, phenyl-S(O) ２ -, phenyl-C １～６ Alkyl-S(O) ２ - (Optionally R ａ R ｂ -substituted by -N-, and -P(O)(C １～３ alkyl) ２ The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent selected from the group consisting of:

7. R ２ but, 7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

8. R ２ is a 5-6 membered heteroaryl, where R ２ optionally, on one or more available carbons, each independently R ｇ and R ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be ｈ The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from:

9. R ２ is a 5-6 membered heteroaryl, where R ２ is optionally substituted on one or more available carbons with hydrogen, cyano, C １～６ Alkyl, C １～６ Alkoxy, and —P(O)(C １～３ alkyl) ２ and R ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be hydrogen, —C １～６ Alkyl-C ３～６ Cycloalkyl, and C ３～６ Cycloalkyl-S(O) ２ 9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from the group consisting of:

10. R ２ but, 10. The compound of claim 8 or 9, selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

11. R ２ Ga-O-C １～６ alkylene-4 to 6-membered heterocyclyl, where R ２ optionally, on one or more available carbons, each independently R ｇ and optionally two R on adjacent atoms are substituted by one, two, or three substituents selected from ｇ together with the atom to which they are attached form a 5- to 6-membered aryl or heteroaryl), R ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be ｈ The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from:

12. R ２ Ga-O-C １～６ alkylene-4 to 6-membered heterocyclyl, where R ２ optionally, on one or more available carbons, hydrogen, halogen, hydroxyl, and C １～６ alkyl (optionally substituted with 1, 2, or 3 fluorine atoms), and optionally R ２ The heterocycle of R may be substituted on two adjacent atoms, and the two substituents together with the atoms to which they are attached form a fused phenyl; ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be hydrogen, C １～６ Alkyl, and C １～６ Alkyl-S(O) ２ 12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from the group consisting of:

13. R ２ but, 13. The compound of claim 11 or 12, selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

14. R ２ Ga-O-C １～６ The compound of any one of claims 1 to 4, which is alkylene-5 to 6-membered heteroaryl, or a pharmaceutically acceptable salt thereof.

15. R ２ but, 15. The compound of claim 14, selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

16. R ２ But, -C ２～６ Alkyl, C ２～６ Alkenyl, and C ３～６ cycloalkyl, wherein R ２ are optionally each independently R ｇ 5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally substituted by one, two, three or more substituents selected from:

17. R ２ But, -C ２～６ Alkyl, C ２～６ Alkenyl, C ３～６ Cycloalkyl, —C １～６ Alkylene-C ３～６ cycloalkyl, and —C １～６ Alkenylene-C ３～６ cycloalkyl, wherein R ２ is optionally cyano, chlorine, fluorine, hydroxyl, C １～６ Alkoxy, phenyl, and R ａ R ｂ 17. The compound of claim 16, or a pharmaceutically acceptable salt thereof, optionally substituted by 1, 2, 3, or more substituents each independently selected from the group consisting of N-.

18. R ２ but, 18. The compound of claim 16 or 17, selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

19. R ２ Ga-O-C １～６ alkyl, where R ２ are optionally each independently R ｇ 5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally substituted by one, two, three or more substituents selected from:

20. R ２ Ga-O-C １～６ alkyl, where R ２ is optionally cyano, deuterium, chlorine, fluorine, hydroxyl, oxo, C １～６ alkoxy (optionally substituted by 1, 2, or 3 fluorine atoms), C ３～６ Cycloalkoxy, —O—C １～６ Alkylene-C ３～６ cycloalkyl, —(CO)—(NR ａ )-C １～６ Alkylene-C ３～６ Cycloalkyl, C １～６ Alkyl-O—C(O)—, R ａ R ｂ N- (where R ｂ is optionally -OCH ３ Or -OCF ３ substituted by), C １～６ Alkyl-N(R ａ ) - (where C １～６ Alkyl is optionally fluoro, cyano, or —OCH ３ substituted by), R ａ R ｂ NC(O)-, -P(O)(C １～３ alkyl) ２ , C １～６ Alkyl-N(R ａ )-C(O)-, C １～６ Alkyl-N(R ａ )-C(O)-N(R ａ ) -, C １～６ Alkyl-SO ２ -N(R ａ ) -, C ３～６ Cycloalkyl-SO ２ -N(R ａ )-, and 4- to 6-membered heterocyclyl-SO ２ -N(R ａ 20. The compound of claim 19, or a pharmaceutically acceptable salt thereof, optionally substituted by 1, 2, 3, or more substituents each independently selected from the group consisting of:

21. R ２ but, 21. The compound of claim 19 or 20, selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

22. R ２ Ga-O-C ３～６ cycloalkyl or —O-4- to 6-membered heterocyclyl, where R ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be ｈ The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from:

23. R ２ Ga-O-C ３～６ cycloalkyl or —O-4- to 6-membered heterocyclyl, where R ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be １～６ Alkyl-SO ２ -N(R ａ )- and C ３～６ Cycloalkyl-SO ２ -N(R ａ 23. The compound of claim 22, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent selected from the group consisting of:

24. R ２ but, 24. The compound of claim 22 or 23, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

25. R ２ -N (R ａ )-C １～６ alkyl, where R ２ are optionally each independently R ｇ 5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally substituted by 1, 2, or 3 substituents selected from:

26. R ２ -N (R ａ )-C １～６ alkyl, where R ２ is optionally fluoro, —C(O)OH, cyano, oxo, R ａ R ｂ N-, C １～６ Alkoxy, phenyl, -C ３～６ Cycloalkyl, C ３～６ Cycloalkyl-SO ２ -N(R ａ )-, and -(CO)-(NR ａ )-C １～６ Alkylene-C ３～６ 26. The compound of claim 25, or a pharmaceutically acceptable salt thereof, optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of cycloalkyl.

27. R ２ but, 27. The compound of claim 25 or 26, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

28. R ２ Ga-O-C １～６ Alkylene-C ３～６ cycloalkyl, where R ２ are optionally each independently R ｇ 5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally substituted by 1, 2, or 3 substituents selected from:

29. R ２ Ga-O-C １～６ Alkylene-C ３～６ cycloalkyl, where R ２ is optionally fluoro, hydroxyl, R ａ R ｂ N-, cyano, and C １～３ and optionally substituted by 1, 2, or 3 substituents each independently selected from the group consisting of alkyl, wherein C １～３ The alkyl is optionally hydroxyl, R ａ R ｂ N-, cyano and C １～３ 29. The compound of claim 28, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent selected from the group consisting of alkoxy.

30. R ２ but, 30. The compound of claim 28 or 29, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

31. R ２ is -O-C(O)-N(R ａ )-C １～６ The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R is alkyl.

32. R ２ but, 32. The compound of claim 31 , represented by: or a pharmaceutically acceptable salt thereof.

33. R ２ -N (R ａ )-4 to 6-membered heterocyclyl, where R ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be ｈ The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from:

34. R ２ -N (R ａ )-4 to 6-membered heterocyclyl, where R ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be １～６ Alkyl-SO ２ -N(R ａ )- and C ３～６ Cycloalkyl-SO ２ -N(R ａ 34. The compound of claim 33, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent selected from the group consisting of:

35. R ２ but, 35. The compound of claim 33 or 34, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

36. R ２ Ga-C １～６ alkylene-4 to 6-membered heterocyclyl, where R ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be ｈ The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent selected from:

37. R ２ Ga-C １～６ alkylene-4 to 6-membered heterocyclyl, where R ２ When contains a substitutable ring nitrogen atom, the ring nitrogen atom may optionally be １～６ Alkyl, C １～６ Alkyl-SO ２ -N(R ａ ) - and C ３～６ Cycloalkyl-SO ２ -N(R ａ )-, wherein C １～６ 37. The compound of claim 36, or a pharmaceutically acceptable salt thereof, wherein the alkyl is optionally substituted with 1, 2, or 3 fluorine atoms.

38. R ２ but, 38. The compound of claim 36 or 37, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

39. R ２ but, -CHF ２ 、-CH ２ OH、-H ２ OCH ３ 、-CH ２ CN、-OH、 The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

40. R ２ is halogen, and optionally R ２ is selected from the group consisting of fluoro, chloro, and bromo, and further optionally, R ２ The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein is bromo.

41. R １ and R ２ or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, wherein: together with the atom to which they are attached form a 5-membered heteroaryl;

42. R １ and R ２ or a pharmaceutically acceptable salt thereof, wherein: together with the atom to which they are attached form a furanyl.

43. A compound according to claim 41 or 42, or a pharmaceutically acceptable salt thereof, represented by:

44. R ３ 44. The compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, wherein is hydrogen.

45. R ３ is OH or -NH ２ 44. The compound of any one of claims 1 to 43, wherein:

46. R ３ But -N(R ａ )-C １～６ alkyl, and —N(R ａ )-C １～６ 44. The compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, wherein alkyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of fluoro and hydroxyl.

47. R ３ but, 47. The compound of claim 46, selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

48. R ３ But -N(R ａ )-C １～６ Alkylene-C ３～６ cycloalkyl, and —N(R ａ )-C １～６ Alkylene-C ３～６ 44. The compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, wherein cycloalkyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of fluoro and hydroxyl.

49. R ３ but, 49. The compound of claim 48, represented by: or a pharmaceutically acceptable salt thereof.

50. R ３ But -O-C １～６ alkyl, and —O—C １～６ The alkyl may optionally contain fluorine, hydroxyl, and R ａ R ｂ 44. The compound according to any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, optionally substituted by 1, 2, 3, or more substituents each independently selected from the group consisting of N-.

51. R ３ but, 51. The compound of claim 50, selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

52. R ３ But -O-C １～６ Alkylene-C ３～６ cycloalkyl, and —O—C １～６ Alkylene-C ３～６ 44. The compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, wherein cycloalkyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of fluoro and hydroxyl.

53. R ３ but, 53. The compound of claim 52, represented by: or a pharmaceutically acceptable salt thereof.

54. R ３ But -O-C １～６ Alkylene-N(R ａ )-C(O)-OC １～６ 44. The compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, which is alkyl.

55. R ３ but, 55. The compound of claim 54, represented by: or a pharmaceutically acceptable salt thereof.

56. R ４ 56. The compound of any one of claims 1 to 55, or a pharmaceutically acceptable salt thereof, wherein is hydrogen.

57. R ５ 57. The compound of any one of claims 1 to 56, or a pharmaceutically acceptable salt thereof, wherein is selected from the group consisting of hydrogen, deuterium, bromine, chlorine, and fluorine.

58. R ６ 58. The compound of any one of claims 1 to 57, or a pharmaceutically acceptable salt thereof, wherein is selected from the group consisting of hydrogen and deuterium.

59. R ７ 59. The compound of any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, wherein is selected from the group consisting of hydrogen and deuterium.

60. 60. The compound of any one of claims 1 to 59, or a pharmaceutically acceptable salt thereof, wherein all atoms of said compound are present in their naturally occurring isotopic abundance.

61. A compound represented by formula (IIa) or a pharmaceutically acceptable salt thereof: During the ceremony, X is —O— and —N(R ａ )- is selected from the group consisting of L is a linear or branched C １～８ alkylene, where C １～８ alkylene is optionally substituted with one or more hydroxyl or one or more fluoro; R ２－ＩＩａ is hydrogen, cyano, -NR ａ R ｂ , C １～２ Alkoxy, C ３～６ Cycloalkyl-SO ２ -N(R ａ ) -, C １～６ Alkyl-SO ２ -N(R ａ )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C ３～６ cycloalkyl, wherein C １～２ Alkoxy, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C ３～６ Cycloalkyl optionally has one or more available carbon atoms selected from the group consisting of halogen, hydroxyl, —NR ａ R ｂ , C １～２ Alkyl (optionally -NR ａ R ｂ , hydroxyl, or 1, 2, or 3 halogens), and C １～２ and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C １～３ optionally substituted by alkyl, R ５ is selected from the group consisting of hydrogen, deuterium, and halogen; R ６ is selected from the group consisting of hydrogen and deuterium; R ７ is selected from the group consisting of hydrogen and deuterium; R ａ and R ｂ is, for each occurrence, independently selected from hydrogen and C １～３ Alkyl (optionally containing one or more halogens, cyano, or C １～２ substituted by alkoxy).

62. X is —O—, —N(H)—, or —N(CH ３ 62. The compound of claim 61, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

63. L, (where * and # represent R ２－ＩＩ and represents the point of covalent attachment to X).

63. The compound of claim 61 or 62, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

64. R ２－ＩＩ is hydrogen, cyano, -NH ２ , -N(CH ３ ), -N(H)CH ２ CF ２ , -N(CH ３ )(CH ３ CH ２ ), -N(CH ３ )(CH ３ CH ２ OCH ２ ), -N(CH ３ )(CH ３ CH ２ CN), -OCH ２ , -OCF ３ , ３ , 64. The compound of any one of claims 61 to 63, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

65. R ５ 65. The compound of any one of claims 61 to 64, or a pharmaceutically acceptable salt thereof, wherein is selected from the group consisting of hydrogen, deuterium, and fluorine.

66. A compound represented by formula (IIb) or a pharmaceutically acceptable salt thereof: During the ceremony, X is —O— and —N(R ａ )- is selected from the group consisting of L is a linear or branched C １～６ is alkylene, R ２－ＩＩｂ is hydrogen, cyano, -NR ａ R ｂ , C １～２ Alkoxy, C ３～６ Cycloalkyl-SO ２ -N(R ａ ) -, C １～６ Alkyl-SO ２ -N(R ａ )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C ３～６ cycloalkyl, wherein phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C ３～６ Cycloalkyl optionally has one or more available carbon atoms selected from the group consisting of halogen, hydroxyl, —NR ａ R ｂ , C １～２ alkyl (optionally substituted with 1, 2, or 3 halogens), and C １～２ and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C １～３ optionally substituted by alkyl, R ５ is selected from the group consisting of hydrogen, deuterium, and halogen; R ６ is selected from the group consisting of hydrogen and deuterium; R ７ is selected from the group consisting of hydrogen and deuterium; R ａ and R ｂ is, for each occurrence, independently selected from hydrogen and C １～３ alkyl.

67. X is —O—, —N(H)—, or —N(CH ３ 67. The compound of claim 66, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

68. L, (where * and # represent R ２－ＩＩ and represents the point of covalent attachment to X).

68. The compound of claim 66 or 67, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

69. R ２－ＩＩ is hydrogen, cyano, -NH ２ , -N(CH ３ ) ２ , -OCH ３ , 69. The compound of any one of claims 66 to 68, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

70. R ５ 70. The compound of any one of claims 66 to 69, or a pharmaceutically acceptable salt thereof, wherein is selected from the group consisting of hydrogen, deuterium, and fluorine.

71. A compound represented by formula (III) or a pharmaceutically acceptable salt thereof: During the ceremony, X ＩＩＩ is a bond, -CH ２ -, -NR ａ -, -O-, -O-CH ２ - and -OCH ２ -CH ２ - selected from the group consisting of m is 1, 2, or 3; n is 1, 2, or 3; R １－ＩＩＩ is hydrogen, halogen, hydroxyl, cyano, -NR ａ R ｂ , C １～２ alkyl (optionally substituted with 1, 2, or 3 halogens), and C １～２ alkoxy (optionally substituted with 1, 2, or 3 halogens); R ２－ＩＩＩ is hydrogen, C １～４ Alkyl, —C(O)—C １～４ Alkyl, —C(O)—O—C １～４ Alkyl, —C(O)—N(R ａ )-C １～４ Alkyl, —S(O) ２ -C １～４ Alkyl, and —S(O) ２ -C ３～６ cycloalkyl, wherein C １～４ Alkyl, —C(O)—C １～４ Alkyl, —C(O)—O—C １～４ Alkyl, —C(O)—N(R ａ )-C １～４ Alkyl, —S(O) ２ -C １～４ Alkyl, and —S(O) ２ -C ３～６ Cycloalkyl is optionally substituted with halogen, hydroxyl, cyano, -NR ａ R ｂ , C １～２ alkyl (optionally substituted with 1, 2, or 3 halogens), and C １～２ alkoxy (optionally substituted with 1, 2, or 3 halogens); R ５ is selected from the group consisting of hydrogen, deuterium, and halogen; R ６ is selected from the group consisting of hydrogen and deuterium; R ７ is selected from the group consisting of hydrogen and deuterium; R ａ and R ｂ is, for each occurrence, independently selected from hydrogen and C １～３ alkyl.

72. X ＩＩＩ is a bond, -CH ２ -, -O-, -NH-, and -O-CH ２ 72. The compound of claim 71, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

73. R ２－ＩＩＩ is hydrogen, isopropyl, -CH ２ CF ３ , -S(O) ２ -CH ３ , and -S(O) ２ 73. The compound of claim 71 or 72, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: -cyclopropyl.

74. R ５ 74. The compound of any one of claims 71 to 73, or a pharmaceutically acceptable salt thereof, wherein is selected from the group consisting of hydrogen, deuterium, and fluorine.

75. A compound represented by formula (IV) or a pharmaceutically acceptable salt thereof: During the ceremony, X ＩＩＩ is -O- and -N(R ａ )- is selected from the group consisting of L ＩＩＩ is a linear or branched C １～６ alkylene, where C １～６ The alkylene is optionally substituted with hydroxyl or fluoro; R ３－ＩＩＩ is hydrogen, -NR ａ R ｂ , -N(R ａ )-C(O)-OC １～６ Alkyl, hydroxyl, fluoro, C １～２ Alkoxy, 4- to 6-membered heterocyclyl, and —C ３～６ cycloalkyl, wherein 4- to 6-membered heterocyclyl and —C ３～６ Cycloalkyl optionally has one or more available carbon atoms selected from the group consisting of halogen, hydroxyl, —NR ａ R ｂ , C １～２ alkyl (optionally substituted with 1, 2, or 3 halogens), and C １～２ and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C １～３ may be substituted by alkyl, or L ＩＩＩ -R ３－ＩＩＩ is hydrogen, R ５ is selected from the group consisting of hydrogen, deuterium, and halogen; R ６ is selected from the group consisting of hydrogen and deuterium; R ７ is selected from the group consisting of hydrogen and deuterium; R ａ and R ｂ is, for each occurrence, independently selected from hydrogen and C １～３ alkyl.

76. A compound represented by formula (V) or a pharmaceutically acceptable salt thereof: During the ceremony, X Ｖ represents a bond, —O—, and —N(R ａ )- is selected from the group consisting of L Ｖ is a bond or a linear or branched C １～８ alkylene, where C １～８ The alkylene is optionally substituted with one or more hydroxyl or fluoro; R ２－Ｖ is hydrogen, halogen, cyano, -NR ａ R ｂ , C １～２ Alkoxy, C ３～６ Cycloalkyl-SO ２ -N(R ａ ) -, C １～６ Alkyl-SO ２ -N(R ａ )-, phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C ３～６ cycloalkyl, wherein phenyl, 5- to 6-membered heteroaryl, 4- to 6-membered heterocyclyl, and C ３～６ Cycloalkyl optionally has one or more available carbon atoms selected from the group consisting of halogen, hydroxyl, —NR ａ R ｂ , C １～２ Alkyl (optionally, —NR ａ R ｂ , hydroxyl, or 1, 2, or 3 halogens), and C １～２ and alkoxy (optionally substituted with 1, 2, or 3 halogens), and when the 5- to 6-membered heteroaryl or 4- to 6-membered heterocyclyl contains a substitutable ring nitrogen atom, the ring nitrogen atom is optionally substituted with C １～３ optionally substituted by alkyl, R ５ is selected from the group consisting of hydrogen, deuterium, and halogen; R ６ is selected from the group consisting of hydrogen and deuterium; R ７ is selected from the group consisting of hydrogen and deuterium; R ａ and R ｂ is, for each occurrence, independently selected from hydrogen and C １～３ alkyl.

77. X Ｖ 77. The compound of claim 76, or a pharmaceutically acceptable salt thereof, wherein is a bond or -O-.

78. L Ｖ But the bond, (where * and # represent R ２－Ｖ and X Ｖ represents the point of covalent attachment to 78. The compound of claim 76 or 77, selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

79. R ２－Ｖ is hydrogen, bromo, cyano, -OCH ３ , 79. The compound of any one of claims 76 to 78, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

80. R ５ , R ６ , and R ７ 80. The compound of any one of claims 76 to 79, or a pharmaceutically acceptable salt thereof, wherein each is hydrogen.

81. 5-{1-fluoro-3-hydroxy-7-[2-(morpholin-4-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-3-yl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, Propan-2-ylcarbamic acid 8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ) ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl, 5-(9-fluoro-7-hydroxynaphtho[2,1-b]furan-8-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(azetidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-methoxy(4- ２ H) naphthalen-2-yl](4,4- ２ H ２ ) -1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(methylamino)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-4-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-7-{[3-fluoro-1-(propan-2-yl)pyrrolidin-3-yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-7-[(3-fluoropyrrolidin-3-yl)methoxy]-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}pentanenitrile, 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-1-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(piperidin-4-yl)methoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3,3-dimethylpentanenitrile, 5-{7-[(3,3-dimethylbutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1,4-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[( ２ H ３ ) methyloxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-methoxyethoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2-dimethylbutanenitrile, 5-{7-[2-(3-aminobicyclo[1.1.1]pentan-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[2-(dimethylamino)ethyl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)(4,4- ２ H ２ ) -1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}ethyl)cyclopropanesulfonamide, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropanesulfonamide, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)azetidin-3-yl]amino}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanenitrile, [1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropyl]acetonitrile, 5-{7-[2-(dimethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1H-pyrazol-4-yl)methoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-methylpropoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxypropoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, N-(cyclopropylmethyl)-8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxamide, 5-[1-fluoro-3-hydroxy-7-(2-{[2-(trifluoromethoxy)ethyl]amino}ethoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2-methoxyethyl)amino]ethoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[3-(methylamino)propyl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(ethylamino)propyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[5-(dimethylphosphoryl)thiophen-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclopropylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(methylamino)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(ethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)amino]ethoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(diethylphosphoryl)propoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3S)-3-hydroxybutoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1,4-difluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3R)-3-hydroxybutoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropyl-2-hydroxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4S)-4-hydroxypentyl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3-oxopentyl)oxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-hydroxybutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, N-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-3-methylbutanamide, 5-[1-fluoro-3-hydroxy-7-(4,4,4-trifluorobutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 1-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropane-1-carbonitrile, 5-(1-fluoro-3-hydroxy-7-{2-[1-(methoxymethyl)cyclopropyl]ethoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[(cyclopropylmethyl)amino]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2,2-difluoropropyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3,3-dimethyl-4-(methylamino)butoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-phenylethyl)amino]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3-amino-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(4,4,4-trifluorobutyl)amino]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(difluoromethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(dimethylphosphoryl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3,3,3-trifluoropropyl)amino]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-methoxy-3-methylbutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylpropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-({2-[(propan-2-yl)oxy]ethyl}amino)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3-yl]methoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}butanenitrile, 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethyl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4-amino-3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[2-(azetidin-1-yl)ethyl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]oxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-methoxyethyl)amino]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3,3,3-trifluoropropoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}methyl)cyclopropane-1-carbonitrile, 5-[1-fluoro-3-hydroxy-7-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[3-(1H-pyrazol-1-yl)propoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(4-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(hydroxymethyl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)piperidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(1H-pyrazol-1-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(piperidin-3-yl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(2,2-difluorocyclopropyl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(1-methylcyclopropyl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(3-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(2-aminophenyl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,2-difluoroethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2,2,2-trifluoroethoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-7-(2-fluoroethoxy)-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropane-1-carbonitrile, 5-{1-fluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(2-methylpropyl)amino]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(cyclopropylmethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetonitrile, 5-[1-fluoro-3-hydroxy-7-(3-methylbutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1,8-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)azetidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)azetidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, (2E)-3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]prop-2-enenitrile, 5-[7-(2-cyclopropylethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2,2-difluorocyclopropyl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclopropylmethoxy)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(cyclobutyloxy)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)oxy]ethoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3-ethoxypropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-tert-butoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[rac-(1R,2R)-2-ethylcyclopropyl]methoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-methylpentyl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[3-(2,2-dimethylpropyl)pyrrolidin-1-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(1-chloro-3-hydroxypropan-2-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)pyrrolidin-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(cyclopropyloxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(2-cyclopropylethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-methyl-1H-imidazol-2-yl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(azetidin-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(5-methoxythiophen-2-yl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetonitrile, 5-[1-fluoro-3-hydroxy-7-(methoxymethyl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3-methyloxetan-3-yl)methoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3S)-pyrrolidin-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(3R)-pyrrolidin-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(8-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3,3-difluorocyclobutyl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-cyclopropyl-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanecarbonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(4-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(E)-2-cyclopropylethenyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1E)-4-methylpent-1-en-1-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(pentamethylphenyl)ethenyl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropylmethyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(4-bromo-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(2-cyclopropylethyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(1E)-3-methoxyprop-1-en-1-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-ethoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(1,1-dioxo-1λ ６ -thian-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(oxan-3-yl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methyl}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methyl}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[methyl(2-methylpropyl)amino]ethoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxolan-2-yl)methoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(oxolan-3-yl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)piperidin-4-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-2-yl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)piperidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(difluoromethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]methyl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(pyrrolidin-3-yl)methyl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,5-dihydrofuran-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,6-dihydro-2H-pyran-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,5-dihydro-1H-pyrrol-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(pyridin-3-yl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(azetidin-3-yl)methyl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}acetamide, 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-N-methylbutanamide, N-ethyl-N'-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)urea, 5-{1-fluoro-3-hydroxy-7-[(oxan-3-yl)methoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(1-chloro-3-hydroxypropan-2-yl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxan-4-yl)methoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(oxetan-3-yl)oxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyridin-4-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,7-dihydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-propoxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[(propan-2-yl)oxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}acetic acid, N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetamide, N,N-diethyl-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetamide, 5-{1-fluoro-3-hydroxy-7-[2-oxo-2-(pyrrolidin-1-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]oxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(oxolane-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2-methoxyethanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{1-[(oxan-2-yl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(4,4,4-trifluorobutane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(butane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{1-[(1,4-dioxan-2-yl)methanesulfonyl]-2,5-dihydro-1H-pyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-2,5-dihydro-1H-pyrrole-1-sulfonyl}pentanenitrile, 5-{1-fluoro-3-hydroxy-7-[1-(pentane-2-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(ethanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(propane-2-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)oxetane-3-sulfonamide, 5-[1-fluoro-3-hydroxy-7-(piperidin-4-yl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(2-methylpropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-ethoxy-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2,2-difluoroethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclopropanesulfonyl)-1H-pyrazol-4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[(3R)-1-(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]amino}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]amino}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-7-{[3-fluoro-1-(methanesulfonyl)pyrrolidin-3-yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(propane-2-sulfonyl)pyrrolidin-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)ethanesulfonamide, 5-{1-fluoro-7-[1-(furan-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-methylbutane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(thiophene-3-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(benzenesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(cyclobutanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, (2S)-2-amino-4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanoic acid methyl ester, 5-{7-[(3,5-dimethyl-1H-pyrazol-4-yl)methoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,5-dimethyl-1H-pyrazol-4-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclohexylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-1H-imidazole-4-carbonitrile, 5-{1-fluoro-3-hydroxy-7-[2-(2,2,4-trimethyl-1,3-dioxolan-4-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,4-dihydroxy-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(4,4-difluorobutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{[rac-(2R,4R)-2,4-dihydroxypentyl]oxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(2-oxoimidazolidin-1-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(2-hydroxybutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(6-amino-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{6-[(4,4-difluorobutyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{6-[(cyclopropylmethyl)amino]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-6-[(3-methylbutyl)amino]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-6-[(3-hydroxy-3-methylbutyl)amino]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-6-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-6-methoxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, (2-{[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1λ ６ tert-butyl 2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)carbamate, 5-[6-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[6-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-6-(3-methylbutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[6-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3S)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-3,3-dimethylbutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-hydroxy-2,2-dimethylpropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[1-(3-aminopropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, (3R)-5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy-3-methylpentanenitrile, (3S)-5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy-3-methylpentanenitrile, 5-{7-[(5-amino-3,3-dimethylpentyl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{3-[(propan-2-yl)amino]propyl}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxolan-3-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopentylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclobutylethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(trifluoromethoxy)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-hydroxy-3-methylbutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopropylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3,6-dihydroxy-7-methoxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-ethyl-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3,6-dihydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-methylbutoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclobutylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-butoxy-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(2-cyclopentylethoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4,4-difluorobutoxy)-1-fluoro-3,6-dihydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 4-{[8-fluoro-3,6-dihydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2-dimethylbutanenitrile, 5-{1-fluoro-3,6-dihydroxy-7-[2-(oxolan-3-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[1-(3-hydroxypropane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-bromo-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[1-fluoro-3,6-dihydroxy-7-(4-methylpentyl)naphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-[7-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(oxetan-3-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[1-(hydroxymethyl)cyclobutyl]ethoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(4,4-difluoro-5-hydroxypentyl)oxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[3-(aminomethyl)bicyclo[1.1.1]pentan-1-yl]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{[3-(2-hydroxyethyl)bicyclo[1.1.1]pentan-1-yl]methoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(bicyclo[1.1.1]pentan-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[1-(aminomethyl)cyclobutyl]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3-hydroxy-7-[2-(3-hydroxy-3-methylazetidin-1-yl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(1-fluoro-3-hydroxy-7-{2-[(2-methoxyethyl)(methyl)amino]ethoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(1,3-dihydro-2H-isoindol-2-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{1-fluoro-3,6-dihydroxy-7-[2-(1-methylcyclopropyl)ethoxy]naphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3,6-dihydroxynaphthalen-2-yl}-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 5-(7-{2-[ethyl(methyl)amino]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, 3-[(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ ６ ,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)(methyl)amino]propanenitrile, 5-(1-fluoro-3-hydroxy-7-{2-[(2,2,2-trifluoroethyl)amino]ethoxy}naphthalen-2-yl)-1λ ６ , 2,5-thiadiazolidine-1,1,3-trione, and pharmaceutically acceptable salts thereof A compound selected from the group consisting of:

82. 82. A pharmaceutically acceptable composition comprising a compound of any one of claims 1 to 81 and a pharmaceutically acceptable carrier.

83. 83. The composition of claim 82, formulated for oral administration.

84. 82. A method of treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of a compound of any one of claims 1 to 81 in combination with an additional therapeutic agent.

85. 84. A method of treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of the pharmaceutically acceptable composition of claim 82 or 83 in combination with an additional therapeutic agent.

86. 86. The method of claim 84 or 85, wherein the additional therapeutic agent is an immunotherapeutic agent.

87. 87. The method of claim 86, wherein the immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody.

88. 82. A method of treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of a compound of any one of claims 1-81.

89. 84. A method of treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of the pharmaceutically acceptable composition of claim 82 or 83.

90. 84. A method for treating type 2 diabetes in a patient in need thereof, comprising administering to said patient an effective amount of a compound of any one of claims 1 to 81 or a composition of claim 82 or 83.

91. 84. A method for the treatment and / or management of obesity in a patient in need thereof, said method comprising administering to said patient an effective amount of a compound according to any one of claims 1 to 81 or a composition according to claim 82 or 83.

92. 84. A method of inhibiting further weight gain in an overweight or obese patient in need thereof, said method comprising administering to said patient an effective amount of a compound of any one of claims 1 to 81 or a composition of claim 82 or 83.

93. 84. A method for treating a metabolic disorder in a patient in need thereof, comprising administering to said patient an effective amount of a compound according to any one of claims 1 to 81 or a composition according to claim 82 or 83.

Images